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 Summary 
In this thesis, we performed a comparative evaluation of adaptive melanoma immunity focusing on 
the immunosuppressive network surrounding indoleamine 2,3-dioxygenase (IDO), an 
immunosuppressive enzyme known to have a negative prognostic value in melanoma. To do so, we 
have chosen for a translational approach, aiming to clarify the in vivo relevance of the investigated 
immunosuppressive mechanisms in melanoma patients.  
In the first part of this thesis, we set out to identify IDO expression in the primary melanoma by 
immunohistochemistry. The role and pattern of IDO expression by tumour cells versus host cells was 
compared, and found to be different. Sentinel IDO-positivity was inversely correlated with CD8+ 
lymphocytes and tumour-infiltrating lymphocytes (TILs) in the primary melanoma, which are both 
markers of an active anti-tumour response. Remarkably, endothelial IDO expression was found to be 
highly consistent in the primary, the sentinel and metastatic tissues of melanoma patients, indicating 
that immune suppression in melanoma is determined very early in the disease course. These results 
show that IDO expression in melanoma is a marker of the patients’ anti-tumour immune response with 
an independent prognostic value. 
In the second part of this thesis, we used multi-colour flow cytometry to comparatively assess the 
clinical relevance of six circulating cell types with a role in anti-tumour adaptive immunity. We 
demonstrated that circulating plasmacytoid dendritic cells (pDCs) and myeloid-derived suppressor 
cells (MDSCs) represent a single immunologic system and have prognostic value in melanoma patients, 
independent of disease stage. Both were correlated  with cytotoxic and regulatory T-cell frequencies, 
indicating that they are key players in the systemic immunological climate of melanoma patients. 
In the third part of this thesis, IDO expression could be identified in pDCs and mMDSCs using multi-
colour flow cytometry. This IDO expression increased in advanced disease stage and its functional 
activity was confirmed by concomitant tryptophan breakdown, which was measured by ultra-
performance liquid chromatography (UPLC) in the patients’ serum. Systemic IDO expression was 
associated with increased circulating programmed death ligand 1 (PD-L1+) cytotoxic T-cells, and high 
levels of circulating PD-L1+ cytotoxic T-cells in turn correlated with increased cytotoxic T-lymphocyte 
antigen-4 (CTLA-4) expression by Tregs. This illustrates that negative feedback immune mechanisms in 
melanoma should be considered as one interrelated signaling network. Moreover, both increased PD-
L1+ T-cells and CTLA-4 expression in Tregs conferred a negative prognosis, indicating their in vivo 
relevance. 
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In the fourth part of this thesis, we wanted to test whether these systemic immunosuppressive 
mechanisms are relevant during immunotherapy. We chose adjuvant IFN-α2b therapy for patients 
with high-risk melanoma as a model. IDO expression was upregulated by circulating pDCs in melanoma 
patients treated with adjuvant IFN-α2b. This was associated with tryptophan consumption in the 
patients’ serum and higher Treg and PD-L1+ cytotoxic T-cell frequencies in the blood. We hypothesize 
that in IFN-α2b treated patients, IDO activity could act as a negative feedback mechanism and might 
thus limit the clinical efficacy of IFN-α2b by failing to overcome T-cell anergy. 
In conclusion, we believe that this work has contributed to clarifying the in vivo role of IDO expression 
in various compartments of the immune system of stage I to IV melanoma patients. By placing these 
data in the context of current immunotherapeutic strategies, they could have implications for both 
immunoprofiling and immunotherapy.  
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 Samenvatting 
In deze thesis werd een vergelijkende evaluatie van het adaptieve immuunsysteem in 
melanoompatiënten uitgevoerd. Hierbij lag de klemtoon op indoleamine 2,3-dioxygenase (IDO), een 
immunosuppressief enzym waarvan de negatieve impact op de prognose in melanoom gekend is.  Er 
werd gekozen voor een translationele benadering, om zo de in vivo relevantie van de onderzochte 
immunosuppressieve mechanismen in melanoompatiënten te verduidelijken.  
In het eerste deel van deze thesis werd immuunhistochemie gebruikt om IDO expressie in het primaire 
melanoom te identificeren. De rol en het patroon van IDO expressie door tumorcellen enerzijds en 
gastheercellen anderzijds werd vergeleken en bleek verschillend te zijn. IDO expressie in de 
sentinelklier was omgekeerd gecorreleerd met een CD8+ T-cel infiltraat in het primaire melanoom, dit 
laatste is een gekende merker van een actieve antitumorale immuunrespons. IDO expressie door 
endotheelcellen in het primaire melanoom, de sentinelklier en in metastasen bleek ook opmerkelijk 
consistent. Dit alles geeft aan dat immuunsuppressie al vroeg in het verloop van een melanoom kan 
ontstaan. Onze resultaten tonen dat IDO expressie in melanoompatiënten mogelijk een merker is van 
de antitumorale immuunrespons, met een onafhankelijke prognostische waarde. 
In het tweede deel van deze thesis hebben we acht-kleuren flow cytometrie gebruikt om een 
vergelijkende evaluatie uit te voeren van zes verschillende circulerende celtypes die een rol hebben in 
het adaptieve immuunsysteem. We konden aantonen dat circulerende plasmacytoïde dendritische 
cellen (pDCs) en myeloid-derived suppressor cellen (MDSCs) deel uitmaken van eenzelfde 
immunologisch systeem. Deze celtypes hadden bovendien een prognostische waarde in melanoom, 
ongeacht het ziektestadium waarin de patiënt zich bevond. 
In het derde deel van deze thesis hebben we IDO expressie kunnen vaststellen in circulerende pDCs en 
mMDSCs door middel van acht-kleuren flow cytometrie. Deze IDO expressie was hoger in patiënten 
met gevorderde ziekte, en ging gepaard met afbraak van tryptofaan in het serum van de patiënten. De 
concomitante tryptofaanafbraak onderbouwt dat de gemeten IDO expressie ook functioneel actief is, 
ze werd gemeten met “ultra-performance liquid chromatography” (UPLC). Systemische IDO expressie 
was gecorreleerd met verhoogde niveaus van circulerende programmed-death ligand 1 (PD-L1)-
positieve cytotoxische T-cellen. Deze laatste waren op hun beurt gecorreleerd met een toegenomen 
cytotoxic T-lymphocyte antigen-4 (CTLA-4) expressie door regulatoire T-cellen (Treg). Dit alles 
illustreert dat verschillende negatieve feedback mechanismen in melanoom als een signaalnetwerk 
met elkaar in verbinding staan. Bovendien gingen verhoogde niveaus van circulerende PD-L1+ 
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cytotoxische T-cellen en CTLA-4 expressie in Tregs gepaard met een slechtere prognose, wat de in vivo 
relevantie van deze celtypes onderstreept.  
Tenslotte wilden we in het vierde deel van deze thesis nagaan of de geïdentificeerde systemische 
immunosuppressieve mechanismen ook relevant zijn tijdens immunotherapie. Hiervoor werd de 
adjuvante behandeling met interferon-alfa (IFN-α2b) voor melanoompatiënten met een hoog risico op 
herval als model gekozen. Patiënten die  behandeld werden met IFN-α2b hadden een verhoogde IDO 
expressie in circulerende pDCs. Dit ging gepaard met tryptofaan verbruik in het serum, alsook met 
hogere frequenties van Tregs en PD-L1+ cytotoxische T-cellen in het bloed. We vermoeden daarom dat 
in deze patiëntengroep, IDO activiteit deel zou kunnen uitmaken van een negatief feedback 
mechanisme. Hierdoor zou dan de capaciteit van IFN-α2b om T-cel anergie te overwinnen kunnen 
beperkt worden, wat de werkzaamheid ervan mogelijk limiteert.  
Als conclusie kunnen we stellen dat we geloven dat dit werk heeft bijgedragen tot het verhelderen van 
de in vivo rol van IDO expressie in verschillende delen van het immuunsysteem van stadium I tot IV 
melanoompatiënten. Door deze data te interpreteren in de context van de immunotherapieën die 
momenteel gebruikt worden, kunnen hieruit gevolgen getrokken worden voor zowel 
immunoprofilering als immunotherapie.  
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1. Melanoma  
Melanoma is a malignant tumour that arises from melanocytes and is most commonly cutaneous in 
origin. It can also occur on mucosal surfaces and within the uveal tract of the eye. Four major subtypes 
of melanoma have been described (superficial spreading melanoma, nodular melanoma, lentigo 
maligna melanoma and acral lentiginous melanoma), but more rare variants also exist. While the 
majority of melanomas are brown-black in colour due to melanin deposition, some are skin-coloured 
to pink-red (amelanotic melanomas). Clinical observations such as incomplete or complete regression 
of melanoma, melanoma-associated development of vitiligo-like depigmentations and a higher 
incidence of melanoma in immunosuppressed patients point to the fact that melanoma is an 
immunogenic tumour.1 Over the last decades, the incidence rates of cutaneous melanoma have 
significantly increased. The annual rise in melanoma incidence varies depending on the population 
(Caucasians are most at risk), but is estimated to be between 3% and 7%. These estimates predict a 
doubling of melanoma incidence rates every 10-20 years.2 Mortality rates from melanoma peaked 
around the 1990s’. Subsequently trends have been less uniform, but tend to remain more or less 
stable.3 This is probably due to improved detection, as there is an ongoing trend for diagnosis of thinner 
melanomas in Western Europe.4 The vertical tumour thickness (Breslow thickness) is indeed the most 
important local prognostic factor in primary cutaneous melanoma. Other independent prognostic 
markers are ulceration and the number of mitoses present in the dermis. The importance of tumour 
thickness reflects the biology of a primary melanoma, that encompasses several phases. In the radial 
growth phase, melanoma cells grow within the epidermis. Next, individual melanoma cells start 
infiltrating the superficial dermis. When the vertical growth phase fully develops, tumour cell nests can 
be found in the dermis, where further expansion will take place. When the melanoma expands in the 
dermis, tumour cell nests can also develop at a certain distance from the primary lesion. These are 
called microsatellites (arising at 0.5 to 20 mm from the primary melanoma), and their presence 
immediately classifies a melanoma as stage III. The current American Joint Committee on Cancer (AJCC) 
classification for staging of melanoma takes all these factors into account, an overview can be found 
in addendum 1.5, 6 
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2. Current management of melanoma  
The guidelines and principles that are outlined here are based on the recommendations of the Belgian 
Association for Dermato-Oncology (BADO) that we published in the Belgian journal ‘OncoHemato’. This 
article can be found in addendum I.7 
 Local disease (stage I&II) 
The treatment of a primary melanoma starts with the diagnostic excision, using a 2 mm margin. If the 
diagnosis of melanoma is confirmed, a thorough physical examination with total skin inspection is 
necessary. After all, patients with a history of melanoma have a 0.2-8% risk of developing a second 
primary melanoma, and 30 to 40% of these will occur synchronously.8 At the same time, the presence 
of cutaneous or lymphoid metastases has to be checked. There is no consensus on which imaging 
should be done, but BADO has made recommendations for each tumour stage. If there is no evidence 
for metastasis, a wide local excision is the next therapeutic step, aiming to decrease the risk of local 
recurrence. The margins for this second excision are based on the Breslow thickness and range from 
0.5 to 2 cm. In melanomas of stage pT1b or more, a sentinel lymph node biopsy can be performed at 
the same time. This procedure allows for a more careful staging, but does not affect survival.9 If 
(micro)metastases are detected in the sentinel lymph node, the patient has stage III disease.  
 Regional disease (stage III) 
Patients who are diagnosed with stage III melanoma due to lymph node involvement or in-transit 
metastasis, should be surgically treated. Both micro- and macro-metastases necessitate a complete 
lymph node dissection. Adjuvant treatment with interferon-alpha (IFN-α) can also be proposed, 
because these patients have a high risk of relapse. Currently, IFN-α is the only therapy approved in 
Europe for adjuvant use in patients with resected melanoma at high risk of recurrence. In Belgium, 
intermediate-dose IFN-α2b is used with an induction phase of 10x106 U/m² IV 5d/week, followed by a 
maintenance phase of 5x106 U subcutaneously 3x/week for 2 years. Significant relapse-free survival 
(RFS) benefits have been demonstrated, but impact on overall survival (OS) is modest.10 An important 
hiatus in the use of IFN-α is the lack of knowledge on which patient subgroup benefits most from this 
treatment. A recent post-hoc analysis of EORTC trials 18952 and 18991 suggests that adjuvant IFN-α 
has the greatest impact in patients with microscopic regional disease and/or an ulcerated primary 
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melanoma.11 This interesting idea is now being investigated in a prospective clinical trial (EORTC 18081) 
for patients with ulcerated primary melanomas (T2b-4b) who have no regional or systemic disease.12 
 Systemic disease (stage IV) 
Melanoma that has disseminated to distant sites is regarded as incurable, with 5-year survival rates of 
around 10% and a median overall survival of 9 months (Fig. 1).13 Until 2010, DTIC (dacarbazine) was 
the standard therapy for stage IV melanoma patients, with response rates of around 20% and a median 
duration of response of 5-6 months. Nevertheless, treatment with DTIC never produced a significant 
survival benefit.14  
 
 
Figure 1: Stage-specific overall survival in melanoma.  
Fifteen-year survival curves comparing localized melanoma (stages I and II), regional disease (stage III), 
and systemic disease (stage IV). The numbers in parentheses are patients from the AJCC melanoma 
staging database used to calculate the survival rates. The differences between the curves are 
significant (P < 0.0001). Adapted from Balch et al., 2001.13 
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Since 2010, this landscape has changed spectacularly, as two distinct treatment approaches have 
shown survival benefit for patients with metastatic melanoma: targeting mutations in the tumour cells 
and immunomodulation.  
Targeted therapy 
Melanoma is a molecularly heterogeneous disease, and the discovery of driver mutations in various 
melanoma subtypes has led to the development of inhibitors that target the mutated signal 
transduction cascade.15 A V600 BRAF mutation causes constitutive activation of the MAPK signalling 
pathway, resulting in increased cell proliferation. On average, 41% of all melanomas is BRAF-positive, 
but this percentage increases to 49% for melanomas arising in younger individuals, on non-chronically 
sun-damaged skin and melanomas of the superficial spreading type.16 Vemurafenib (Zelboraf®) was 
the first BRAF-inhibitor to be approved as a first-line treatment for V600-mutant melanomas, and a 
second BRAF-inhibitor (dabrafenib - Tafinlar®) has recently followed. Treatment with vemurafenib 
produces median progression-free survival  rates of 6.9 months, compared to 1.7 months with DTIC. 
Similarly, median overall survival rises from 9.7 months with DTIC to 13.6 months with vemurafenib. 
The most remarkable features of treatment with vemurafenib are the high response rates (48%), which 
occur fast (1.45 months) and a relatively good tolerance. The most common side-effects are arthralgia 
(59%), fatigue (42%) and cutaneous manifestations such as rash (52%), photosensitivity (52%) and 
squamous cell carcinomas or kerato-acanthomas (26%). Data on dabrafenib are less mature, but 
similar clinical responses are seen and good responses have been registered with this compound in 
patients with brain metastases.17 Dabrafenib’s toxicity profile seems to be more favourable compared 
to vemurafenib, with less photosensitivity and fewer squamous-cell carcinomas (7% of patients versus 
20-30%).18 Unfortunately, even though the clinical responses with BRAF-inhibitors can be spectacular, 
they are usually short-lived (median 6 months).19 Possible mechanisms of resistance are an area of 
active research, and combining BRAF inhibition with MEK (a molecule downstream in the MAPK 
pathway) inhibition seems a promising approach.20   
Immunotherapy 
Ipilimumab (Yervoy®) is a fully human monoclonal antibody that binds to and blocks CTLA-4, which is 
an immune checkpoint molecule that downregulates T-cell activation in physiological circumstances. 
The mechanism of action will be discussed in more detail later on in this thesis. In 2010  the results of 
a phase III clinical trial were published, demonstrating a significant survival benefit with ipilimumab 
compared to a gp100 vaccine. Median overall survival was 10.1 months, which is a 34% increase 
compared to the control group. One year after treatment, 46% of patients was still alive, compared to 
25% in the control population.21 Even though the response rate is limited to 15-20%, an important and 
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previously unseen phenomenon occurs in the so-called “tail-of-the-curve”; about 15% of all patients 
treated with ipilimumab are still alive 4 years after treatment.22 An important limitation to treatment 
with ipilimumab is that responses are delayed up to 3 months or more. Adverse events occur in 40% 
of patients and comprise mostly auto-immune phenomena affecting the skin (dermatitis23, pruritus), 
gastro-intestinal organs (colitis, hepatitis) and the endocrine system (hypophysitis, adrenal 
insufficiency). Grade 3–4 adverse events occur in less than 10% of patients, but can be fatal. Adverse 
events usually resolve spontaneously or after steroid treatment, but endocrine failure frequently 
needs permanent hormonal supplementation. In Belgium, ipilimumab is approved as a second-line 
therapy in stage IV melanoma patients.  
3. Immune response in melanoma: basic principles & concepts  
 Cancer immunoediting: from elimination over equilibrium to escape 
The idea that the immune system plays an important role in cancer biology is not new. The first 
milestone in the discovery of tumour immunology occurred in 1863, when Rudolph Wirchow perceived 
that tumours are commonly infiltrated with leukocytes. In the early 20th century, Paul Ehrlich predicted 
the existence of immune surveillance and in the 1950’s Burnet and Thomas laid the foundations for 
the concept of immune tolerance.24 The role of the immune system in cancer remained controversial 
until the development of genetically-modified mouse models for immunodeficiency in the 1990’s. Ever 
since, there has been a growing recognition that the immune system can also play a tumour-promoting 
role, eventually leading to the immunoediting hypothesis.23, 25 The process of cancer immunoediting 
consists of 3 phases, as outlined here (and reviewed in detail by Dunn et al. in 2002).23  
Elimination (=immune surveillance) 
The origin of an anti-tumour immune response lies in signals derived from apoptotic or necrotic 
tumour cells and their surroundings, such as damage-associated proteins (DAMP). These are 
internalised by immature dendritic cells (DCs), which are potent antigen presenting cells (APCs) that 
subsequently process the tumour-associated antigens (TAA) and present them on their cell surface. 
After migration to the lymphoid tissues the activated mature DCs stimulate naïve T-cells to become 
skin-homing effector cells that should eliminate the causal stimulus (Fig. 2).26 Apart from lymphocytes, 
cells from the innate immunity (such as natural killer cells and macrophages) can also kill tumour cells. 
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Equilibrium 
If some tumour cells are not killed, the process can progress to the second phase in which the tumour 
persists but is prevented from expanding by immune pressure. In this way, tumours can be controlled 
by the immune system for long periods of time. T-cells, IL-12 and IFN-γ are known to sustain this 
dormant state.27 Cancer cells in equilibrium proliferate poorly, but when they eventually become 
edited, an escape from immune control can occur.  
Escape 
The third phase begins as the delicate balance between tumour growth and immune control turns over 
to the former.28 Continuous pressure from the immune system on genetically unstable cells can lead 
to the generation of tumour variants that are no longer recognized by the immune system, have 
become insensitive to the effector mechanisms or induce an immunosuppressive, tolerant 
microenvironment. Tumours that were non-immunogenic from the start will directly go into the 
escape phase. In this phase, regulatory T-cells, myeloid-derived suppressor cells and many other 
immunosuppressive mechanisms play a role.29 The result of the escape phase is the formation of 
clinically detectable, progressively growing tumours.  
In the following paragraphs, the role of the different immune cells of adaptive immunity that play a 
leading role in the (failing) anti-melanoma immune response will be described. This discourse will be 
limited to those cell subsets that are further investigated in this thesis.  
 Antigen presentation: dendritic cells  
Dendritic cells originate from hematopoietic progenitor cells in the bone marrow upon stimulation by 
various soluble factors such as granulocyte/macrophage colony-stimulating factor (GM-CSF), stem cell 
factor (SCF) and IL-3.30 Most DCs develop along the myeloid-lineage pathway that also produces 
macrophages and granulocytes as mature end-products.  
Pathogens are internalized by DCs upon encounter and degraded by enzymes to produce small 
antigenic peptides to be presented to naïve T-cells via major histocompatibility complex (MHC) class I 
and II molecules. This recognition of an MHC-bound antigen on APCs by the T-cell receptor (TCR) 
constitutes the first step of T-cell activation. Secondly a co-stimulatory signal is required, in which CD28 
on the T-cell interacts with CD80 or CD86 (also known as B7-1 and B7-2) on the DC.  Together, these 
two signals will stimulate T-cell proliferation. A third signal, which is either a DC-derived cytokine (IL-
12 and type I IFNs) or CD40 ligation, will drive the polarization of the T-cell into a specific functional 
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subset.31 Before encounter of a pathogen, DCs are immature and reside in the skin as epidermal 
Langerhans cells  or dermal DCs. Immature DCs have a low expression of MHC and co-stimulatory 
molecules, but they are not entirely passive. Immature DC are not only capable of inducing regulatory 
T-cells to preserve tolerance to foreign and self-antigens, they also cause anergy of effector T-cells.32  
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Two important subsets of DCs circulate in the blood: myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). 
Both subsets are competent stimulators of T-cell function and share the lineage (CD3, 14, 15, 19, 20, 
56) negative and MHC class II (HLA-DR) positive phenotype. Myeloid DCs are CD11c+ CD123- and 
require GM-CSF for growth and function, they primarily secrete IL-12 and IL-18. Plasmacytoid DCs are 
CD11c-CD123+, depend on IL-3 for survival in vitro and produce high levels of IFN-α.31, 33 These DC 
subsets have complementary functions, but accumulating evidence indicates that to generate an 
effective anti-tumour immune response, extensive cross-talking between both subsets is required.34, 
35  
 
Figure 2: Movement of dendritic cells and T-cells in the skin.  
Left: antigen presenting cells (APC) that reside in the skin, such as Langerhans' cells and dermal 
dendritic cells, can internalize foreign antigens (such as tumour-associated antigens [TAA] in 
melanoma patients) in the skin and migrate through the afferent lymphatics to the sentinel skin-
draining lymph nodes, where they present the TAA to naïve T-cells. Centre: these naïve T-cells 
continuously screen the lymphoid organs via high endothelial venules (HEV) until their corresponding 
peptide is presented to them in the context of the MHC (blue loop). When a TAA is presented by an 
APC to its specific naïve T-cell, the T-cell will become activated. Right: it will then proliferate and 
acquire “antigen memory” and a distinct set of adhesion molecules that will allow it to navigate outside 
of the blood vessels and the lymphoid organs, to the peripheral tissues and organs (like the melanoma 
metastases) where it will be able to be reactivated upon re-presentation of the same TAA (red loops). 
Adapted from Robert and Kupper, 1999.26 
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Dendritic cells have a central role in anti-tumour immunity. They constitute the crucial link between 
innate and adaptive immunity, and their capacity to induce either immune activation or tolerance 
makes them powerful players in the maintenance of this delicate balance. Consistent with their central 
role, both local and systemic DC dysfunction often occur in cancer. One contributing factor is the 
deficient maturation of immature myeloid cells to mature DCs, a process that will be discussed in the 
chapter on myeloid-derived suppressor cells. Secondly, the migration and function of normal DCs are 
also impaired in the tumour-microenvironment, which is characterized by hypoxia.36 In the hypoxic 
microenvironment, DCs upregulate the transcription factor hypoxia-inducible factor 1 alpha (HIF-1α). 
This ultimately results in increased expression of vascular endothelial growth factor (VEGF) and of the 
pro-inflammatory cytokines IL6 and IL8. However, expression of immunosuppressive mediators such 
as IL-10, transforming growth factor beta2 (TGF-β2) and indoleamine 2,3-dioxygenase (IDO) will also 
be increased. DCs primed by hypoxia can cause increased tumour vascularisation and promote tumour 
growth in mice.37 
The presence of mDCs and pDCs in the tumour microenvironment has been correlated with poor 
clinical outcome. In melanoma patients, circulating DC frequencies have been reported to be 
unchanged in stage I-III,38, 39 and reduced in stage IV.39-41 Similar patterns in circulating DC alterations 
have been described in breast, liver, head and neck and lung cancer.42-45 
 Effector function: cytotoxic T-cells 
After appropriate activation by APCs, antigen-primed T-cells start to proliferate and differentiate. 
When they arrive at the site of immune attack, effector T-cells will exert their function by releasing 
cytokines to mediate local inflammation. The most important cytokine in cytotoxic  T-cell function is 
IFN-γ, which mediates its effects via activation of STAT1 (signal transducer and activator of 
transcription 1).28 Effector T-cells will also secrete cytotoxic granules (containing granzymes and 
perforin) by exocytosis in the vicinity of tumour cell membranes. Granzymes are a family of structurally 
related serine proteases with various substrate specificities and perforin is a membrane-disrupting 
protein, both will induce apoptosis of the target (tumour) cell.46 
However, in the tumour microenvironment, cytotoxic T-cells are often in an immunotolerant state that 
interferes with their cytotoxic function. This results in a reduced IFN-γ and perforin expression.47 
Tumour cells secrete factors (such as Galectin-3) that can induce apoptosis of cytotoxic T-cells.48 
Furthermore, the function of cytotoxic T-cells will also be affected by regulatory cells, as is outlined in 
the paragraphs below. The functional state of tumour-specific T-cells in the peripheral blood and 
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metastatic melanoma tissues has been compared, showing that tumour-infiltrating lymphocytes (TILs) 
expressed lower levels of IFN-γ and perforin than peripheral T-cells, indicating a local state of 
tolerance. However, cytotoxic activity could be restored when these CD8+ TILs were stimulated in 
culture, indicating that the local induction of tolerance can be reversible.47  
Infiltration of a primary melanoma by immune cells is an early event in malignant transformation, and 
several studies in melanoma patients have correlated the quantity, quality and distribution of TILs with 
patient survival.49, 50 Both TILs and CD8+ lymphocytes in the primary melanoma are established positive 
prognostic markers.49, 51 
 Regulatory function: Tregs and MDSCs 
Regulatory T-cells  
Regulatory T-cells (CD3+CD4+CD25+FoxP3+ cells) are naturally present in the immune system, being 
necessary for the maintenance of self-tolerance and immune homeostasis. They are produced in the 
thymus as a functionally mature T-cell subpopulation, but can also be induced in the periphery from 
naïve T-cells under certain conditions, such as antigenic stimulation in the presence of high amounts 
of TGF-β.52 Tregs are characterized by the expression of the transcription factor forkhead box P3 
(FoxP3), a master regulator in their development and function. Treg dysfunction, for example due to 
mutations in the FoxP3 gene, causes fatal autoimmune disease and immunopathology in mice.53 FoxP3 
controls the genes encoding proteins that are necessary for the suppressive function of Tregs. These 
include CD25, glucocorticoid-induced TNF receptor (GITR) and cytotoxic T-lymphocyte antigen-4 
(CTLA-4). Moreover, FoxP3 also inhibits the production of effector cytokines caused by TCR activation, 
such as IL-2 and IFN-γ.54, 55  
Regulatory T-cells can suppress the activation, proliferation and effector function of a wide range of 
cells including CD8+ cytotoxic T-cells and APCs, both in vitro and in vivo, but the exact mechanisms are 
incompletely understood (Fig. 3).56 Several ways by which Tregs can directly suppress effector T-cells 
have been described. One is by inhibiting the transcription of cytokines such as IL-2 in the responder 
cells.57 Several soluble factors (such as IL-10, TGF-β and galectin-1) secreted by Tregs have also been 
postulated to suppress T-cell function, by causing cell cycle arrest and inhibiting the production of pro-
inflammatory cytokines. Galectin-1 could also mediate this effect via direct cell contact.58 Another 
mechanism is by cytolysis of target cells through the perforin/granzyme pathway that is usually 
associated with cytotoxic T-cell function.59 Apart from directly targeting effector T-cells, Tregs can also 
suppress DC function which will then indirectly cause defective effector T-cell function. An important 
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indirect mechanism acts through CTLA-4, which is constitutively expressed by Tregs and will bind to 
CD80/CD86 on DCs. This abrogates the capacity of the DCs to co-stimulate naïve T-cells through CD28.60  
There are several hypotheses regarding why and how Tregs infiltrate in tumours. One putative 
mechanism is that tumour cells and tumour-associated macrophages secrete the C-C motif chemokine 
ligand 22 (CCL22), which chemo-attracts Tregs that express the C-C chemokine receptor 4 (CCR4).61 
After migration from the circulation to the tumour site, Tregs become activated and expand after 
recognizing TAA or self-antigens released from dying tumour cells. Alternatively, tumour cells are 
known to secrete IL-10 and TGF-β, which can induce FoxP3+ Tregs from non-Tregs directly or indirectly 
by inducing tolerogenic DC that subsequently induce Tregs.62, 63 
 
 
 
Figure 3: Migration and action of Tregs.  
FOXP3+ Tregs (purple cells) infiltrate into tumour tissues through chemo-attraction (e.g. via CCR4–
CCL22) and recognize self-antigens -including tumour antigens- present in tumour tissues. 
Proliferated/differentiated Tregs efficiently suppress the activation of tumour antigen-specific effector 
T-cells. Adapted from Nishikawa, 2014.64 
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Evidence for the pathways and mechanisms mentioned above was largely obtained in vitro. The Tregs’ 
central role in suppressing T-cells and APCs has made them an attractive target for therapy, which 
could provide more in vivo evidence for their function in cancer patients in the future. 
The powerful regulatory function of Tregs acts as a double-edged sword; on one hand it is vital to 
prevent auto-immune disease and tolerance in non-pathological conditions such as pregnancy, but on 
the other hand it enables Tregs to suppress anti-tumour immune responses and favour tumour 
progression. Large numbers of Tregs have been found in tumours and tumour-draining lymph nodes 
(TDLN) in patients with different malignancies, correlating with poor prognosis in patients with breast, 
gastric and ovarian cancer.65-67 Treg infiltrations also occur in primary melanomas and sentinel lymph 
nodes. An association with disease progression or vertical growth phase in melanoma has been 
described, but the impact on the patients’ prognosis seems to be limited.68-70  
Myeloid-derived suppressor cells 
Myeloid cells with a suppressive function were first described more than 20 years ago, but their 
importance in the immune system was underestimated until the last decade.71 In healthy individuals, 
immature myeloid cells (IMC) quickly differentiate into mature granulocytes, macrophages and 
dendritic cells. By contrast, in pathological conditions that affect the immune system (such as cancer, 
sepsis, autoimmune disorders,…), a partial block in the differentiation of IMCs occurs, leading to their 
accumulation. When IMCs become activated in pathological conditions, immunosuppressive 
mechanisms are initiated that result in the expansion of an immunosuppressive IMC population that 
is defined as “myeloid-derived suppressor cells” (MDSCs).72 In humans, MDSCs are usually defined as 
CD14-CD11b+ cells that express the common myeloid marker CD33 but lack the expression of markers 
of mature myeloid and lymphoid cells (CD3, CD16, CD19, CD20, and CD56) and of the MHC class II 
molecule HLA-DR. In healthy subjects, IMCs represent +/- 0.5% of peripheral blood mononuclear cells 
(PBMCs) but tenfold higher levels can be found in the circulation of cancer patients.73, 74 Current data 
suggest that these MDSCs are not a defined subset of cells, but rather a phenotypically heterogeneous 
group of myeloid cells that share a common biologic activity. Two subsets have been defined in 
humans; CD14- polymorphonuclear MDSCs (pmnMDSCs) and CD14+ monocytic MDSCs (mMDSCs). In 
some studies, the CD14- MDSCs are further subdivided in promyelocytic MDSC and pmnMDSCs, the 
first being CD15- and the latter CD15+.75 
The consequences of the failed maturation of IMCs to DCs in cancer patients are depicted in figure 4. 
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Figure 4: Tumour-derived factors affect normal dendritic cell differentiation in the bone marrow.  
This abnormal differentiation has at least three main effects: decreased production of mature, 
functionally competent DCs; accumulation of immature DCs (iDCs); and an increased production of 
immature myeloid cells (iMCs). iDCs can process and present antigen in the context of MHC class I 
molecules. However, these cells do not express co-stimulatory molecules or adequate levels of MHC 
class II molecules. Together with the lack of production of cytokines that are required for T-cell 
stimulation, antigen presentation by iDCs might result in the induction of tolerance. iMCs can also 
process and present antigens in the context of MHC class I molecules. They inhibit T cells through 
direct cell-cell contact and the production of reactive oxygen species (ROS), mainly H2O2. Adapted 
from Gabrilovich, 2004.32  
 
The process of MDSC function in cancer patients can be divided in their accumulation and activation. 
Accumulation of MDSCs is caused by cytokines (such as GM-CSF, G-CSF, M-CSF, VEGF, IL-3, TGF-β) 
which promote myelopoiesis and are chiefly tumour-derived. Most of these factors will converge in 
signalling pathways that trigger persistent STAT3 phosphorylation and activation in myeloid progenitor 
cells. STAT3 is argued to be the main transcription factor responsible for MDSC expansion in cancer 
patients.76 Next, activation of MDSCs is initiated by pro-inflammatory factors derived from the tumour 
stroma (such as IL-1β, IL-6, S100-A8 and S100-A9) and cytokines released by activated T-cells (IFN-γ, IL-
4, IL-10 and IL-13). These factors activate several different pathways that involve STAT1, STAT6 and 
NF-kB, ultimately conferring immunosuppressive properties to the MDSCs.77  
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STAT1 is a prototypical pathway that is activated by IFN-γ signalling and will lead to inducible nitric 
oxide synthase (iNOS) expression by MDSCs, one of the mediators of the suppressive function of 
MDSCs.78 Other immunosuppressive MDSC characteristics, such as arginase1 expression, are mediated 
by the STAT6 pathway which is activated by IL4 and IL13.79 iNOS and arginase1 are two different but 
related enzymes that catabolise L-arginine to generate urea and NO respectively, depleting this non-
essential amino-acid from the tumour microenvironment. Thirdly, MDSCs also produce reactive-
oxygen species (ROS). The detailed molecular mechanisms underlying the immunosuppressive effects 
of MDSCs are beyond the scope of this thesis, but have been comprehensively reviewed elsewhere.80  
This two-tiered arrangement that requires both accumulation and activation to generate 
immunosuppressive MDSCs allows for careful regulation of this system. This also explains why in 
certain conditions (such as for example infection) an accumulation of IMCs can be seen that does not 
lead to an immunosuppressive effect. One should note that the available evidence on MDSC function 
and regulation has mostly been obtained in murine tumour models, and might therefore not be fully 
relevant or complete for humans. In human cancer patients, some data on MDSC function and clinical 
significance do exist. Significant increases in circulating MDSC frequencies have been detected in the 
blood of patients with a.o. glioblastoma, breast, colon, lung and kidney cancer. A correlation with 
disease burden and prognosis was described in breast and colon cancer.72, 77  
 
4. Immunotherapy for melanoma 
The immunogenicity of melanoma has inspired the medical community for decades as a possible 
means to fight this aggressive malignancy. One of the first immunotherapies to become a standard in 
melanoma treatment was IFN-α2b. Even though clinical success rates with this compound are modest, 
it is currently the best/only approved adjuvant therapy for disease-free melanoma patients who are at 
a high risk of relapse. Over the last 5 years, a revolution has taken place as immune checkpoints have 
arisen as therapeutic targets in stage IV melanoma patients. The first of these was an anti-CTLA-4 
antibody, but in the near future anti-PD1 antibodies are expected to become standard treatments for 
melanoma too. In the following paragraphs, the theoretical framework supporting the three 
immunotherapies for which clinical data are available will be outlined. 
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 Adjuvant interferon-alpha-2b 
Interferons are classically grouped as type I (IFN-α and IFN-β) and type II (IFN-γ) interferon. The IFN-α 
family is composed of 13 IFN subtypes which all share the IFN-α receptor system and have similar 
biologic activities.81 With over 50 years of research as a foundation, there still is relatively limited 
certainty on the exact mechanism of action of IFN-α as an anti-tumour therapy.82 For a long time, its 
anti-tumour properties were attributed to direct inhibitory effects on tumour cell growth and function. 
These effects do exist, as IFN-α can directly inhibit the proliferation of tumour cells in vitro and in vivo. 
Tumour cells genetically modified to express IFN-α are also more sensitive to apoptosis induced by 
cytotoxic agents.83 However, IFN-α also exerts several effects via host immune cells that can play an 
important role in the anti-tumour immune response. IFN-α enhances proliferation and survival of CD8+ 
T cells in response to antigens.84 It also provides a bridge between innate and adaptive immunity 
through pDCs, which were originally even designated as “naturally IFN-producing cells” based on their 
high IFN production upon microbial challenge.85 Conversely, DCs also respond to IFN-α with increased 
maturation and differentiation.86 Nowadays the anti-tumour mechanism of action of IFN-α is believed 
to be mainly immunomodulatory, but results of previous research to completely elucidate it have been 
inconclusive so far.10, 87 Nevertheless, a systemic immunomodulatory effect can be inferred from the 
observed correlation between clinical response to IFN-α therapy and the occurrence of auto-immune 
phenomena such as vitiligo and circulating auto-antibodies.88  
Interferons, like most cytokines, are produced by the body to act locally. When used as a systemic 
pharmacologic compound, non-negligible side effects can be observed. These include weight and 
appetite loss, fatigue, fever, exacerbation of auto-immune diseases and neurological effects such as 
depression. The combination of considerable side-effects and limited clinical responses has fuelled the 
search for predictive biomarkers to identify those patients who would benefit the most from adjuvant 
IFN-α therapy. Some have suggested that only a subset of patients is sensitive to IFN-α.89, 90 This 
hypothesis is substantiated by the fact that there is no clear association between the outcome of 
treatment with adjuvant IFN-α and dose or duration of the treatment regimen. Currently, ulceration 
of the primary melanoma seems to be a promising predictive biomarker to pre-identify responders. 
However this remains to be validated in (ongoing) prospective trials,12 and the molecular mechanisms 
behind this effect are unknown to date.10 
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 Immune checkpoint inhibitors 
Immune checkpoints and adaptive immune resistance 
The term “immune checkpoint” refers to the abundance of receptor/ligand pairs that have a biologic 
role as regulators of T-cell activation, generally because they provide co-stimulatory signals that are 
required for full T-cell activation in addition to the antigen-specific signal mediated by the T-cell 
receptor (TCR). These pathways are inherent to the immune system and are crucial to maintain self-
tolerance. In addition, they cover the modulation of the duration and magnitude of physiological 
immune responses, which is necessary to minimize collateral tissue damage in peripheral tissues. 
Tumours can make use of immune checkpoint pathways as a mechanism of immune resistance, 
particularly against TAA-specific T-cells. Because many of the immune checkpoints are initiated by 
ligand-receptor interactions, they can be targeted by antibodies. The anti-CTLA-4 antibody was the 
first of this class of immunotherapeutic compounds to achieve approval by the US Food and Drug 
Administration (FDA). Preliminary findings with another checkpoint-inhibitor, programmed cell death 
protein 1 (PD-1), are promising and indicate broad and diverse opportunities to enhance anti-tumour 
immunity with the potential to produce durable clinical responses.91, 92  
Both CTLA-4 and PD-1 depend on the principle of adaptive resistance, which can succinctly be defined 
as the induction of inhibitory ligands in response to immune attack. When the immune system is 
activated, it positions itself for self-regulation by making T-cells susceptible to inhibitory signals that 
will occur later on in the immune response. This homeostatic mechanism is the theoretical basis for 
the two most promising immunotherapies currently available in melanoma, as will be discussed in the 
following paragraphs.   
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) 
CD28 is a widely recognized co-stimulatory molecule that is expressed exclusively on T-cells and binds 
with the ligands B7-1 (CD80) and B7-2 (CD86) on APCs.93 Apart from supporting T-cell activation, 
ligation of CD28 will also induce an upregulation of CTLA-4 expression on the T-cell surface.94 CTLA-4 
shares the ligands CD80 and CD86 with CD28, but has a much higher affinity for them. Ligation of CTLA-
4 with CD80/86 will antagonise early T-cell activation, causing a decreased IL-2 production, inhibition 
of cell-cycle progression and modulation of TCR signalling.95 This inhibitory signal is caused by the 
competition with CD28, resulting in reduced T-cell costimulation. When CTLA-4 binds with CD80 or 
CD86, it can also remove CD80 and CD86 from the APC, resulting in a reduced co-stimulatory capacity.96 
Apart from these cell-extrinsic mechanisms, CTLA4 ligation will also actively deliver inhibitory signals 
to the T-cell. The specific pathways have not been elucidated yet, but the activation of phosphatases 
that counteract the kinase signals induced by TCR and CD28 activation has been proposed.97 CTLA-4 
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signalling will thus down-modulate CD8+ effector T-cells and CD4+ helper T-cells,  but it can also 
enhance regulatory T-cell activity. Tregs constitutively express CTLA-4, since this is a target gene of the 
transcription factor FoxP3 that determines the Treg lineage.98  Exactly how CTLA-4 mediates the 
immunosuppressive function of Tregs is unknown, but Treg-specific knock-out of CTLA-4 abrogates the 
Tregs’ immunosuppressive function.60  
Taken together, the following (simplified) mechanism of action is proposed for CTLA-4 blockade (Fig. 
5): CTLA-4 outcompetes the stimulatory receptor pair CD28/CD80-CD86, thereby inhibiting the 
activation and expansion of naïve T-cells by APCs. Additional inhibition of CTLA-4 on Tregs is probably 
also in part responsible for the effects of CTLA-4 blockade. 
 
 
Figure 5: Proposed mechanism for CTLA-4 blockade.  
After antigen-specific activation of a naïve or memory T-cell in lymphatic tissue (left), CTLA-4 is 
upregulated leading to decreased effector function (middle). CTLA-4 blockade will reconstitute T-cell 
activation via CD28-CD80/86 ligation (right). Adapted from Ott et al., 2013.92 
 
 
The clinical results of CTLA-4 blockade are discussed above. The most remarkable feat of ipilimumab 
is certainly the ability to induce long-term survival in a subset of patients, leading to speculations that 
these patients could be clinically cured.22, 99 The logic behind this is that the immune system, once 
appropriately activated, has the plasticity that is needed to keep a continuously transforming tumour 
under control. This contrasts with targeted drugs, which will sooner or later become subject to 
resistance caused by newly acquired mutations. In this small subset of responding patients, CTLA-4 is 
presumably the dominant inhibitory driver of pre-existing tumour-specific T-cells. The 3-month delay 
that is typically seen before a clinical response to ipilimumab occurs is thought to reflect the time 
needed for these tumour-specific T-cells to become activated, expand and infiltrate into the tumour.92  
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Programmed cell death protein 1 (PD-1) 
Similar to CTLA-4, PD-1 is a cell-surface molecule that is expressed by activated T and B-cells, as well 
as monocytes and DCs. It has two ligands, PD-L1 (also known as B7-H1 or CD274) and PD-L2 (also known 
as B7-H2 or CD273), which have a different expression pattern. In mice, PD-L1 is broadly expressed by 
leukocytes, non-hematopoietic cells and non-lymphoid tissues. In humans, data on PD-L1 expression 
are more limited but indicate expression by activated T-cells, pDCs, mDCs and monocytes. Expression 
is also found in keratinocytes, liver, lung and placental tissues. PD-L2 expression by immune cells is 
limited to DCs and monocytes, both in mice and humans, but it can also be found in human lung and 
placental tissues.100 Signalling through PD-1  limits the function of activated T-cells by reducing 
proliferation and IFN-γ production and increasing T-cell apoptosis.101 Similar to CTLA-4, the exact 
mechanisms remain to be elucidated but have been suggested to imply the inhibition of kinases that 
induce T-cell activation.102 PD-1 is also expressed on Tregs, and binding with its ligand enhances Treg 
development and FoxP3 expression.103 This could implicate that tumour-infiltrating Tregs, known to 
inhibit effector immune responses, are also possible targets for blockade of the anti-PD1 pathway. 
Simply put, the rationale for the current use of PD-1 blocking antibodies in melanoma is the 
observation of a dual expression pattern (Fig. 6). On one hand, PD-1 expression by CD8+ TILs is 
associated with an anergic state and reduced cytokine secretion.104 On the other hand, PD-L1 
expression by melanoma cells has been reported, and ligation with PD-1 can inhibit local anti-tumour 
T-cell responses.105 Blocking either PD-1 or PD-L1 should therefore enhance anti-tumour immune 
effector functions in the tumour microenvironment. 
 
 
Figure 6: Proposed mechanism for PD-1/PD-L1 blockade. 
T-cells become antigen-experienced after adequate stimulation by an APC (left). PD-1 is mainly 
expressed on antigen-experienced memory T cells in peripheral tissues. The immune modulation 
mediated by this pathway ensures protection of the tissue from collateral damage during an 
inflammatory response. Tumour cells can also use this regulatory mechanism to evade a tumour-
directed T-cell response by upregulating the PD-1 ligand B7-H1 (middle). Antibodies directed against 
either PD-1 or B7-H1 will prevent this immunomodulation from taking place (right). Adapted from Ott 
et al., 2013.92 
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How PD-L1 expression by malignant cells arises is not yet completely clear, but two mechanisms could 
play a role. Firstly, the occurrence of an oncogenic mutation could induce PD-L1 expression. This was 
demonstrated in gliomas, where loss of PTEN function lead to an increased PD-L1 expression.106 
Secondly, the principle of adaptive immune resistance also applies to tumour cells. Expression of PD-
L1 can be induced in response to adaptive anti-tumour immunity, such as the presence of IFN-γ.105  
Clinical results with a PD-1 blocking antibody (nivolumab, BMS) are very promising, to the extent that 
a recent randomized controlled phase III trial in melanoma patients (going by the name of Checkmate-
066) was ended prematurely because an improved survival compared to dacarbazine could already be 
demonstrated.107 With nivolumab, the median progression-free survival was 5.1 months, with a 1-year 
survival rate of 72.9%. Objective responses were seen in 40.0% of patients, with an additional 16.7% 
experiencing stable disease.108 Median overall survival was not reached in Checkmate-066, but in 
previous reports the median duration of response was 2 years, in the subgroup of patients with an 
objective response.109 Treatment with nivolumab had an acceptable safety profile, the most common 
adverse events in melanoma patients were fatigue (19.9%), pruritus (17%) and nausea (16.5%).  Grade 
3 to 4 adverse events occurred in 11.7% of patients, but no drug-related deaths were seen in 
melanoma patients.108 Another PD-1 inhibitor (lambrolizumab) is also being tested in early phase 
clinical trials, as well as PD-L1 inhibitors.  
Differences between CTLA-4 and PD-1 blockade 
CTLA-4 and PD-1 have in common that they are both immune checkpoints working by the principle of 
adaptive resistance, but significant differences between them also exist. If their roles were 
overlapping, the absence of either CTLA-4 or PD-1 would not be expected to result in autoimmunity. 
However, mice deficient for either molecule both develop autoimmune phenotypes, but the severity 
and timing is significantly different. CTLA-4-deficient mice develop lymphoproliferative disorders and 
die within 3-4 weeks after birth.110 In contrast, PD-1 deficient mice take several months to develop 
autoimmunity, and the disease is targeted at specific organs depending on the genetic background of 
the mice.111 As outlined above, blockade of these two pathways not only results in different response 
rates, but also in a distinct safety profile. Several theories exist that help to explain the differences 
between the two compounds. 
The major role of PD-1 is to limit the activity of T-cells upon re-presentation of antigens in peripheral 
tissues at the time of an inflammatory response, limiting autoimmunity. In the tumour micro-
environment, this translates into a mechanism of immune resistance.100 In contrast, the physiological 
role of CTLA-4 lies in limiting the initial activation of naïve T-cells in lymphoid tissues (such as the 
tumour-draining lymph node). An important draw-back of anti-CTLA-4 therapy therefore is its lack of 
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specificity; replacement of CD28 by CTLA-4 downregulates T-cell activation within 24 to 48 hours. The 
theory that CTLA-4 blockade could therefore lead to more important, diffuse and non-specific T-cell 
activation is indeed in concordance with the clinically observed immune-related adverse events. PD-1 
blockade acts at a much more local level, in peripheral tissues where an inflammatory response is 
already ongoing. These differences in time and space help to explain (1) why CTLA-4 blockade is 
associated with more severe immune-related adverse events and (2) why PD-1 blockade produces 
more early clinical responses (Fig. 7).92  
 
 
 
Figure 7: Differences between CTLA-4 and PD-1.  
Upper panel (a): CTLA-4 is induced in T-cells at the time of their initial response to antigen. Naive and 
memory T-cells express high levels of cell surface CD28 but do not express CTLA-4 on their surface. 
Instead, CTLA-4 is sequestered in intracellular vesicles. After the TCR is triggered by antigen encounter, 
CTLA-4 is transported to the cell surface. The stronger the stimulation through the TCR (and CD28), the 
greater the amount of CTLA-4 that is deposited on the T-cell surface. Lower panel (b): By contrast, the 
PD-1 pathway will regulate inflammatory responses by effector T-cells recognizing an antigen in 
peripheral tissues. Activated T-cells upregulate PD1 and continue to express it in tissues. Inflammatory 
signals in the tissues induce the expression of PD1 ligands, which downregulate the activity of T-cells 
and thus limit collateral tissue damage in response to inflammation. Excessive induction of PD1 on T-
cells in the setting of chronic antigen exposure can induce an exhausted or anergic state in T-cells. 
Adapted from Pardoll, 2012.91 
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Compared to CTLA-4, PD-1 is more broadly expressed. Both are found on activated T-cells, but PD-1 is 
additionally expressed by other activated non-T-cell populations, such as B-cells and NK cells.112, 113 
Thus, in addition to enhancing the activity of effector T-cells, PD-1 blockade might also enhance NK 
and B-cell activity. In theory, these observations could help explain the greater clinical effect of PD-1 
blockade, as observed in the first clinical trials, compared to CTLA-4 inhibition. 
Even though both of these immunotherapeutic strategies are very promising, combinatorial strategies 
will likely be necessary to increase the proportion of melanoma patients who can benefit from the 
long-lasting clinical responses that appear to be within reach. In this context, both combinations of 
multiple immunotherapies and of immunotherapies with targeted therapies are possible and even 
actively investigated. Even though this subject is beyond the scope of this thesis, it will be touched 
upon in the discussion.  
 
5. Indoleamine 2,3-dioxygenase (IDO)  
 The IDO family and function  
IDO1 is a cytosolic enzyme encoded by the INDO gene located on human chromosome 8p12. The 
principal effect of IDO1 is the catabolism of tryptophan to kynurenine and its downstream metabolites. 
Tryptophan depletion is a mechanism of immunoregulation,  but tryptophan metabolites such as 
kynurenine, kynurenic acid, 3-hydroxy-kynurenine and 3-hydroxy-anthralinic acid can also actively 
suppress T-cell function (Fig. 8). 
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Figure 8: Tryptophan catabolism by IDO or TDO and downstream enzymes.  
Tryptophan can be converted either by IDO or by TDO in the liver. Kynurenine is then converted into 
secondary metabolites.114 
 
Tryptophan is an essential amino acid that is necessary for vital cellular functions and its degradation 
by IDO can cause a tryptophan deficiency. This deficiency can lead to “death by starvation” by inducing 
an accumulation of uncharged tryptophan-tRNA. Uncharged tRNAs (as a proxy for cellular deficiencies 
in amino acids) are sensed by the stress-response kinase general control nonderepressible 2 (GCN2), 
which then prevents T-cell activation. T-cells in which GCN2 is genetically disrupted are not susceptible 
to IDO-mediated proliferation suppression in vivo, and these T-cells are not anergized by IDO-
expressing DCs.115 Apart from the GCN2-pathway, amino acid withdrawal can also affect the nutrient-
sensing mammalian target of rapamycin (mTOR) pathway. In mammalian cells, TOR links nutrition to 
cellular functions. Inhibition of mTOR can be caused by amino acid withdrawal, leading to the 
promotion of Treg differentiation and induction of tolerogenic DCs.116 The mTOR pathway has been 
implicated in IDO-mediated immunosuppression, and is proposed to act independent of GCN2.117 
Another effect of IDO-mediated tryptophan depletion is the production of kynurenine, that can bind 
the aryl hydrocarbon receptor (AhR). The biological effects of AhR activation include inhibition of T-
cell activation, induction of Treg activation and IDO expression by DCs.118-120   
Apart from IDO1 (designated as “IDO” in this thesis), two other enzymes exist that catabolize 
tryptophan along the same pathway; indoleamine 2,3-dioxygenase 2 (IDO2) and tryptophan 
dioxygenase (TDO). IDO2 is encoded by the INDOL1 gene, located just downstream of INDO and is 
structurally very similar to IDO. It is mainly expressed in the kidney, liver and reproductive organs, 
which is a more limited expression pattern than IDO’s. Important genetic polymorphisms exist for 
IDO2, abolishing the enzyme’s function in up to 50% of Caucasians.121 IDO2 can also be expressed by 
DCs, albeit without exerting enzymatic activity.122 Taken together, these data imply that the clinical 
relevance of IDO2 in cancer patients remains debated. TDO (encoded by the gene TDO2) is expressed 
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in high levels in the liver, and was long thought to solely mediate tryptophan homeostasis in the body 
by metabolising dietary tryptophan intake. More recently, TDO expression was also found in human 
tumour cell lines -including melanoma- and was likewise capable of suppressing anti-tumour immune 
responses.123 No TDO expression in host immune cells has been documented so far, so the clinical 
relevance of this enzyme in immunomodulation remains to be clarified.  
 IDO is a mechanism of acquired tolerance 
Acquired tolerance of tumours is undesirable and unfavourable to the host. Then again, acquired 
tolerance for other types of antigens is necessary and often to the host’s advantage. IDO has been 
demonstrated to be a normal endogenous mechanism of acquired peripheral tolerance in vivo, in a 
variety of settings. IDO is expressed in the placenta, which is the site of one of its most compelling 
tolerogenic effects. Pregnant mice treated with the pharmacologic IDO-inhibitor 1-methyl-trypophan 
(1MT) developed T-cell responses against paternal allo-antigens, leading to the rejection of their 
concepti.124 Many other examples of IDO-mediated acquired tolerance exist, such as at mucosal 
interfaces in gastrointestinal and pulmonary tissues.125-127 One of the most telling observations is that 
murine tissue allografts designed to overexpress IDO are not rejected, even in cases with full MHC 
haplotype mismatches, without the need for any additional immunosuppression.128-130 As powerful as 
IDO may be in inducing acquired systemic tolerance to foreign antigens, it does not seem to play a role 
in the constitutive maintenance of tolerance to self-antigens.  This can be deduced from the fact that 
mice genetically modified to lack IDO (IDO-/- mice) do not develop spontaneous autoimmune or 
lymphoproliferative disorders.131 
 IDO expression patterns 
IDO expression and regulation 
Many tumour types express IDO, as discussed below. However, IDO expression can also be found in 
non-tumour tissues such as the placenta, mucosal and lymphoid tissues. Literature reports on IDO 
expression in human tissues have not always been consistent, which can probably be explained by the 
variety of different antibodies, concentrations and detection systems that have been used. IDO 
expression is also context-dependent; constitutive expression is rare, and IDO is upregulated upon 
various inflammatory stimuli.  
In placental tissues, IDO expression is found in CD31-positive endothelial cells at the feto-maternal 
interface.132, 133 IDO is also expressed in normal lymphoid tissues, such as lymph nodes and spleen, 
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predominantly by mature interdigitating dendritic cells.134, 135 Constitutive IDO expression also exists 
in interstitial cells of the duodenum, small bowel and colon and in epithelial cells from the female 
reproductive tract.125, 133, 136 In lung parenchyma, IDO expression was also found in endothelial cells.133 
The functional consequences of these constitutive IDO expression patterns in normal human tissues 
remain debated, and there is no consensus on how it is regulated. Dendritic cells are the most 
extensively studied non-malignant cell type in this context. The promotor of the INDO gene contains 2 
gamma-activated sequences (GAS-2 and GAS-3) and 2 IFN-γ-stimulated response elements (ISRE-1 and 
ISRE-2), which are involved in activating IDO gene expression.137  These are implicated in IFN-γ-induced, 
STAT-1 mediated IDO expression in dendritic cells. Other inflammatory signals known to induce IDO 
expression are amongst others type I IFNs, IL-1, IL-6 and TNF-α. Additional T-cell-derived signals can 
also regulate IDO expression by DCs, including reverse signalling via CD80/86 and CTLA-4 or CD40 and 
CD40L.138 Apart from these mechanisms that induce IDO as part of a negative feedback signal 
accompanying inflammation, immunosuppressive cytokines such as TGF-β have also been reported to 
induce IDO expression.139  
IDO expression in the tumour microenvironment 
Tumour cells can express IDO, as has been demonstrated in many different malignancies including 
melanoma.140, 141 The relevance of IDO expression by tumour cells is illustrated by the correlations that 
have been found with variables such as poor survival, increasing disease stage, presence of metastatic 
disease, decreased tumour-infiltrating lymphocytes and increased FoxP3+ Tregs.142-145 IDO expression 
by tumour cells can be part of genetic changes involved in malignant transformation, through loss of 
Bin1.146 Alternatively, IDO is known to be inducible in tumour cells by stimulation with IFN-γ or other 
inflammatory mediators.147 IDO is also expressed by host cells in the tumour microenvironment. The 
mechanisms that play a role here are thought to be similar to those in the TDLNs, as discussed in the 
next paragraph. 
The tumour-associated IDO expression patterns are summarized in Figure 9.  
IDO expression in the tumour-draining lymph node 
The sentinel lymph node is the key site for immunological interactions between the hosts’ resting naïve 
T-cells and TAAs presented by APCs. This is classically thought to lead to T-cell activation, but it can 
also lead to antigen-specific tolerance induction. The TDLN is therefore crucial in the orientation of the 
anti-tumour immune response.148 IDO is expressed in sentinel lymph nodes, predominantly by host 
cells rather than by metastatic tumour cells.135, 149 It remains to be indisputably proven which cell type 
is responsible for host IDO expression, but plasmacytoid dendritic cells seem plausible.70, 135 The IDO-
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competent subtype of DCs in TDLNs has been shown to suppress T-cell responses and induce antigen-
specific immune tolerance.115, 134 Moreover, the effect of IDO+ DCs is mediated by bystander 
suppression, meaning that IDO+ DCs can suppress T-cell responses to antigens presented by 
neighbouring IDO- DCs.134 This explains how even small populations of IDO+ DCs can have a powerful 
effect in vivo.  
 
 
 
Figure 9: Expression of IDO in host immune cells and tumour cells. 
Antigen-presenting cells (APCs) can be induced to express IDO by tumour cells themselves (via factors 
such as TGF-β) or by Tregs recruited by the tumour (via interactions between B7 molecules on APCs 
and CTLA4 on Tregs). Both host APCs and tumours cells can upregulate IDO expression and lead to: (1) 
local tryptophan depletion that activates the GCN2-kinase pathway; and/or (2) local production of 
bioactive kynurenine pathway compounds, which activate the transcription factor AhR. Both of these 
pathways are capable of driving anergy of effector T-cells and activation of Tregs. Figure adapted from 
Johnson and Munn, 2012.150 
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 Clinical relevance of IDO: impact on prognosis 
The expression of IDO in the tumour microenvironment has been associated with the outcome of many 
different malignancies (Table 1). In most cases, IDO expression conferred a worse prognosis, which is 
compatible with its proposed mechanism of action as outlined in the previous paragraphs. However, a 
seemingly paradoxical positive prognostic effect has also been observed. There are two hypotheses 
that explain this putative contradiction. In the first place, local tryptophan deprivation with inherent 
accumulation of toxic metabolites has been reported to also decrease tumour cell proliferation.147, 151 
Secondly, the most powerful cytokine to induce IDO expression is IFN-γ.151 During an anti-tumour 
immune response, large quantities of pro-inflammatory cytokines (including IFN-γ) are secreted. IDO 
expression could therefore also be a marker of an ongoing immune response, which is beneficial for 
the patient.  
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Table 1: Prognostic data for IDO expression 
Type of cancer Authors Tissue 
Number of 
patients 
Prognosis 
AML 
Fukuno et al., 
2004152 
Leukemic blasts n= 62 Worse prognosis 
 
Chamuleau et al., 
2008153 
Leukemic blasts n = 286 Worse prognosis 
 
Folgiero et al., 
2014154 
Leukemic blasts N=37 
Worse prognosis 
(children) 
Breast cancer 
Specht et al., 
2009155 
Primary tumour n = 70 Better prognosis 
 
Jacquemier et al., 
2012156 
Primary tumour n = 1749 
Better prognosis  (basal-
like breast cancer) 
 Chen et al., 2014157 
Primary tumour 
stroma 
N=202 Worse prognosis 
 
Sakurai et al., 
2013158 
Tryp/Kyn ratio N=32 
Worse prognosis (for 
low Tryp/Kyn ratio) 
 
Soliman et al., 
2013159 
Primary tumour N=203 
Better prognosis (only in 
node-positive patients) 
Cervical 
cancer 
Inaba et al., 2010160 Primary tumour n = 112 Worse prognosis 
Colorectal 
cancer 
Huang et al., 
2002161 
Serum tryptophan n = 66 Worse prognosis 
 
Brandacher et al., 
2006143 
Primary tumour 
 
n = 143 
 
Worse prognosis 
 
 
Gao et al., 2009162 
 
Primary tumour 
Sentinel nodes 
n = 60 
n = 60 
Worse prognosis 
Worse prognosis 
 
Ferdinande et al., 
2012163 
Primary tumour n = 265 Worse prognosis 
DLBCL 
Yoshikawa et al., 
2010164 
L-kynurenine in 
serum 
n = 73 Worse prognosis 
 
Ninomiya et al., 
2011165 
Tumour cells n = 119 Worse prognosis 
Endometrial 
cancer 
Ino  et al., 2006144 Primary tumour n = 80 Worse prognosis 
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De Jong et al., 
2012166 
Primary tumour N=355 Worse prognosis 
Glioma 
Wainwright et al., 
2012167 
Primary tumour N=343 Worse prognosis 
 
Mitsuka et al., 
2013168 
Primary tumour N=68 Worse prognosis 
Hepatocellular 
carcinoma 
Pan et al., 2008169 Primary tumour n = 138 Better prognosis 
 Lin et al., 2013170 Primary tumour N=89 Worse prognosis 
Hodgkin 
lymphoma 
Choe et al., 2014171 
Tumour-associated 
macrophages, DC, 
EC 
N=121 Worse prognosis 
Lung 
Astigiano et al., 
2005172 
Primary tumour n = 25 Worse prognosis 
 
Karanikas et al., 
2007173 
Primary tumour N=28 No impact on prognosis 
Melanoma 
Munn et al., 
2004134 
Sentinel nodes n = 40 Worse prognosis 
 
Weinlich et al., 
2007174 
Trytophan in serum 
n = 87 
 
Worse prognosis (of 
lower tryptophan 
concentration) 
 
Brody et al., 
2009140 
Melanoma 
metastases 
n = 15 Worse prognosis 
 
Speeckaert et al., 
201170 
Sentinel nodes n = 116 Worse prognosis 
 
Chevolet et al., 
2014175 
Primary melanoma 
(ECs) 
N=87 Worse prognosis 
 Ryan et al., 2014176 Sentinel nodes N=56 Worse prognosis 
Non-Hodgkin 
lymphoma 
Liu et al., 2014177 
Tumour (lymph 
node) 
N=57 Worse prognosis 
Osteosarcoma 
Urakawa et al., 
2009178 
Primary tumour n = 139 Worse prognosis 
Ovarian 
cancer 
Okamoto et al., 
2005179 
Primary tumour n = 24 
Worse prognosis  
(serous type) 
 
Takao et al., 
2007180 
Primary tumour n = 122 
Worse prognosis  
(serous type) 
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 Inaba et al., 2009181 Primary tumour N=60 
Worse prognosis  
(all types) 
Renal cell 
carcinoma 
Riesenberg et al., 
2007182 
Primary tumour 
and metastases 
(ECs) 
n = 107 Better prognosis 
 Yuan et al., 2012183 Primary tumour N=40 Better prognosis 
SCC 
(laryngeal) 
Ye et al., 2013184 Primary tumour N=187 Worse prognosis 
SCC 
(esophageal) 
Zhang et al., 
2011185 
Primary tumour N=135 Worse prognosis 
SCC (oral) 
Laimer et al., 
2011186 
Primary tumours n = 88 Worse prognosis 
SCC (vulvar) 
Sznurkowski et al., 
2011187 
Primary tumours  
Lymph node 
metastases 
n = 76 
n = 35 
Worse prognosis 
 
De Jong et al., 
2012188 
Primary tumour N=286 No impact on prognosis 
AML: acute myeloid leukemia, DLBCL: diffuse large cell B-cell lymphoma, SCC: squamous cell 
carcinoma, DC: dendritic cell, EC: endothelial cell 
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 IDO-inhibitors 
In 1991, Cady and Sono reported that 1-methyl tryptophan (1MT) could inhibit IDO activity in rabbits 
by competition with tryptophan.189 In this study, the racemic mixture of 1MT was used (i.e. containing 
both the L-1MT and D-1MT isomers). Later on, in vivo data in various mouse tumour models showed 
that 1MT can induce an immune-mediated delay in tumour development but cannot prevent tumour 
growth.141, 146, 190 Its efficacy does improve when combined with chemotherapy, such as paclitaxel.191 
In 2007, the D-isomer was demonstrated to be a superior anti-cancer agent compared to L-1MT in 
chemo-immunotherapy regimens.191 Remarkably, in the same year Metz and co-workers 
demonstrated that D-1MT selectively inhibits IDO2, whereas L-1MT inhibits IDO1.121 This is important, 
as IDO1 (and not IDO2) has been shown to  mediate tryptophan degradation in tumour cells and 
DCs.122, 192 The observation that D-1MT can even upregulate IDO1 transcription in tumour cells in vitro 
further fuelled the controversy about this compound.193 Several hypotheses have been formulated to 
explain the clinical efficacy of D-1MT, such as an in vivo racemization process leading to the formation 
of L-1MT, a possible underestimation of IDO2 activity in cancer or the modulation of yet unknown 
targets. Supported by the preclinical efficacy data, D-1MT (Indoximod®, Incyte corp.) is currently being 
evaluated in phase II clinical trials for patients with breast and prostate cancer, combined with either 
taxotere or a DC vaccine. No data on the results in humans have been published so far.  
Concerns about the inhibitory effects of D-1MT fuelled the search for pharmacologically superior IDO 
inhibitors. Two IDO inhibitors have entered clinical trials, INCB024360 and the less studied NLG919. 
Some promising preclinical data on both have been reported, albeit all by investigators who have 
reported conflicts of interest with Incyte, the developing corporation.194, 195 Interestingly, INCB024360 
was recently reported to show cross-reactivity with TDO as well.196 This compound is currently being 
tested in a phase II trial for melanoma patients in combination with a peptide vaccine (clinicaltrials.gov 
identifier NCT01961115) as well as in patients with ovarian cancer as a monotherapy before surgery 
(clinicaltrials.gov identifier NCT02042430) or in combination with a peptide vaccine (phase I, 
clinicaltrials.gov identifier NCT02166905). 
The discovery of circulating IDO-specific CD8+ T-cells that could recognize IDO1 and IDO2-positive 
tumour cells as well as IDO1+ DCs, and are associated with pro-inflammatory cytokine profile, has 
paved the way for IDO-based vaccines.197-199 Results of a phase I trial with an IDO-based peptide vaccine 
in patients with non-small cell lung carcinoma showed disease stabilisation without significant 
toxicity.200  
 Chapter 1 | Introduction 
48 
 
As results obtained with the various IDO inhibitors are trickling in, the question arises as to what will 
be the best way to use them. Several large research groups are working on this issue, and they tend to 
have a somewhat different view. The group of Mellor and Munn (who are involved in Incyte) seem to 
hold on to D-1MT apart from the enzyme inhibitors mentioned above, and envisage combinations with 
chemotherapy. Platten’s group (who placed TDO on the map) is screening for small-molecule inhibitors 
of the interaction between kynunerine and AhR, which could theoretically inhibit the downstream 
effects of both IDO and TDO. A Belgian group lead by Van Den Eynde (co-founder of ITEOS, a spin-off 
company also working on an IDO inhibitor) is working on a novel compound that should inhibit both 
IDO and TDO, aiming to use it in combination with a cancer vaccine.201  
Even though research on the possible clinical applications for IDO as a therapeutic target or biomarker 
is moving forward, we are still far from understanding its precise function in the immune system.   
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Addendum I: Verslag van de BADO launch meeting7 
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Aims 
Melanoma is one of the most immunogenic tumours. This is reflected by the recent progress in 
immunotherapeutic strategies. Nonetheless, clinical responses are only obtained in a minority of 
patients.1 The patients’ immune response appears to play an important role in determining response 
rates and survival, but many gaps exist in the existing knowledge on this topic. Our research group was 
previously able to show that expression of IDO in tumour-free sentinel lymph nodes of melanoma 
patients is associated with a worse prognosis, independent of other prognostic markers.2  
The current research project was initiated starting from this striking observation, aiming to broadly 
explore where and when IDO expression occurs in melanoma patients, and what the clinical relevance 
of the expression patterns is. Research on local or systemic factors that skew the immune system into 
an immunosuppressed state may reveal new biomarkers, or identify subsets of patients with a 
different prognostic profile. Furthermore, new therapeutic targets may be found. Our first aim was to 
identify and characterise IDO expression in the primary melanoma. Secondly, circulating immune 
subsets were assessed for their prognostic relevance and IDO expression. Thirdly, we wanted to test if 
IDO expression is altered in patients treated with adjuvant interferon-alpha. 
 
Outlines 
 Evaluation of IDO expression in the primary melanoma 
Starting from our previous observations on IDO in tumour-free sentinel lymph nodes, the question of 
whether IDO is also expressed in primary and metastatic melanoma tissues suggested itself. As IDO 
can be expressed by tumour cells but also by host cells, we carefully assessed both expression patterns 
separately. To gain insight in the immune contexture in which IDO expression is found, FoxP3 (as a 
marker for immunosuppression by Tregs) and CD8 (indicating the presence of cytotoxic T-cells) 
expression were added.  
 
 Identification of possible candidates for immunoprofiling in the blood 
Before examining the presence of immunosuppressive mechanisms in the peripheral blood of 
melanoma patients, we wanted to gain more overview on their systemic immunity. In melanoma, it is 
currently unclear which circulating immune cell types confer the most powerful prognostic 
information. Besides T-cells, myeloid-derived suppressor cells (MDSCs) and dendritic cells (DCs) are 
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the most elaborately studied circulating cell types. However, these have mostly been studied 
separately, making direct comparisons difficult. Hence, we decided to comparatively examine a panel 
of 6 different circulating immune cell types for their clinical relevance.  
 
 Expression of immunosuppressive markers by the identified circulating cell types  
After confirming the clinical importance of the frequencies of circulating DCs and MDSCs in melanoma 
patients, we sought to assess their expression of immunosuppressive markers. For this purpose two 
immune checkpoint molecules were chosen in addition to IDO. Even though IDO, CTLA-4 and PD-L1 
are promising targets for immunotherapy, data on their expression by immune cells in the peripheral 
blood of melanoma patients are lacking.  In this study, we therefore investigated the in vivo expression 
of IDO, PD-L1 and CTLA-4 by immune cells of the lymphoid and myeloid lineage in the peripheral blood 
of stage I to IV melanoma patients. To ascertain the functional relevance of the detected IDO, 
tryptophan metabolism was also measured. 
 
 Presence of systemic negative feedback mechanisms during IFN-α2b immunotherapy 
Finally, we wanted to test whether our previous observations could be relevant in melanoma patients 
who are actively treated with immunotherapy. To this end, IFN-α2b was chosen as this is the 
immunotherapy with which dermatologists have most experience. The mechanism of action of 
adjuvant IFN-α2b in high-risk melanoma patients is believed to be mainly immunomodulatory, but 
results of previous research to elucidate it have been inconclusive so far. The effect of adjuvant 
treatment with IFN-α2b on OS in melanoma patients is modest and currently limited data exist on 
possible predictors of response. Only few studies have focused on alterations in circulating immune 
cells during adjuvant IFN-α2b treatment. We therefore decided to test the relevance of our results in 
IFN-α2b treated melanoma patients. 
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Patients and biobank 
In our dermatology clinic, a specialised consultation for melanoma patients takes place on a weekly 
basis. Patients attending this consultation were invited to take part in this research project. The 
minimum requirement was that a sentinel lymph node procedure had been done. After informed 
consent was given, a blood sample was drawn. Whenever possible, the archival primary melanoma 
and sentinel lymph node were retrieved. Clinical data were acquired from the patients’ medical file 
and registered in an anonymized database.  
 
Protocols 
 Immunohistochemistry 
Immunohistochemistry was performed on archival formalin-fixed paraffin-embedded (FFPE) tissues. 
Four to five µm sections were cut.  For all immunohistochemical stainings, the sections were placed in 
a Dako PT Link (Dako, Heverlee, Belgium) for deparaffinisation and heat-mediated antigen retrieval at 
97°C for 20 minutes. Subsequently, the sections were stained in a DAKO Autostainer device (Dako). 
CD8 (Dako), indoleamine 2,3 dioxygenase (IDO, clone 10.1, Millipore) and Forkhead Box P3 (Foxp3, 
eBioscience, Hatfield, UK) were used as primary antibodies. For all stainings, an incubation time of 30 
minutes was used, except for IDO and Foxp3 which required an incubation time of 1 hour. As Foxp3 
was a biotin-linked antibody, the standard avidin biotin complex (ABC) method was used. All other 
stainings were carried out using the Envision Flex (Dako) substrates. For IDO staining in primary and 
metastatic melanomas, a mouse-linker was added to the protocol (Dako). 
 PBMC isolation 
Venous blood was drawn using 9 mL EDTA tubes. PBMCs were isolated within 4 hours after sample 
procurement. The blood was diluted in RPMI 1640 and layered on top of 15 mL Ficoll-Hypaque (GE 
Healthcare, Uppsala, Sweden). After 30 minutes of centrifugation, the buffy coat containing PBMCs 
was collected. After 3 wash steps with RPMI 1640, the cells were frozen at -80°C in freezing medium 
which consisted of heat-inactivated foetal bovine serum (FBS) supplemented with 10% 
dimethylsulfoxyde (DMSO). Frozen PBMC samples were stored in liquid nitrogen until analysis.  
At the same time, a serum sample was also obtained. These were centrifuged for 10 min, and stored 
at -80°C until analysis.  
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 PBMC culture & stimulation 
PBMCs were cultured overnight in a medium containing Iscove’s Modified Dulbecco’s Medium (IMDM) 
supplemented with 20% FBS and 1% glutamine. PBMCs were also stimulated to induce IDO expression 
by adding either 1000U/ml recombinant human IFN-γ (Imukin, Boehringer Ingelheim) or 5µg/ml 
recombinant human CTLA-4 (R&D Systems) to the same medium for 12h at 37°C in 10% CO2. After 
incubation, adherent and non-adherent cells were collected for flow cytometry.  
 Flow cytometry 
Controls 
Isotype controls were used to assess the staining quality. Fluorescence-minus-one (FMO) controls were 
used to set the gates. The FMO controls contained every colour in the panel except the one being 
controlled for in that sample, with the addition of an isotype for the omitted colour.  
To provide a representative sample, a median amount of 500 000 cells was analysed per cell mix. 
Samples with less than 100 000 cells were excluded to ensure that only samples of adequate quality 
were used for interpretation. 
Antibodies  
The following antibody combinations were used to define the different cell subsets: 
BV421: Brilliant Violet 421, Tcyt: cytotoxic T-cell. 
 Treg  Tcyt  pDC  mDC  mMDSC  pmnMDSC  
CD3 - BV421  +  +      
CD4 - APC-Cy7  +       
CD25 - FITC +       
FoxP3 - PerCP-Cy5.5  +       
CD8 - APC   +      
HLA-DR - PerCP-Cy5.5    +  +  -  -  
Lineage - FITC    -  -  -  -  
CD123 - BV421   +  -    
CD11c - APC   -  +    
CD33 - BV421     +  +  
CD11b - APC-Cy7     +  +  
CD14 - APC     +  -  
CTLA-4 - APC 
IDO - PE 
?      
? ? ? ? ? ? 
PD-L1 - PE-Cy7 ? ? ? ? ? ? 
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The antibodies in the lower part of the table (marked with ‘?’) were used undiluted to allow for mean-
fluorescence intensity (MFI) calculation. Intracellular stainings were added after surface staining of the 
PBMCs. To do so, PBMCs  were fixed and permeabilized with fixation⁄permeabilization solution (BD 
Biosciences), and then stained with antihuman IDO PE (R&D Systems), CTLA-4 APC (BD Biosciences) 
and FoxP3 PerCP-Cy5.5 (eBioscience) antibodies. The gating strategies that were used are illustrated 
in addendum II.  
In some studies, the CD14- MDSCs have been subdivided in promyelocytic MDSC and pmnMDSCs, the 
first being CD15- and the latter CD15+.1 In our own work a CD15 staining could not be included, we will 
use the term pmnMDSC to encompass both.  
 Ultra-performance liquid chromatography (UPLC) 
UPLC-MS/MS (Waters Acquity TQD) was used to quantify tryptophan and its metabolites on stored, 
frozen patient sera. These analyses were done in a collaboration with the Laboratoire de Toxicologie, 
CHU Lille (Lille, France). The following tryptophan metabolites were quantified: kynurenine, kynurenic 
acid, quinaldic acid, 3-OH-kynurenine, 5-OH-tryptophan and 5-HT (serotonin). 
 
References 
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Addendum II: gating strategies 
In the flow cytometry experiments that were performed, up to 8 colours were used to identify specific 
cell populations. Each monoclonal antibody is linked to a different fluorochrome, therefore the 
different cell types can be distinguished from each other by the combination of colours they emit when 
they pass through the laser beam in the flow cytometer.  Gates are set for each fluorochrome, to 
separate positive from negative cells. To quantify the number of cells present in a certain cell 
population, the sample is gated by progressively selecting a more defined subpopulation in a step-wise 
manner. This procedure is known as a “gating strategy”. The gating strategies for the cell types that 
were investigated in this thesis are outlined here. Live cells are selected based upon a live/dead 
staining, this is often the first gate. The forward/side scatter (FSC/SSC) is used to select a population of 
cells based on their size and granularity respectively, thereby also excluding any debris that could be 
present in the sample.  
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 Cytotoxic T-cells 
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 Regulatory T-cells 
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 Dendritic cells 
Gate to exclude debris is not shown.  
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 Myeloid-derived suppressor cells 
Gates to exclude dead cells and debris are not shown.  
 
 Chapter 4 | Results 
92 
 
 
  
 Chapter 4 | Results 
93 
 
 
 
 
 
CHAPTER 4: 
Results 
 Chapter 4 | Results 
94 
 
  
Chapter 4.1 | Peri-tumoral IDO expression in melanoma 
95 
 
 
 
 
PERI-TUMORAL INDOLEAMINE 2,3-DIOXYGENASE 
EXPRESSION IN MELANOMA: AN EARLY MARKER OF 
RESISTANCE TO IMMUNE CONTROL? 
 
Chevolet I, Speeckaert R, Haspeslagh M, Neyns B, Krüse V, Schreuer M, Van Gele M, Van Geel N,  
Brochez L 
British Journal of Dermatology 2014;171(5):987-95 
Chapter 4.1 | Peri-tumoral IDO expression in melanoma 
96 
 
Abstract 
Background: The immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) is an emerging 
immunomodulating factor in cancer. IDO expression in tumor-negative sentinel lymph nodes of 
melanoma patients has a negative prognostic value. 
Objectives: To analyse the IDO-expression pattern and the associated immunological changes in 
corresponding primary melanomas, sentinel lymph nodes and metastases. 
Methods: In a cohort of 120 melanoma patients, primary melanomas with corresponding sentinel 
lymph nodes (n=85) and metastases (n=18) were analysed by immunohistochemical staining for IDO, 
CD8 and FoxP3. Tumor-infiltrating lymphocytes (TILs) were scored. In 27 patients, IDO expression in 
stimulated PBMCs was analysed by flow cytometry.  
Results: IDO expression in the sentinel node strongly correlated with endothelial IDO expression in the 
peritumoral stroma of the corresponding primary (P<0.001) and metastatic melanoma (P=0.048). 
Sentinel IDO-positivity was inversely correlated with CD8+ lymphocytes (P=0.005) and TILs (P=0.047) 
in the primary melanoma. Both IDO expression in the sentinel and the primary melanoma had a 
negative prognostic effect on overall survival (Cox regression analysis, P=0.001 and P=0.035 
respectively), independent of Breslow thickness, gender, age, ulceration and sentinel invasion. IDO 
expression by PBMCs after stimulation with CTLA-4 was not correlated with sentinel IDO expression 
but tended to correlate with disease stage (P=0.044). 
Conclusion: Endothelial IDO expression is highly consistent in the primary, the sentinel and metastatic 
tissues of melanoma patients, indicating that immune suppression in melanoma is determined very 
early in the disease course. These results provide evidence that IDO expression in melanoma is a 
marker of the patients’ antitumor immune response with an independent prognostic value. 
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1. Introduction 
Indoleamine 2, 3-dioxygenase (IDO) is the rate-limiting enzyme in the pathway that catabolises 
tryptophan to kynurenines. It was first discovered for its beneficial inhibitory effect in various 
infectious diseases, based on a reduction of the availability of the essential amino-acid tryptophan in 
the inflammatory environment.1 Later, interest shifted towards the central role that IDO plays in 
immune tolerance.2-4 In recent years, IDO-research has focused on its role in the induction of immune 
resistance in malignant tumours.5, 6 We previously demonstrated an independent negative prognostic 
effect of IDO expression in the sentinel lymph node (SLN) on both relapse free (RFS) and overall survival 
(OS) in patients with stage I and II melanoma. IDO expression in the SLN was also correlated with 
changes in systemic immunity, such as a higher expression of CTLA-4 in circulating regulatory T-cells 
(Tregs).7 IDO has been studied in many human cancer types and its expression by cancer cells has 
commonly been associated with a worse prognosis.8-13 These results however have not been consistent 
and in some cancer types IDO expression has even been associated with improved patient survival.14, 
15  Apart from its expression in malignant cells, IDO has also been found in a variety of normal human 
cells such as antigen presenting cells and endothelial cells.3, 4, 16, 17 This has led to the hypothesis that 
the biological effect of IDO expression depends on the cell type it is expressed in, which could explain 
the inconsistent results reported in literature. Evidence for a possible predictive role of IDO expression 
is also emerging as pre-treatment IDO expression in tumour biopsies has been associated with 
response to anti-CTLA4 immunotherapy in melanoma, and endothelial IDO expression has been 
observed in this context.18, 19 IDO clearly has an important role in melanoma-associated 
immunomodulation, but whether this is exerted mainly by the tumoral cells or by the surrounding host 
cells is still unknown. Therefore in the present study the primary endpoint was firstly to investigate if 
IDO expression in the sentinel lymph node of  melanoma patients is associated with tumoral and peri-
tumoral IDO expression, tumour-infiltrating lymphocytes (TILs) and FoxP3 in the corresponding 
primary tumour. Secondly, the consistency of IDO expression in the primary tumour and the sentinel 
was also analysed. As a consequence of the observations that were made, metastatic tissues of a 
subgroup of patients were also included, and the impact of IDO expression by circulating immune cells 
was assessed. 
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2. Materials and methods 
 
Table 1: database patient characteristics 
Characteristic  
Patient characteristics 
 Number of patients 120 
 Follow-up time (median) 88 months (IQR 47.2-110) 
 Age diagnosis (median) 49.5 years (IQR 35.7-61.2) 
 Gender (%) 62% female - 38% male 
Location of primary melanoma 
 Head & neck 7.5% (9/120) 
 Trunk 31.7% (38/120) 
 Extremities 60.8% (73/120) 
Clinical stage at diagnosis 
 Stage I 45% (54/120) 
 Stage II 30% (36/120) 
 Stage III 25% (30/120) 
Melanoma characteristics 
 Breslow (median) 1.73 (IQR 1,20-2,52) 
 Ulceration (%) 27.1% (32/118) 
 Regression (%) 3.0% (3/101) 
 Sentinel node invasion (%) 22.5% (27/120) 
Evolution during follow-up 
 Disease progression (%) 31.0% (36/116) 
 Melanoma related death (%) 21.2% (25/118) 
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 Patients 
One-hundred-and-twenty melanoma patients who underwent a sentinel lymph node procedure 
were enrolled in this study, with a median follow-up time of 88 months. The SLN was available in 116 
patients, the primary melanoma (PM) was available in 87 patients and both tissues were retrieved in 
85 patients. Detailed patient characteristics of the whole patient cohort (n=120) can be found in 
Table 1, a flow chart of the excluded patients can be found in Figure 1. In 27 additional patients 
venous blood samples were drawn, with a median interval of 33 months (IQR 23-151) after 
progression. In 9 patients one or more corresponding in-transit metastases (n=14) were present, with 
a median delay of 17 months (IQR 12-72 months) after the first melanoma surgery. In 9 other 
patients one or more corresponding stage IV metastases were present (n=15), with a median delay of 
42 months (IQR 11-90 months) after the first melanoma surgery. This study was approved by the 
local medical ethical committee, all included patients signed written informed consent.  
 
 
Figure 1: Flow chart depicting the characteristics and follow-up of the in- and excluded patients for 
each analysis. 
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 Immunohistochemistry 
All samples of PMs, SLNs and metastases were formalin-fixed paraffin-embedded archival tissues. 
Immunohistochemical staining of 4-5 μm sections was performed according to standard avidin-biotin-
peroxidase protocols (Envision Flex+, Dako, Denmark). The signal was visualized by incubation with 3-
amino-9-ethylcarbazole (AEC) substrate (Dako). Sections were counterstained with hematoxylin. For 
antigen retrieval, slides were boiled (97°C) for 20 min (PT Link, Dako). Serial sections were incubated 
with a monoclonal anti-FoxP3 (1/100, eBioscience, San Diego, USA) and a monoclonal anti-IDO 
antibody (clone 10.1, 1/200, Millipore, Billerica, USA) for 1h. For IDO staining of PMs and metastases, 
a mouse linker was added to the protocol (Dako). For staining with CD3 (RTU, Dako), CD8 (RTU, Dako) 
and CD31 (RTU, Dako) antibodies, an incubation time of 30 min was used.  
Tumor-infiltrating lymphocytes (TILs) were scored as “brisk”, “non-brisk” and “absent”.20 CD8 
expression in the PM was scored as “present” or “absent”. IDO expression in SLN and peri-tumoral 
stromal tissue of the primary and metastatic melanoma could be dichotomized as “present” or 
“absent”. Total IDO expression by the melanoma cells in the primary was calculated as the product of 
a proportion score and an intensity score, resulting in a total score ranging from 0 to 9, as previously 
described.8 We defined IDO expression as a total score > 6.5. The percentage of FoxP3 positive cells 
was assessed with ImageJ software. Three hotspots (400x magnification) were photographed and the 
mean percentage of positively stained cells over the total number of counted nuclei was calculated. 
More than 10% and 5% of FoxP3 positive cells was regarded as over-expression in the SLN and the PM, 
respectively. All slides were assessed blinded with regard to the results of other immunostainings and 
clinical patient data.  
 Isolation and stimulation of PBMCs 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized venous blood by 
centrifugation on a Ficoll-Hypaque gradient (GE Healthcare, Uppsala, Sweden) within 4h of 
venepuncture. The PBMCs were cryopreserved in liquid nitrogen in heat-inactivated foetal bovine 
serum (FBS) supplemented with 10% dimethyl sulphoxide (DMSO) until analysis.  
To induce IDO expression, PBMCs were stimulated for 12h at 37°C in 10% CO2 with 1000U/ml human 
recombinant interferon-gamma (R&D systems, Minneapolis, USA) or 5µg/ml recombinant Human 
CTLA-4 (R&D Systems) in a medium containing Iscove’s Modified Dulbecco’s Medium (IMDM) 
supplemented with 20% FBS and 1% glutamine. After incubation, adherent and non-adherent cells 
were collected for flow cytometry.21 
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 Flow cytometry analysis 
Flow cytometry for IDO expression was performed on stimulated PBMCs. For intracellular IDO staining, 
PBMCs were fixed and permeabilized with fixation⁄permeabilization solution (BD Biosciences), and 
then stained with antihuman IDO (ab55305, Abcam, Cambridge, UK) and a secondary goat-anti-mouse 
antibody (Dylight650, Abcam). Live/dead staining was performed using an aqua Dead Cell Stain kit (Life 
Technologies Europe, Ghent, Belgium). Patients with less than 50% living cells were excluded (n=4). 
Cells were analysed on a FACSCanto™ II  flow cytometer (BD Bioscience, Erembodegem, Belgium) using 
FlowJo software (Tree Star Inc, Ashland, OR, USA). 
 Statistical analysis  
All multivariate Cox- and logistic regression analyses were corrected for  sex, age at time of diagnosis, 
Breslow index, ulceration, sentinel invasion and location of the PM. Median values were compared by 
the Mann-Whitney U-test. To compare proportions of categorical variables, Pearson’s Chi² test or 
Fisher’s Exact test were used. All statistical analyses were performed using SPSS 21.0 (SPSS Inc, 
Chicago, IL, USA), a P-value less than 0.05 was considered statistically significant. 
 
3. Results 
 Sentinel IDO expression is strongly correlated with IDO expression in the corresponding 
primary melanoma and metastases. 
In the sentinel lymph nodes (n=116), IDO expression could be found in the cytoplasm of perisinusoidal 
immune cells but was most prominent in CD31+ high endothelial venules (HEV) in the paracortex, in 
30.2% of patients. In the primary melanomas (n=87), 2 distinct IDO expression patterns were 
identified. On one hand, the malignant melanoma cells showed a dusty cytoplasmatic IDO staining in 
a clonal distribution in 30.3% of patients. On the other hand, endothelial cells in the peri-tumoral 
stroma closely surrounding the melanoma showed a paranuclear dot-like IDO positivity in 39.1% of 
patients (Fig. 2). Some IDO positivity in stromal cells could also be observed, but this was not included 
in the further analyses. The 2 different expression patterns (tumoral versus peri-tumoral endothelial) 
were not correlated (P=0.069). For an overview of patient characteristics per IDO expression pattern, 
see Table 2.  
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Figure 2: Immunohistochemical pictures showing presence (arrow) and absence (dotted arrow) of 
expression of indoleamine 2, 3-dioxygenase (IDO) in different melanoma tissues: (a) present and (b) 
absent IDO expression in peri-tumoral endothelium of a primary melanoma, (c) present and (d) absent 
IDO expression in the sentinel node and (e) present and (f) absent IDO expression in peri-tumoral 
endothelium of an in-transit metastasis. 
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Table 2: patient characteristics per IDO expression pattern  
  
Characteristic IDO PM MC 
positive 
IDO PM END 
positive 
IDO SLN  
positive 
TOTAL 
Number of patients 30.3% 
(27/89) 
39.1% 
(34/89) 
30.2% 
(35/116) 
100% 
(n=120) 
Breslow thickness (median – IQR) 1.40 
(1.12-2.00) 
1.54 
(1.15-2.10) 
1.82  
(1.13-2.54) 
1.73  
(1.20-2.52) 
Evolution during follow-up  
 Melanoma related death 22.2%  
(6/27) 
14.7%  
(5/34) 
26.5%  
(9/35) 
21.2% 
(25/118) 
 New stage IV metastases 26.9%  
(7/26) 
21.2%  
(7/34) 
35.3% 
(12/34) 
31.0% 
(36/116) 
 New in-transit metastases 4.8%  
(1/21) 
10.7%  
(3/34) 
10.3% 
(3/29) 
11.3% 
(11/97) 
Clinical stage at diagnosis  
 Stage I 59.3% 
(16/27) 
55.9% 
(19/34) 
42.9% 
(15/35) 
45%  
(54/120) 
 Stage II 18.5%  
(5/27) 
29.4% 
(10/34) 
42.9% 
(15/35) 
30%  
(36/120) 
 Stage III 22.2%  
(6/27) 
14.5%  
(5/34) 
14.3%  
(5/35) 
25%  
(30/120) 
Tumor-infiltrating lymphocytes 
 Absent 42.3% 
(11/26) 
53.1% 
(17/34) 
68%  
(17/25) 
46.6% 
(41/88) 
 Non-brisk 57.7% 
(15/26) 
40.6% 
(13/34) 
28%  
(7/25) 
47.7% 
(42/88) 
 Brisk 0% 
(0/26) 
6.3%  
(2/34) 
4%  
(1/25) 
5.7%  
(5/88) 
PM immune infiltrate 
 FoxP3 (median – IQR) 3.11% 
(1.29-9.09) 
1.83%  
(0-4.52) 
1.74%  
(0-3.89) 
2.19%  
(0-5.15) 
 CD4 44.4% 
(12/27) 
34.4% 
(11/34) 
32%  
(8/25) 
39.1% 
(34/87) 
 CD8 88.9% 
(24/27) 
78.8% 
(26/34) 
74% 
(20/27) 
85.6% 
(77/90) 
SLN FoxP3 positivity (median – IQR) 7.69%  
(5.18-12.36) 
7.40%  
(5.03-10.81) 
8.19% 
(6.11-13.23) 
7.60% 
(5.30-11.47) 
IDO, indoleamine 2,3-dioxygenase; PM, primary melanoma; MC, melanoma cells; END,peri-tumoral 
endothelium; SLN, sentinel lymph node; IQR, interquartile range.  
 
 
 
Chapter 4.1 | Peri-tumoral IDO expression in melanoma 
104 
 
Peri-tumoral endothelial IDO expression in the PM was strongly correlated with IDO positivity in the 
SLN (n=85, P<0.001). In patients without peri-tumoral IDO expression in the PM, the corresponding 
SLN was also IDO-negative in 92.3%. In patients with peri-tumoral IDO expression, the corresponding 
SLN was also IDO-positive in 66.7%. This correlation was confirmed by multivariate logistic regression 
analysis (P<0.001, Fig. 2). There was no correlation between IDO expression in the melanoma cells and 
in the sentinel (P=0.516). 
Similar to PMs, in-transit metastases (n=9) also showed these two distinct expression patterns 
(tumoral and peri-tumoral endothelial) of IDO positivity (Fig. 2). In 9 patients with in-transit 
metastases, endothelial IDO-positivity in the peri-tumoral stroma of the metastasis showed a trend 
towards correlation with prior IDO expression in the SLN (P=0.048). In 8/9 patients, there was complete 
accordance of peri-tumoral endothelial IDO expression in the 3 tissues (PM, SLN and metastasis). Peri-
tumoral IDO expression was consistent in metachronous metastases per patient (Table 3). In 9 other 
patients with distant metastases, endothelial IDO positivity could also be distinguished from its 
expression in other (both malignant and inflammatory) cell types. In 8/9 patients, IDO expression in 
the SLN and in the peri-tumoral endothelium of the metastasis were congruent  (P=0.083, Table 3). 
Although this sample is too small to reach a solid conclusion, prior treatment with DTIC or interferon-
alpha did not seem to alter IDO expression (Table 3). 
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Table 3: IDO expression in metastases 
 Case 
n° 
IDO 
SLN 
IDO 
PM 
Tissue type 
META 1 
IDO 
META 1 
Tissue type 
META 2 
IDO 
META 2 
Tissue type 
META 3 
IDO 
META 3 
IN
 T
R
A
N
SI
T 
M
ET
A
ST
A
SE
S 
1. ? - In-transit *,° -     
2. + + In-transit +     
3. - - In-transit +     
4. - ? In-transit * -     
5. - ? In-transit -     
6. - ? In-transit * - In-transit * -   
7. - - In-transit - In-transit -   
8. + + In-transit + In-transit + In-transit + 
9. + ? Lymph node + In-transit +   
ST
A
G
E 
IV
 M
ET
A
ST
A
SE
S 
10. + + Peritoneal ° +     
11. + + Liver * -     
12. - - Lung -     
13. - - Lymph node * -     
14. + + Lymph node + Lung * +   
15. - - Lymph node - Subcutaneous -   
16. - - Lung * - Colon * -   
17. - - Lung * - Gastric *,° -   
18. - - Subcutaneous * - Lung * - Colon *,° - 
IDO, indoleamine 2,3-dioxygenase; SLN, sentinel lymph node; PM, primary melanoma; META, 
metastatic melanoma.”?”, tissue not available. * indicates patient was treated with adjuvant 
interferon before the metastasis was removed. ° indicates patient was treated with DTIC before 
metastasis was removed.  
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 Endothelial IDO expression is prognostic both in the PM and the SLN 
We have previously reported the independent negative prognostic effect of IDO expression in the 
tumor-negative SLN. In the present study, with a longer follow-up time (median 88 months), this 
prognostic effect on both RFS (P=0.006, HR 3.75) and OS (P=0.001, HR 6.40) was confirmed (Fig. 3).7 
The impact on OS was present in both invaded (P=0.012, HR 20.13) and non-invaded SLNs (P=0.015, 
HR 6.80). Endothelial IDO expression in the PM also had an independent negative prognostic effect on 
OS (P=0.035, HR 5.65, Fig. 3) but not on RFS (P=0.177). This prognostic effect on OS was strongest in 
patients without TILs (P=0.018).  
 
 
 
Figure 3: Kaplan Meier plots for melanoma-specific survival according to (a) IDO expression in the peri-
tumoral endothelial cells of the primary melanoma and (b) IDO expression in the sentinel lymph node 
of melanoma patients. 
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 Sentinel IDO expression is related to the immune micro-environment in the primary 
melanoma 
Both TILs and CD8+ T-lymphocytes are established prognostic immunological markers in primary 
melanomas.20, 22 A CD8+ infiltrate was present in 51.7% of PMs. TILs were absent in 46.6%, non-brisk 
in 47.7% and brisk in 5.7% of patients. TILs were dichotomized into present/absent for subsequent 
analyses. The independent prognostic effect of both CD8+ lymphocytes infiltrating or close to the PM 
(P=0.003) and of the presence of TILs (P=0.047) was confirmed in our dataset (Fig. 4). Strikingly, the 
presence of TILs and mainly CD8+ lymphocytes in the PM was inversely related to IDO expression in 
the SLN (P=0.017 and P=0.003, Fig. 5). These observations were confirmed in multivariate logistic 
regression analysis (P=0.004; OR 0.188 and P=0.003; OR 0.048).  
 
 
Figure 4: Kaplan Meier plots for melanoma-specific survival according to the presence or absence of 
CD8+ lymphocytes in the primary melanoma. 
 
Tregs are highly immunosuppressive cells known to be induced by IDO. Overexpression of the Treg 
marker FoxP3 was present in 26.3% of PMs and in 29.1% of SLNs. The percentage of FoxP3 positive 
cells was lower in tumor-negative  SLNs (P=0.002) and a positive association with IDO expression was 
found in patients with uninvolved sentinels (P=0.029). IDO expression by the melanoma cells showed 
a trend towards correlation with a local rise in FoxP3 expression (P=0.054).  
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Figure 5: The frequency of IDO expression in the sentinel is shown, according to the presence or 
absence of CD8+ lymphocytes in the primary melanoma. Error bars indicate 95% confidence intervals. 
 
 IDO expression by circulating lymphocytes tends to correlate with disease stage 
Upon stimulation with either IFN-γ or CTLA-4, PBMCs (n=23) expressed variable levels of IDO. The mean 
fluorescence intensity (MFI) for IDO expression was higher after CTLA-4 stimulation. The MFI for IDO 
after CTLA-4 stimulation tended to be higher in increased disease stage (P=0.044) and in patients with 
in-transit metastases (P=0.012) (Fig. 6). There was also a tendency to a higher MFI for IDO in patients 
progressing after diagnosis (P=0.051). IDO expression after stimulation with IFN-γ did not correlate 
with clinical variables. IDO expression in PBMCs and IDO expression of the SLN or the PM did not 
correlate. 
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Figure 6: Box-and-whisker plots showing the 
mean fluorescence intensity (MFI) for IDO in 
peripheral blood mononuclear cells of 
melanoma patients after stimulation with 
CTLA-4 according to:  
(A) the presence of  in-transit metastases, (B) 
clinical stage at last consultation and  
(C) progression after the first melanoma 
diagnosis. 
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4. Discussion 
Melanoma is known to be a highly immunogenic tumor. In the primary melanoma, this is illustrated by 
the positive prognostic value of both TILs and CD8+ lymphocytes.20, 22, 23 However, the initial anti-
tumoral immune response is often skewed towards immunosuppression, causing T-cell anergy and an 
accumulation of Tregs. High expression of FoxP3 in primary melanomas has been  associated with a 
worse prognosis.24 The immunosuppressive enzyme IDO plays a central role in this process, as it can 
potently suppress antitumoral immune responses when it is expressed by host immune cells.6, 16, 17 The 
functional consequences of IDO expression by dendritic cells include both the inhibition of effector T-
cell proliferation and the induction of differentiation of FoxP3+ regulatory T-cells in vitro.16, 17, 25 The 
role of IDO as a mechanism of immune escape in cancer has been explored over the last years, with 
increasing reports on its prognostic properties and even as a possible target for future therapies.6, 7, 19, 
26, 27 Mainly IDO expression by host cells seems to be crucial for the induction of systemic tumor 
tolerance, a topic that was recently thoroughly reviewed by Johnson and Munn.6 To date, early 
markers to pre-identify patients with a failing anti-tumor immune response are lacking. In this study, 
we investigated the pattern of IDO expression in different stages of melanoma, and its impact on 
prognosis. 
We report a strong and independent correlation between peri-tumoral IDO expression in the primary 
tumor and the corresponding sentinel lymph node. IDO expression even seems to persists in metastatic 
tissues that occurred with a median delay of 41.5 months after the first melanoma surgery. Both IDO 
expression by HEVs in the sentinel and by peri-tumoral endothelial cells in the primary melanoma had 
an independent negative prognostic effect on overall survival. This effect is independent of the vicinity 
of tumor cells, as it was equally strong in patients with tumor-negative and tumor-invaded SLNs. 
Moreover, in our patient population IDO expression by melanoma cells failed to show an effect on 
progression-free or overall survival. Hence, we hypothesize that IDO expression by the malignant 
melanoma cells and IDO expression by the host endothelial cells can have different biologic effects. 
Bearing in mind that IDO modulates complex immune responses also in non-tumor bearing hosts, it is 
expected that IDO expression produces different effects depending on timing and site. Our data 
suggest that endothelial IDO expression could be a valuable marker in melanoma, as its expression is 
not only prognostic but also consistent throughout different tumor stages. The prognostic effect of 
IDO is most likely immune-mediated, as there is a correlation with local and systemic regulatory T-cells 
and an inverse correlation with a cytotoxic TIL response in the primary tumor.7 These observations 
could also explain the sometimes conflicting results on the prognostic effect of IDO published  in 
literature.8-15  
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Indoleamine 2,3-dioxygenase activity has been most extensively studied in dendritic cells, but there is 
also evidence that IDO expression by endothelial cells can play an important role in immune regulation. 
The importance of endothelial IDO has been demonstrated by experiments in mice, where IDO-
expression by endothelial cells could prevent the rejection of cardiac allografts.3, 4 Moreover, IDO 
expression in monocyte-derived endothelial-like cells has also been described in infantile 
haemangioma.28 In renal cell cancer, IDO expression in tumor-associated endothelial cells was found 
to have a positive prognostic effect, but this concerned mainly intra- and not peri-tumoral vessels and 
the prognostic results were based on qRT-PCR, and not on immunohistochemistry.14 A recent clinical 
study also demonstrated that IDO expression, partly by endothelial cells, could be a predictor for 
response in melanoma patients treated with anti-CTLA-4 therapy.19 Based on all the above results, 
endothelial IDO could be used to pre-identify stage I to III melanoma patients with more aggressive 
disease, caused by a skewed immune response. The clinical relevance of IDO expression in melanoma 
is further supported by the observed increase in IDO expression by PBMCs in patients with higher 
disease stage, after stimulation with CTLA-4.  
Both TILs and CD8+ lymphocytes in the primary melanoma are established prognostic markers.20, 22 In 
patients with a CD8+ infiltrate in their primary melanoma, we detected a decreased IDO-positivity in 
the sentinel lymph node. This suggests that an initial cytotoxic response in the primary tumor can 
prevent future immune suppression. These results are in line with previous studies that have 
associated IDO expression with increased FoxP3 expression and decreased (CD8+) TILs in other tumor 
types.8, 9, 12, 29 Different results have been described in melanoma metastases, where the combined 
expression of markers for active immune response (CD8) and multiple immunosuppressive 
mechanisms (IDO, FoxP3 and PD-L1) has been reported. These immunosuppressive mechanisms act as 
a negative feedback mechanism to T-cell infiltration and hence immune activation.30, 31 As IDO is known 
to be induced by IFN-γ and IDO-negative tumor cells have been reported to start expressing IDO when 
exposed to an inflammatory  immune environment, the combined expression of CD8, FoxP3, IDO and 
PD-L1 in a metastatic tumor is not surprising.32 
In the current era of immunotherapy for melanoma, the immune micro-environment has been of 
increasing interest to researchers looking for markers to predict or interfere with the susceptibility of 
patients for different immunotherapeutic strategies.18, 30, 33 The response to immunotherapy might be 
increased by reversing mechanisms of immune resistance. In a mouse melanoma model, the addition 
of an IDO inhibitor to anti-CTLA-4 therapy significantly increased responses when compared to anti-
CTLA-4 therapy alone.27 Our data suggest that susceptibility to immunotherapy might be determined 
right from the first diagnosis of melanoma and long before metastatic disease occurs. This could open 
the possibility to use the patient’s primary tumor or sentinel lymph node to evaluate his immunological 
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susceptibility. Predictive immunoprofiling may not only provide therapeutic strategies to stimulate the 
immune response, but possibly even to have a preventive impact on the development of metastatic 
disease. The latter is supported by experiments where IDO inhibition by means of skin administration 
of IDO short hairpinRNA not only delayed tumor growth in a subcutaneous hepatoma model in mice, 
but also suppressed tumor growth in distant metastases.34 
In conclusion, in contrast to tumoral IDO expression, peri-tumoral IDO expression in melanoma is not 
only prognostic, but also consistent over time in different disease stages of the patient and related to 
the immune response at the primary tumor. Further studies are needed to establish if IDO can be part 
of prognostic and predictive immunoprofiling efforts in melanoma clinical practice.  
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Abstract 
Background: Immune markers in the peripheral blood of melanoma patients could provide prognostic  
information. However, there is currently no consensus on which circulating cell types have more 
clinical impact. We therefore evaluated myeloid-derived suppressor cells (MDSC), dendritic cells (DC), 
cytotoxic T-cells and regulatory T-cells (Treg) in a series of blood samples of melanoma patients in 
different stages of disease. 
Methods: Flow cytometry was performed on peripheral blood mononuclear cells of 69 stage I to IV 
melanoma patients with a median follow-up of 39 months after diagnosis to measure the percentage 
of monocytic MDSCs (mMDSCs), polymorphonuclear MDSCs (pmnMDSCs), myeloid DCs (mDCs), 
plasmacytoid DCs (pDCs), cytotoxic T-cells and Tregs. We also assessed the expression of PD-L1 and 
CTLA-4 in cytotoxic T-cells and Tregs respectively. The impact of cell frequencies on prognosis was 
tested with multivariate Cox regression modelling. 
Results: Circulating pDC levels were decreased in patients with advanced (P=0.001) or active (P=0.002) 
disease. Low pDC levels conferred an independent negative impact on overall (P=0.025) and 
progression-free survival (P=0.036). Even before relapse, a decrease in pDC levels was observed 
(P=0.002, correlation coefficient 0.898). High levels of circulating MDSCs (>4.13%) have an 
independent negative prognostic impact on OS (P=0.012). High MDSC levels were associated with 
decreased CD3+ (P<0.001) and CD3+CD8+ (P=0.017) T-cell levels. Conversely, patients with high MDSC 
levels had more PD-L1+ T-cells (P=0.033) and more CTLA-4 expression by Tregs (P=0.003). pDCs and 
MDSCs were inversely correlated (P=0.004). The impact of pDC levels on prognosis and prediction of 
the presence of systemic disease was stronger than that of MDSC levels. 
Conclusion: We demonstrated that circulating pDC and MDSC levels are inversely correlated but have 
an independent prognostic value in melanoma patients. These cell types represent a single 
immunologic system and should be evaluated together. Both are key players in the immunological 
climate in melanoma patients, as they are correlated with cytotoxic and regulatory T-cells. Circulating 
pDC and MDSC levels should be considered in future immunoprofiling efforts as they could impact 
disease management.  
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1. Introduction 
Melanoma is a highly immunogenic tumour that is capable of successfully evading the patients’ 
immune response. Evidence for an anti-tumoral immune reaction, as well as concomitant 
immunosuppressive mechanisms, can already be observed in the primary tumour and in tumour-free 
sentinel lymph nodes.1, 2 The possibility to integrate immune markers in the existing TNM-classification 
is currently being investigated in melanoma. The primary objective is to increase prognostic accuracy 
but it could also become a strategy to pre-select patients for adjuvant therapies.3 Immunoprofiling 
initiatives such as the “Immunoscore” focus on markers in the primary and metastatic tumour site, 
mainly assessed by immunohistochemistry 4. However, options to evaluate the immune status in a 
tumour-free patient during clinical follow-up are currently lacking. In this context, circulating 
biomarkers could be a practical approach. 
In melanoma, it is currently unclear which circulating immune cell types confer the most powerful 
prognostic information. Besides T-cells, myeloid-derived suppressor cells (MDSCs) and dendritic cells 
(DCs) are the most elaborately studied circulating cell types, but research is often focused on the 
tumour microenvironment.  
MDSCs are HLA-DR- lineage- CD33+ CD11b+ cells that do not constitute a defined subset of cells but 
rather a group of phenotypically heterogeneous myeloid cells that have a common biological activity.5 
Two clinically relevant subsets have been defined, monocytic (CD14+) and polymorphonuclear (CD14-
CD15+) MDSCs (resp. mMDSCs and pmnMDSCs). An expanding body of evidence shows increased 
levels of MDSCs in almost all cancer types, correlating with advanced clinical cancer stage and a worse 
prognosis.6, 7 Myeloid differentiation is often disturbed in cancer patients, leading to an accumulation 
of immunosuppressive immature myeloid cells such as MDSCs and reduced frequencies of mature, 
immunostimulatory dendritic cells (DCs).8, 9 Tumour-derived factors are thought to inhibit the natural 
differentiation of immature myeloid cells, resulting in the accumulation of MDSCs.5 This concomitant 
increase in MDSCs and decrease in mature DCs in the peripheral blood has been described in several 
cancer types.10 High MDSC frequencies in the peripheral blood of melanoma patients have also been 
reported to have a negative impact on prognosis, but their relation to dendritic cells or lymphocytes is 
not well documented.  
DCs are potent antigen-presenting cells that play a central role in developing anti-tumour immune 
responses.  Two subsets of DCs have been defined in the blood and in lymphoid tissues, myeloid 
(CD11c+) and plasmacytoid (CD123+ CD11c-) DCs (resp. mDCs and pDCs) 9, 11. Additional surface 
markers for blood DCs exist; BDCA-1 and -3 define two distinct subsets of mDCs and that BDCA-2 and 
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BDCA-4 are present on pDCs. Many other surface markers further characterize these cells, as recently 
reviewed elsewhere 11, 12. The differentiation capacity of DCs is diminished in many cancers, resulting 
in lower frequencies of circulating mature DCs in patients with higher tumour stages or active disease 
9, 13, 14. In melanoma, circulating DC frequencies have been reported to be unchanged in stage I-III 
patients 13, 14, and reduced in stage IV 14-16. Similar patterns in DC alterations have been described in 
breast, liver, head and neck and lung cancer 10, 17-19. However, data on circulating DCs frequencies in 
untreated melanoma patients are limited and their prognostic relevance is unknown. The in vivo 
clinical relevance of these circulating subsets in melanoma therefore remains subject to debate 8. 
Despite evidence that lymphoid cell types such as cytotoxic and regulatory T-cells are important in 
melanoma and are modulated by current immunotherapeutic strategies,20 many recent studies on 
circulating cell types in melanoma have focused on MDSCs alone and have left their relation to 
lymphoid cell types largely unexplored. The presence of regulatory T-cells (Tregs) in the melanoma 
tumour microenvironment confers a negative prognosis.21 However, the prognostic relevance of 
circulating Tregs in untreated melanoma patients is unclear. Cytotoxic T-cells are powerful allies in the 
anti-tumoral immune response and their presence in the melanoma micro-environment is protective,1 
but data on circulating cell frequencies in untreated patients are scarce. 
Even in stage I and II melanoma a shift in systemic immune activity can be present and these systemic 
immune alterations have been reported to increase as patients develop metastatic disease. Many 
different cell types have separately been described in this context, but there is no consensus on which 
alterations have the predominant immunosuppressive effect. We therefore performed a comparative 
evaluation of the presence of different circulating immune subsets in untreated melanoma patients in 
different stages of disease, with a focus on DCs and MDSCs. The clinical relevance of circulating DC and 
MDSC subsets and their relation with regulatory and cytotoxic T-cells was assessed.  
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2. Methods 
 Patients  
Sixty-nine patients with melanoma were included in this study, with a median follow-up time of 39 
months after diagnosis and of 15 months after inclusion (inclusion was defined as the time of sample 
procurement).  Venous blood samples were drawn during clinical follow-up, with a median interval of 
21 months after diagnosis. Disease staging was done according to the 2009 American Joint Committee 
on Cancer system (AJCC). Local disease was defined as AJCC stage I and II, regional disease as AJCC 
stage III and systemic disease as AJCC stage IV. The local medical ethical committee approved this 
study; all included patients gave written informed consent. Detailed patient characteristics can be 
found in Table 1.  
Table 1: Patient characteristics 
Number of patients, n 69 
Follow-up time since inclusion, months 
(median - IQR) 
15 (6 - 35) 
Follow-up time since diagnosis, months 
(median - IQR) 
39 (20.5-108) 
Age at diagnosis, years (median - IQR) 53 (41.5 - 60) 
Female sex, % (n) 53.6 (37/69) 
Stage at inclusion, % (n)  
Local (AJCC stage I & II) 46.4 (32/69) 
Regional (AJCC stage III) 37.7 (26/69) 
Systemic (AJCC stage IV) 15.9 (11/69) 
Active disease at inclusion 20.3 (14/69) 
(3 stage III, 11 stage IV) 
Melanoma characteristics 
Breslow (median, IQR) 1.60 (1.08 - 2.60) 
Ulceration, % (n) 35.7 (20/56) 
Sentinel invasion, % (n) 27.1 (16/59) 
Location of primary melanoma 
Head & neck, % (n) 10.6 (7/69) 
Trunk, % (n) 39.4 (26/69) 
Extremities, % (n) 50 (33/69) 
Unknown primary 3 (3/69) 
IQR, interquartile range; AJCC, American Joint Committee on Cancer 
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 PBMC isolation  
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized venous blood by 
centrifugation on a Ficoll-Hypaque gradient (GE Healthcare, Uppsala, Sweden) within 4h of 
venepuncture. The PBMCs were cryopreserved in liquid nitrogen in heat-inactivated foetal bovine 
serum (FBS) supplemented with 10% dimethyl sulphoxide (DMSO) until analysis. Cells were thawed by 
submersion at 37° for 1-2 minutes and resuspended in a medium containing Iscove’s Modified 
Dulbecco’s Medium (IMDM) supplemented with 20% FBS and 1% glutamine.  
 Flow cytometry 
MDSCs were characterized by the HLA-DR- lineage- (CD3, CD19, CD56) CD33+ CD11b+ phenotype, 
mMDSCs are CD14+, pmnMDSCs are CD14-. Dendritic cells were characterized by the HLA-DR+ lineage- 
(CD3, CD14, CD16, CD19, CD20, and CD56) phenotype, pDCs are CD123+ CD11c- and mDCs are CD123- 
CD11c+. Tregs were defined as CD3+ CD4+ CD25+ FoxP3+ and cytotoxic T-cells as CD3+ CD8+ cells. All 
antibodies used in this study were fluorescently conjugated mouse anti-human monoclonal antibodies. 
The following antibodies were purchased from BD Biosciences; CD3 BV421 (563797), CD4 APC-Cy7 
(561839), CD25 FITC (560990), CD33 BV421 (562854), CD11b APC-Cy7 (560914), CD123 BV421 
(562517). The following antibodies were purchased from eBioscience; B7-H1 (PD-L1) PE-Cy7 (25-5983-
42), CD8 APC (9017-0087-025), CD3 FITC (11-0038-41), CD19 FITC (11-0199-41), CD56 FITC (11-0569-
41), CD14 APC (17-0149-41), CD11c APC (17-0116-41), HLA-DR PerCP-Cy5.5 (45-9956-42). For 
intracellular stainings, after surface staining PBMCs were fixed and permeabilized using Live/dead® 
fixable aqua dead cell stain (BD Biosciences), and then stained with antihuman CTLA-4 APC (BD 
Biosciences, 560938) and FoxP3 PerCP-Cy5.5 (eBioscience, 45-4776-42) antibodies. Live/dead staining 
was performed using an aqua Dead Cell Stain kit (Life Technologies Europe, Ghent, Belgium). Patients 
with less than 75% living cells were excluded (n=4). Cells were analyzed on a FACS Canto™ II  flow 
cytometer (BD Bioscience, Erembodegem, Belgium) using FlowJo software (Tree Star Inc, Ashland, OR, 
USA). For setting the gates, isotype and fluorescence-minus-one (FMO) controls were used. To provide 
a representative sample a median amount of 500000 cells were analysed (min 261000 – max 569750). 
Absolute cell counts were corrected for the number of acquired events during flow cytometry. Samples 
with less than 100000 cells were excluded (n=1). 
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 Statistical analysis 
Median values between 2 groups were compared by the Mann-Whitney U-test, between >2 groups 
with Kruskall-Wallis testing. To compare proportions of categorical variables, the Pearson’s Chi² test 
or Fisher’s Exact test were used. To evaluate correlations, Spearman correlation coefficients (CC) were 
calculated. To assess the prognostic relevance of continuous variables, ROC curve analysis was used to 
dichotomize them with the aid of the online tool “cut-off finder”.22 All statistical analyses were 
performed using SPSS 21.0 (SPSS Inc, Chicago, IL, USA), a P-value (double-sided) less than 0.05 was 
considered statistically significant. 
 
3. Results 
Flow cytometry was performed to quantify MDSC and DC subsets, Tregs and cytotoxic T-cells in PBMCs 
from melanoma patients (Table 1). Table 2 summarizes the mean detected cell frequencies for all cell 
types, and the cut-off points for the dichotomized cell frequencies that were used in Cox regression 
models. As a first step, all immune subsets were compared for their relevance with regard to clinical 
variables such as disease stage and outcome. This showed us that both pDCs and MDSCs are associated 
with disease stage and have an impact on prognosis. Therefore further analyses were focused on these 
cell types, as outlined below. 
Table 2: Frequencies of circulating immune subsets in melanoma patients 
Cell type Cell frequency 
(mean % - SD)* 
Dichotomization 
cut-off (%)* 
Patients with “high” 
cell levels (%) 
Dendritic cells (DC) 1.54 (0.54)   
     Plasmacytoid DCs 0.34 (0.18) 0.2515 66.7 
     Myeloid DCs 0.96 (0.40)   
Myeloid-derived suppressor 
cells (MDSC) 
4.00 (2.29) 4.13 33.3 
     Monocytic MDSC 2.94 (2.81)   
     Polymorphonuclear MDSC 1.04 (0.64)   
CD3+ cells 43.60 (9.32) 40.25 68.2 
     Cytotoxic T-cell 14.79 (6.06)   
     Regulatory T-cell 4.77 (1.35)   
     CTLA-4 expression by Tregs 92.32 (4.01) 93.7 37.3 
DC, dendritic cell; MDSC, myeloid-derived suppressor cell; Treg, regulatory T-cell;  SD, standard 
deviation. “*” Percentage of live cells, except for Tregs (percentage of CD4+ cells). 
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 Myeloid-derived suppressor cells (MDSCs) 
Melanoma patients with systemic disease have significantly higher frequencies of circulating MDSCs 
(P=0.046). There was a trend towards higher MDSC frequencies in patients with active disease at time 
of inclusion, but this did not reach significance (Fig 1). 
 
Figure 1: pDC and MDSC frequencies according to melanoma stage and activity. 
Box-and-whisker plots showing variations in the levels of circulating myeloid-derived suppressor cells 
(MDSCs; A and B) and plasmacytoid dendritic cells (pDCs; C and D) according to the presence of  
systemic or active disease at the time of inclusion. Circulating cell frequencies are expressed as a 
percentage of live peripheral blood mononuclear cells (PBMCs). 
 
 
High levels of circulating MDSCs (> 4.13%) conferred a negative impact on OS (Log Rank test, P=0.002). 
This effect was independent of disease stage (P=0.012, HR 4.77, CI 1.42-16.04). There was no impact 
of MDSC frequency on progression-free survival (PFS). Patients who died of melanoma after inclusion 
showed a trend towards more circulating MDSCs at the time of inclusion (P=0.073). 
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 Link between MDSCs and other immunosuppressive markers 
To further evaluate how MDSCs are related to systemic immunity, their relation to cytotoxic Tcells and 
Tregs was also assessed (Table 3).  
 
Table 3: Association of myeloid-derived suppressor cells (MDSCs) and plasmacytoid dendritic cells 
(pDCs) with melanoma disease course and circulating immune markers. 
 MDSCs pDCs 
Melanoma activity and 
prognosis 
  
Systemic disease Increased (P=0.046) Decreased (P=0.001) 
Active disease Increased (P=0.095) Decreased (P=0.002) 
Death 
 
Increased (P=0.073) Decreased (P=0.009) 
Other immune markers   
CD3 cells Inverse (P<0.001) None 
CD8 cells Inverse (P=0.017) None 
PD-L1+ CD8 cells Positive (P=0.033) Inverse (P=0.044) 
Regulatory T-cells Inverse (P=0.007) None 
CTLA-4 expression in Tregs Positive (P=0.003) None 
PD-L1, Programmed-Death Ligand 1; CTLA-4, Cytotoxic T Lymphocyte-Associated Antigen 4; Treg, 
regulatory T-cell. 
 
The frequency of CD3+ cells was inversely correlated with MDSCs (P<0.001, CC -0.519), mMDSCs 
(P<0.001, CC -0.454) and pmnMDSCs (P=0.004, CC -0.349). The cytotoxic T-cell frequency was also 
inversely correlated with MDSCs (P=0.017, CC -0.294). On the other hand, there was a positive 
correlation between PD-L1+ cytotoxic Tcells and MDSCs (P=0.033, CC 0.263), mainly observed in 
pmnMDSCs (P=0.008, CC 0.323). These data suggest that high MDSC frequencies are associated with 
relative lymphopenia and with an immune climate that is unfavourable for cytotoxic T-cells. 
The percentage of MDSCs was inversely correlated with the percentage of Tregs (P=0.007, CC -0.327). 
However, the proportion of highly CTLA-4-positive Tregs was positively correlated with the percentage 
of MDSCs (P=0.002, CC 0.365) and mMDSCs (P=0.008, CC 0.321). This was also the case for the mean 
fluorescence intensity (MFI) of CTLA-4 and MDSCs (P=0.029, CC 0.266). These data suggest that high 
MDSC frequencies are associated with a higher suppressive capacity of circulating Tregs, but not with 
higher Treg frequencies. 
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Patients who died of melanoma during follow-up had a trend towards more circulating highly CTLA-4+ 
Tregs (P=0.081). A high percentage of CTLA-4 positivity in circulating Tregs (>93.7%) conferred a 
negative prognosis (Log Rank test, P=0.003), independent of disease stage (P=0.040, HR 3.80, CI 1.06-
13.70). 
 
 Plasmacytoid dendritic cells (pDCs) 
Melanoma patients with systemic disease have significantly lower frequencies of circulating pDCs 
(P=0.001). This decrease in pDCs was also seen in patients with active disease at the time of inclusion 
(P=0.002) (Fig1). In patients who were disease-free at the time of inclusion but who presented with 
disease relapse or progression in the months after inclusion, a decline in pDCs frequency could already 
be seen. The shorter the time frame between inclusion and relapse, the lower the observed frequency 
of pDCs (P=0.002, CC 0.898).  
A low amount of circulating pDCs (<0.2515%) had a negative prognostic impact on OS, independent of 
disease stage (Fig 2; P=0.025, HR 4.17, CI 1.20-14.52). In patients who were disease-free at the time of 
inclusion, low frequencies of circulating pDCs were also associated with a shorter PFS, independent of 
disease stage (Fig 2; P=0.036, HR 10.29, CI 1.162-90.90).  
 
 Link between pDCs and other immunosuppressive markers 
To further evaluate the impact of pDCs on systemic immunity, their relation to Tregs and cytotoxic 
Tcells was also assessed by flow cytometry. An inverse correlation between pDC frequency and the 
percentage of PD-L1+ cytotoxic T-cells was found (P=0.044, CC -0.249). No correlation with Treg 
frequency or CTLA-4 expression was detected.  
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Figure 2: Impact of pDC and MDSC frequency on overall and progression-free survival. 
Cox regression analysis of overall (A and C) and progression-free (B and D) survival according to the 
levels of circulating plasmaytoid dendritic cells (A and B) or myeloid-derived suppressor cells (C and D), 
after adjustment for disease stage. Percentages should be interpreted as percentages of live peripheral 
blood mononuclear cells (PBMCs).    
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 Relative importance of different immune subsets 
There was no inverse relation between the frequency of DCs and MDSCs in general. However, when 
evaluating the relationship between MDSC and DC subtypes, a significant inverse correlation was 
found between pDCs and MDSCs (P=0.004, CC -0.338). This was due to an increase in the absolute 
number of mMDSCs (P=0.010, CC -0.307), not pmnMDSCs. The observed changes in pDC and MDSC 
frequencies in patients with systemic disease were also reflected by an alteration of the MDSC/DC ratio 
(P=0.048). These data suggest that low pDC frequencies are associated with a defective maturation of 
myeloid cells, and an accumulation of MDSCs. 
To assess the relative importance of pDCs and MDSCs with regard to prognosis (impact on OS), a 
combined Cox regression model was made (Table 4, upper part). MDSC and pDC frequencies had a 
similar impact on OS, independent of each other and of disease stage. When CTLA-4+ Treg levels or 
CD3+ T-cell frequencies were separately added to this model, both lost their effect on prognosis, 
whereas pDCs did not (P=0.008 for adding CTLA-4, P=0.019 for adding CD3). These results indicate that 
circulating myeloid cells (principally pDCs) have a superior impact on prognosis (OS) compared to T-
cells. 
 
Table 4: Combined Cox (upper part) and logistic (lower part) regression models comparing circulating 
myeloid-derived suppressor cells and plasmacytoid dendritic cells in melanoma patients 
Combined Cox regression model: pDC vs MDSC & overall survival 
  Coefficient P-value HR 95% Confidence Interval 
for HR 
Lower Upper 
Stage at inclusion  1.87 <0.001  6.46  2.39  17.46 
MDSC frequency -1.61 0.009 4.98 1.50 16.67 
pDC frequency 1.49 0.019 4.42 1.27 15.33 
Logistic regression model: pDC and MDSC & systemic disease 
  Coefficient P-Value OR 95% Confidence Interval 
for OR 
Lower Upper 
Stage at diagnosis -0.702 0.407 0.496 0.095 2.601 
MDSC frequency -0.248 0.753 0.78 0.167 3.655 
pDC frequency 1.741 0.032 5.705 1.159 28.091 
pDC, plasmacytoid dendritic cell; MDSC, myeloid-derived suppressor cell; HR, hazard ratio; OR, odds 
ratio 
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As pDCs and MDSCs emerge as the most prognostically relevant cell types, we next assessed their 
relative importance to each other in predicting the presence of systemic disease. As indicated in Table 
4 (lower part), a logistic regression model was made. A low pDC frequency at the moment of inclusion 
could predict the presence of systemic disease, independent of the patients’ stage at the time of 
inclusion and independent of MDSC frequency. MDSC frequency itself had no significant predictive 
quality.  
 
4. Discussion 
Various systemic immune alterations have been described in melanoma patients, but a direct 
comparison of their clinical relevance is often lacking. In this study, we demonstrated that an increased 
amount of circulating MDSCs and a decreased number of pDCs were associated with systemic disease 
and had both an independent negative prognostic value, although they were inversely correlated. Both 
MDSCs and pDCs were linked with T-cell anergy. Nonetheless, pDCs and MDSCs were the most 
prognostically relevant cell types. 
In this patient cohort, elevated MDSC frequencies were seen in stage IV melanoma patients, which is 
in accordance with previous publications.23-25 The accumulation of MDSCs in melanoma is most 
prominent in stage IV patients, but has been reported as early as stage I.26 Most authors agree that 
MDSCs are upregulated in melanoma patients compared to healthy controls.23, 25, 26 Whether 
pmnMDSCs or mMDSCs dominate depends on the cancer type. Based on literature and the 
observations made in this patient set, mMDSCs appear to have a higher impact in melanoma.27, 28 A 
negative impact of high CD14- and CD14+ MDSCs on OS and PFS was previously described in stage IV 
melanoma patients.25, 29 Significant increases in circulating MDSC frequencies have also been detected 
in the blood of patients with a.o. glioblastoma, breast, colon, lung and kidney cancer.5, 30  
We observed significantly lower circulating pDC frequencies in stage IV melanoma patients. The 
changes in total DC frequencies in advanced melanoma have been attributed to pDCs rather than 
mDCs.14, 15 Accordingly, we did not observe significant changes in mDC frequencies, contrary to 
reduced pDC levels in stage IV patients. Remarkably, we observed that a decline in pDC levels had a 
negative prognostic effect on both OS and PFS, independent of disease stage or other cell frequencies. 
Previous studies have reported a negative prognostic effect of the presence of pDCs within the tumour 
site,31, 32 but to our knowledge this is the first study to report an independent negative prognostic effect 
of low circulating pDC frequencies in untreated melanoma patients. Moreover, low pDC frequencies 
were not only associated with a decreased PFS, but were also already reduced up to a year before 
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relapse was clinically diagnosed, suggesting that low pDC frequencies could have a predictive value in 
disease-free patients. A possible explanation is that pDC frequencies are regulated by the tumour itself 
and that this regulation takes place very early in the metastatic process. Alternatively, the observed 
low pDC frequencies could also be an indicator of a failing anti-tumoral immune response, making the 
patient more susceptible to relapse. The relevance of pDC frequencies in detecting early disease 
progression should be further investigated in prospective trials with longitudinal follow-up samples. 
Our data demonstrate a disturbed myeloid differentiation in melanoma, resulting in an accumulation 
of MDSCs and a decline in pDCs. To our knowledge, there are no studies directly reporting this effect 
in melanoma patients yet. The independent prognostic effect of both pDCs and MDSCs suggests that 
even a partial dysfunction of myeloid differentiation is sufficient to negatively influence melanoma 
disease course. In our dataset, the effect of pDCs on OS and PFS outweighs that of MDSCs (table 4). An 
alternative interpretation could be that MDSC frequency is related to the actual tumour load, whereas 
adequate pDCs levels could also have a protective effect on disease progression. Regardless of which 
myeloid cell type dominates over the other during the course of the disease, it is clear that the myeloid 
lineage is globally altered in melanoma as a single system involving both differentiated myeloid cells 
and their pathologically activated immature progenitors.30 Additionally, our combined Cox regression 
model showed that the prognostic importance of circulating myeloid cells dominates over circulating 
cytotoxic T-cells and to a lesser extent regulatory T-cells, as the latter two lose their impact on 
prognosis when adjusting for pDC or MDSC frequencies.  
Over the last few years, immunoprofiling efforts are increasing as immunotherapeutic strategies are 
gaining importance in the management of melanoma and other cancers. Several (combinations of) 
markers with predictive or prognostic quality have been suggested, mainly focusing on the tumour 
microenvironment.4, 33 Based on our data, we conclude that circulating pDCs and MDSCs should be 
considered in future prognostic profiling studies. One limitation of our study in this respect is the use 
of cryopreserved PBMC samples, which impedes a direct comparison with studies using fresh whole 
blood samples. MDSCs have already been investigated as possible predictive biomarkers for 
immunotherapy in melanoma and other malignancies. Low mMDSC levels were associated with clinical 
response and improved OS in melanoma patients treated with ipilimumab.34, 35 Moreover, mMDSC 
levels have been reported to be inversely correlated with the presence of tumour-specific T-cells and 
with a CD8+ T-cell rise on ipilimumab therapy.29, 36 The inverse correlation between mMDSC and 
(antigen-specific) cytotoxic T-cell levels that has been observed in independent studies including 
ours,37 also raises the question whether mMDSC-related immune suppression could be limiting the 
therapeutic benefit of ipilimumab. Alternatively, high mMDSC levels could also be a marker for 
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deficient myeloid cell maturation leading to a pDC deficit that hampers efficient immune activation 
after ipilimumab therapy. 
Recently, Schilling and colleagues reported that mMDSC frequencies decline in patients who have a 
response to vemurafenib and rise again when progressive disease occurs. The inhibitory effect of 
vemurafenib on mMDSCs was present in vitro as well as in vivo.38 Finkelstein and colleagues reported 
that high DC/MDSC ratios and low pretreatment MDSC levels could predict response to high-dose IL-2 
therapy in patients with melanoma and renal cell carcinoma.39 In our patient cohort, pDC frequencies 
had the highest impact on prognosis. Furthermore a gradual decline in pDCs levels seemed to occur 
before relapse, but as this was a cross-sectional study these data need to be confirmed in a longitudinal 
study with multiple follow-up samples during disease course.  However, our data do suggest that pDCs 
might also be valuable candidates in predictive immune profiles. The prominent prognostic role of 
circulating pDCs also warrants further research into possible therapeutic strategies, for example with 
Toll-like receptor stimulating drugs which have been shown to enhance pDC activation in the skin 40. 
 
5. Conclusion  
Plasmacytoid dendritic cells (pDC) and myeloid-derived suppressor cells (MDSC) in the peripheral 
blood should be regarded as one system and thus be evaluated together. Both are key players in the 
immunological climate in melanoma patients, as they are correlated with circulating cytotoxic and 
regulatory T-cells. The independent prognostic impact of pDCs and MDSCs makes these cell types 
attractive for future prognostic and possibly even predictive immunoprofiling efforts.  
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Abstract  
In melanoma, both the induction of immunosuppression by tumour cells and the inflammatory anti-
tumour response can induce an upregulation of counterregulatory mechanisms such as indoleamine 
2,3-dioxygenase (IDO), programmed death-ligand 1 (PD-L1) and CTLA-4+ regulatory T-cells (Tregs) in 
the tumour microenvironment. Even though these immunosuppressive mediators are targets for 
immunotherapy, research investigating their expression in the peripheral blood is lacking. We 
therefore performed flow cytometry on PBMCs of stage I-IV melanoma patients. IDO expression was 
detected in plasmacytoid dendritic cells (pDC) and monocytic myeloid-derived suppressor cells 
(mMDSC), and increased in advanced disease stage (P=0.027). Tryptophan breakdown confirmed the 
functional activity of IDO and was linked with increased PD-L1+ cytotoxic T-cells (P=0.009), relative 
lymphopenia (P=0.036), and a higher mDC/pDC ratio (P=0.002). High levels of circulating PD-L1+ 
cytotoxic T-cells were associated with increased CTLA-4 expression by Tregs (P=0.005) and MDSC levels 
(P=0.033). This illustrates that counterregulatory immune mechanisms in melanoma should be 
considered as one interrelated signalling network. Moreover, both increased PD-L1+ T-cells and CTLA-
4 expression in Tregs conferred a negative prognosis, indicating their in vivo relevance. Remarkably, 
circulating CTLA-4, IDO and pDC levels were altered according to prior invasion of the sentinel lymph 
node and IDO expression in the sentinel was associated with more IDO+ PBMCs. We conclude that the 
expression of IDO, PD-L1 and CTLA-4 in the peripheral blood of melanoma patients is strongly 
interconnected, associated with advanced disease and negative outcome, independent of disease 
stage. Combination treatments targeting several of these markers are therefore likely to exert a 
synergistic response. 
  
Chapter 4.3 | Systemic IDO, PD-L1 and CTLA-4 
139 
 
Introduction 
Malignant melanoma has become the prototype of an immunogenic tumour that can be successfully 
treated with immune checkpoint inhibitors such as anti-CTLA-4 and anti-PD-1/PD-L1 antibodies.1, 2 
Clinical responses are more frequent in the subgroup with T-cell inflamed tumours,3 but still less than 
half of this patient subset is estimated to respond. This suggests that counter-regulatory immune 
mechanisms also play a role. Indeed, evidence emerges that anti-tumour immune responses are often 
accompanied by multiple immunosuppressive mechanisms, probably acting as negative feedback 
mechanisms. In this context, Spranger et al. were able to show that in metastatic melanoma tissue, 
the presence of indoleamine 2,3-dioxygenase (IDO), programmed death-ligand 1 (PD-L1) and Forkhead 
box P3 (FoxP3+) regulatory T-cells (Tregs) coincides and is dependent on preceding IFN-γ secretion by 
CD8+ lymphocytes.4 
Indoleamine 2,3-dioxygenase is an immunosuppressive intracellular enzyme that initiates the 
catabolism of the essential amino acid tryptophan to kynurenine and its derivatives.5 IDO expression 
has been described in a variety of immune and stromal cells, but is best characterized in dendritic 
cells.6 The function of IDO is the regulation of adaptive immune responses, consequently contributing 
to tumour-protective immune suppression.7 We were previously able to show that IDO expression in 
the primary tumour or sentinel lymph node has an independent negative prognostic effect on overall 
and relapse-free survival in melanoma.8, 9 
Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is a target gene of FoxP3 and is constitutively 
expressed by Tregs. It has a major physiological role in enhancing Treg activity and down-modulating 
T helper cell activity, by competing with CD28 for binding with CD80.10 CTLA-4 was the first immune-
checkpoint to be clinically targeted, and CTLA-4 inhibition was the first treatment to induce a 
significant improvement of overall survival (OS) in stage IV melanoma patients.11 This success has 
paved the way for other checkpoints inhibitors, such as those targeting the PD1/PD-L1 axis. 
Engagement of PD1 by PD-L1 limits T-cell activity in peripheral tissues at the time of an inflammatory 
response to infection, leading to immune resistance in the tumour micro-environment.10 
These immunosuppressive mechanisms are probably more complex than is currently understood. It 
has for example been shown that PD-L1 can also be a ligand for CD80 in vitro, and that this interaction 
inhibits T-cell proliferation and cytokine production.12 Furthermore, CTLA-4 can induce IDO activity in 
plasmacytoid dendritic cells (pDCs) via reverse signalling with CD80. Adding more complexity to this 
issue, several different cell types have been reported to be implicated in these feedback loops, the 
most important being Tregs and myeloid-derived suppressor cells (MDSC).13 
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Even though IDO, CTLA-4 and PD-L1 are promising targets for immunotherapy, data on their expression 
by immune cells in the peripheral blood of melanoma patients are lacking. We previously 
demonstrated an increased mean-fluorescence intensity (MFI) for IDO in peripheral blood 
mononuclear cells (PBMCs) of melanoma patients with advanced disease after stimulation with CTLA-
4.8 In the present study, we investigated the in vivo expression of IDO, PD-L1 and CTLA-4 by immune 
cells of the lymphoid and myeloid lineage in the peripheral blood of stage I to IV melanoma patients. 
To ascertain the functional relevance of the detected IDO, tryptophan metabolism was assessed by 
ultra-performance liquid chromatography (UPLC).  
 
1. Methods 
 Patients  
Seventy-two melanoma patients were enrolled in this study, with a median follow-up time of 16 
months after inclusion (i.e. the time of venepuncture for blood collection) and of 41.5 months after 
diagnosis. For 69 patients both peripheral blood mononuclear cells (PBMCs) and a serum sample were 
available, in an additional 3 patients only a serum sample was present. Only patients who were without 
treatment for their melanoma at the time of venepuncture were included, to avoid any possible 
influence on marker expression. Of all included patients (n=72), 14 had active disease at the time of 
venepuncture. Disease activity was defined as the presence of metastatic melanoma; 4 patients had 
stage IIIc disease and 10 patients stage IV disease. The sentinel lymph node could be retrieved for 
additional immunohistochemistry in 51 patients, 27.7% of these lymph nodes were invaded and 72.3% 
were tumour-free. Detailed patient characteristics can be found in Table 1. The local medical ethical 
committee approved this study; all included patients signed written informed consent. 
 PBMC isolation  
PBMCs were isolated from heparinized venous blood by centrifugation on a Ficoll-Paque gradient (GE 
Healthcare, Uppsala, Sweden) within 4h of venepuncture. The PBMCs were cryopreserved in liquid 
nitrogen in heat-inactivated foetal bovine serum (FBS) supplemented with 10% dimethyl sulphoxide 
(DMSO) until analysis. Cells were thawed by submersion at 37° for 1-2 minutes and resuspended in a 
medium containing Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 20% FBS and 
1% glutamine. 
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Table 1: Patient characteristics 
Number of patients, n 72 
Follow-up time, months (median - IQR) 16 (21-104.5) 
Age at diagnosis, years (median - IQR) 53 (40.5-65) 
Female sex, % (n) 52.9 (36) 
Stage at inclusion, % (n)  
Local (stage I & II) 50 (36) 
Regional (stage III) 34.7 (25) 
Systemic (IV) 15.3 (11) 
Active disease at inclusion 16.7 (12) 
Melanoma characteristics 
Breslow (median, IQR) 1.81 (1.10-2.80) 
Ulceration, % (n) 36.1 (22) 
Sentinel invasion, % (n) 22.2 (14) 
Location of primary melanoma 
Head & neck, % (n) 13 (9) 
Trunk, % (n) 42 (29) 
Extremities, % (n) 44.9 (31) 
Unknown primary 3 
 
 
 
 PBMC culture and stimulation 
PBMCs were cultured overnight in a medium containing Iscove’s Modified Dulbecco’s Medium (IMDM) 
supplemented with 20% FBS and 1% glutamine. When sufficient cells were available, PBMCs were also 
stimulated to induce IDO expression by adding 1000U/ml human recombinant interferon-gamma 
(Imukin) to the same medium for 12h at 37°C in 10% CO2. After incubation, adherent and non-
adherent cells were collected for flow cytometry.  
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 Flow cytometry 
MDSCs were characterized by the HLA-DR- lineage- (CD3, CD19 and CD56) CD33+ CD11b+ phenotype, 
mMDSCs are CD14+, pmnMDSCs are CD14-. Dendritic cells were characterized by the HLA-DR+ lineage-  
(CD3, CD14, CD16, CD19, CD20, and CD56) phenotype, pDCs are CD123+ CD11c- and mDCs are CD123- 
CD11c+. Tregs were defined as CD3+ CD4+ CD25+ FoxP3+ and cytotoxic T-cells as CD3+ CD8+ cells. All 
antibodies used in this study were fluorescently conjugated mouse anti-human monoclonal antibodies. 
The following antibodies were purchased from BD Biosciences; CD3 BV421 (563797), CD4 APC-Cy7 
(561839), CD25 FITC (560990), CD33 BV421 (562854), CD11b APC-Cy7 (560914), CD123 BV421 
(562517). The following antibodies were purchased from eBioscience; B7-H1 PE-Cy7 (25-5983-42), CD8 
APC (9017-0087-025), CD3 FITC (11-0038-41), CD19 FITC (11-0199-41), CD56 FITC (11-0569-41), CD14 
APC (17-0149-41), CD11c APC (17-0116-41), HLA-DR PerCP-Cy5.5 (45-9956-42). For intracellular 
stainings, after surface staining PBMCs were fixed and permeabilized with fixation⁄permeabilization 
solution (BD Biosciences), and then stained with antihuman IDO PE (R&D Systems, IC6030P), CTLA-4 
APC (BD Biosciences, 560938) and FoxP3 PerCP-Cy5.5 (eBioscience, 45-4776-42) antibodies. Live/dead 
staining was performed using Live/dead® fixable aqua dead cell stain (Life Technologies Europe). 
Patient samples with less than 75% living cells were excluded (n=4). Cells were analyzed on a 
FACSCanto™ II  flow cytometer (BD Bioscience, Erembodegem, Belgium) using FlowJo software (Tree 
Star Inc, Ashland, OR, USA). For setting the gates, isotype and fluorescence-minus-one (FMO) controls 
were used. To provide a representative sample a median amount of 500000 cells was analysed per cell 
type (min 261000 – max 569750). Samples with less than 100000 cells were excluded (n=1). The 
reported frequencies of circulating cell types are percentages of live PBMCs, except for Treg 
frequencies which are percentages of CD4+ cells. 
 Immunohistochemistry for IDO 
All sentinel lymph nodes (n=51) were formalin-fixed paraffin-embedded (FFPE) archival tissues. 
Immunohistochemical staining of 4-5 μm sections was performed according to standard avidin-biotin-
peroxidase protocols (Envision Flex+, Dako, Denmark), a mouse linker was added to the protocol 
(Dako). The signal was visualized by incubation with 3-amino-9-ethylcarbazole (AEC) substrate (Dako). 
Sections were counterstained with hematoxylin. For antigen retrieval, slides were boiled (97°C) for 20 
min (PT Link, Dako). Sections were incubated with a monoclonal anti-IDO antibody (clone 10.1, 1/200, 
Millipore) for 1h.  
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 Statistical analysis 
Median values between 2 groups were compared by the Mann-Whitney U-test, between >2 groups 
with Kruskal-Wallis testing. To compare proportions of categorical variables, the Pearson’s Chi² test or 
Fisher’s Exact test was used. To evaluate correlations, Spearman correlation coefficients (CC) were 
calculated. All statistical analyses were performed using SPSS 21.0 (SPSS Inc, Chicago, IL, USA), a P-
value less than 0.05 was considered statistically significant (double-sided).  
 Ultra-performance liquid chromatography (UPLC) 
Tryptophan, kynurenine and its other downstream metabolites in patient sera were quantified by 
UPLC-MS/MS (Waters Acquity TQD), according to previously published methods, with slight 
modifications.14, 15 An overview of the mean detected serum concentrations for the different molecules 
can be found in table 2.  
 
 
Table2: Mean serum concentrations (nM) of tryptophan and tryptophan catabolites 
Molecule Mean (SD) concentration (nM)  
Tryptophan (Trp) 49586.11 (14926.746) 
Kynurenine (Kyn) 2095.94 (764.201) 
Kyn/Trp ratio  4.43 (1.516) 
Kynurenic acid 179.67 (104.775) 
3-OH-kynurenine 36.47 (40.656) 
5-OH-tryptophan 64.63 (18.823) 
5-HT (serotonin) 841.92 (550.497) 
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2. Results 
Flow cytometry was performed on peripheral blood mononuclear cell (PBMC) samples of 72 American 
Joint Committee on Cancer (AJCC) stage I to IV melanoma patients who were not under active therapy 
for their disease at the time of sample procurement. Detailed patient characteristics can be found in 
table 1. 
 Indoleamine 2,3-dioxygenase 
IDO expression by PBMCs was 3.8-fold upregulated after stimulation with IFN-γ overnight. We 
compared the clinical relevance of IDO expression with and without stimulation with IFN-γ, and found 
no correlation between stimulated IDO expression and any of the clinical variables. All further 
experiments are therefore based on spontaneous, unstimulated IDO expression values. 
IDO expression was predominantly detected in pDCs and monocytic MDSCs (mMDSCs). A lower degree 
of IDO expression was also detected in Tregs, myeloid dendritic cells (mDCs) and polymorphonuclear 
MDSCs (pmnMDSC). There was no IDO expression in cytotoxic T-cells. For a complete overview of IDO 
expression in these cell types, we refer to table 3. IDO expression by pDCs and mMDSCs was strongly 
correlated (P<0.001, CC 0.621). 
To check the clinical relevance of the cell types with the strongest IDO-positivity, their relation to 
disease stage/activity and prognosis was assessed. IDO expression by MDSCs did not correlate with 
disease activity. In patients with stage IV disease, higher frequencies of IDO+ mMDSCs (P=0.027) and 
IDO+ pmnMDSCs (P=0.043) were found compared to patients in stage I-III. However, this had no impact 
on overall- or progression-free survival.   
The percentage of circulating pDCs was dichotomized by ROC analysis into “low” (<0.2515%) and 
“high” (>0.2515%). Patients with high levels of pDCs had a positive prognosis on OS, independent of 
disease stage (P=0.021, HR 4.16, CI 1.24-13.94 – Table 3, part 1). The frequency of IDO+ pDCs had no 
impact on prognosis in a model that corrects for disease stage and the percentage of circulating pDCs. 
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Table 3: IDO and PD-L1 expression by different circulating cell types in AJCC stage I-IV melanoma 
patients 
Cell type Observed cell 
frequency (mean  % - 
SD)* 
Cell frequency  with 
IDO expression (mean 
% - SD) 
Cell frequency  with 
PD-L1 expression 
(mean % - SD) 
All PBMCs NA 0.55 (0.58) 1.22 (0.97) 
Dendritic cells (DC) 1.54 (0.54)   
Plasmacytoid DCs 0.34 (0.18) 1.66 (2.27) 0.71 (0.37) 
Myeloid DCs 0.96 (0.40) 0.015 (0.028) 0.91 (0.38) 
Myeloid-derived 
suppressor cells (MDSC) 
4.00 (2.29)   
Monocytic MDSC 2.94 (2.81) 0.96 (1.95) 0.23 (0.61) 
Polymorphonuclear MDSC 1.04 (0.64) 0.13 (0.26) 1.10 (1.94) 
CD3+ cells 43.60 (9.32)   
Cytotoxic T-cell 14.79 (6.06) 0.0030 (0.0046) 0.17 (0.11) 
Regulatory T-cell 4.77 (1.35) 0.083 (0.19) 0.57 (0.24) 
“*” percentage of live cells, except for Tregs (percentage of CD4+ cells) 
 
 IDO and tryptophan metabolism 
In order to confirm that the measurement of IDO by flow cytometry has functional relevance, we 
assessed tryptophan metabolism by UPLC-MS/MS. A higher MFI for IDO in PBMCs was correlated with 
a higher Kyn/Trp ratio (P=0.008, CC 0.389) and with lower tryptophan levels (P=0.014, CC -0.364). This 
pattern matches tryptophan consumption, confirming metabolic activity of the IDO expression 
measured by flow cytometry. 
There was no impact on prognosis of tryptophan levels or any of the IDO catabolites. However, patients 
with active disease at the time of diagnosis had lower serum tryptophan levels (P=0.041). In parallel, 
higher serum anthralinic acid levels were found in stage IV patients compared to stage I-III (P=0.012). 
For the other metabolites, trends were observed in the same direction. These results confirm that IDO 
activity is more prominent in patients with higher grade or active disease.  
Next we evaluated whether tryptophan catabolism in the serum influences circulating cell frequencies. 
Mean serum concentrations for tryptophan and its catabolites are summarized in table 2. Patients with 
a high serum Kyn/Tryp ratio had lower levels of circulating CD3+ cells (P=0.036, CC -0.267), increased 
PD-L1+ cytotoxic T-cells (P=0.009, CC -0.328) and a higher MFI for IDO in Tregs (P= 0.009, CC 0.371). 
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Moreover, in patients with elevated serum kynurenine levels a shift in DC subset frequencies was 
observed toward a higher mDC/pDC ratio (P=0.002, CC 0.373).  
 PD-L1 
PD-L1 expression was most prominent in pmnMDSCs, but could also be found in other circulating cell 
types (Table 2). Despite its low frequency, PD-L1 expression by cytotoxic T-cells was clinically most 
relevant. Patients who died of melanoma had higher levels of PD-L1+ cytotoxic T-cells at the time of 
inclusion (P=0.004). To further assess the impact of PD-L1+ cytotoxic T-cells on prognosis, the 
frequency of PD-L1+ cytotoxic T-cells was dichotomized by ROC analysis into “low” (<0.1505%) and 
“high” (>0.1505%). High PD-L1+ cytotoxic T-cell levels were present in 42.4%, these patients had a 
negative prognosis on OS (Log Rank test, P<0.001). This effect was independent of disease stage 
(P=0.035, HR 5.82, CI 1.13-29.95) (Fig. 1A). Moreover, in patients who were disease-free at inclusion 
but had disease progression in the following 2 years, a rise in PD-L1+ cytotoxic T-cell frequency could 
already be seen. The closer to relapse, the higher the PD-L1+ cytotoxic T-cell frequencies were 
(P=0.021, CC 0.829), suggesting that PD-L1+ cytotoxic T-cells could be relevant to detect impending or 
subclinical relapse.  
Next, the relation of PD-L1 to IDO and Tregs was assessed. A high MFI for IDO correlated with a high 
MFI for PD-L1 in unstimulated, cultured cells (P<0.001, CC 0.506), indicating that both 
immunosuppressive mechanisms occur together. PD-L1+ cytotoxic T-cells were also correlated with 
the percentage of Tregs (P=0.048, CC 0.247), the levels of CTLA-4 expression by Tregs (P=0.005, CC 
0.346) and with MDSCs (P=0.033, CC 0.263). Furthermore, levels of PD-L1+ cytotoxic T-cells were 
inversely correlated with pDC levels (P=0.044, CC -0.249). These results indicate that PD-L1 expression 
by cytotoxic T-cells is part of an immunosuppressive environment in the peripheral blood. 
 
 CTLA-4 expression by Tregs 
CTLA-4 expression was only assessed in regulatory T-cells, which were all to some extent CTLA-4-
positive. The level of CTLA-4 expression by Tregs was dichotomized by ROC analysis into “low” (<93.7%) 
and “high” (>93.7%). The mean percentage of patients with high CTLA-4 expression was 37,3%. 
Patients with high levels of CTLA-4 expression by Tregs had a negative prognosis on OS (Log Rank test, 
P=0.003), independent of disease stage (P=0.040, HR 3.80, CI 1.06-13.64) (Fig. 1B). 
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The link between Tregs, IDO and PD-L1 was described in the previous paragraphs. We also observed 
that the subgroup of patients with head and neck melanoma had increased frequencies of Tregs with 
high CTLA-4 expression (P=0.026). 
 
 
Figure 1: Impact of PD-L1+ cytotoxic T-cells and CTLA-4+ Tregs on overall survival 
Cox regression analysis of overall survival according to the levels of circulating PD-L1+ cytotoxic T-cells 
(A) and CTLA-4 expression level of regulatory T-cells (B), after adjustment for disease stage. Data are 
presented as percentages of live peripheral blood mononuclear cells (PBMCs). 
 
 
 Link between the sentinel lymph node and circulating immune cells 
As clinically relevant immune changes can even occur in tumour-free sentinel lymph nodes, we also 
evaluated whether invasion of the sentinel lymph node had an impact on circulating immune cells. The 
mean interval between surgical removal of the sentinel and venepuncture for PBMC isolation was 21 
months (IQR 6.5-79.5 months). Patients with an invaded sentinel lymph node had increased 
frequencies of circulating highly CTLA-4+ Tregs (P=0.045) and a higher MFI for CTLA-4 (P=0.036). 
Invasion of the sentinel lymph node was also associated with higher frequencies of circulating pDCs 
(P=0.034) (Fig. 2). 
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Figure 2: Systemic immune changes in 
melanoma patients according to sentinel 
invasion 
Box-and-whisker plots showing variations 
in the level of CTLA-4 expression by 
regulatory T-cells (Tregs, A), mean-
fluorescence intensity of CTLA-4 in Tregs 
(B) and plasmacytoid dendritic cells (pDCs; 
C) according to tumour-invasion of the 
sentinel lymph node. Circulating cell 
frequencies are expressed as a percentage 
of live peripheral blood mononuclear cells 
(PBMCs). 
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We previously demonstrated that IDO expression in the sentinel is an early marker of immune 
suppression, irrespective of sentinel invasion. Therefore, the sentinel lymph nodes of the included 
patients were immunohistochemically stained for IDO and assessed as previously reported.8 
Remarkably, patients with an IDO-positive sentinel had more circulating IDO-positive PBMCs (cultured, 
unstimulated cells, P=0.016). This could be attributed to higher levels of IDO+ mMDSCs (Fig. 3), which 
were found to be associated with IDO status of the sentinel (P=0.018). IDO-positivity of the sentinel 
was also associated with higher frequencies of circulating dendritic cells (P=0.037, data not shown). 
 
 
 
Figure 3: Systemic IDO expression according to IDO expression in the sentinel lymph node 
Box-and-whisker plots showing variations in the level of IDO-positive PBMCs (A) and IDO-positive 
monocytic myeloid-derived suppressor cells (mMDSCs, B) according to IDO expression in the sentinel 
lymph node. Circulating cell frequencies are expressed as a percentage of live peripheral blood 
mononuclear cells (PBMC). 
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3. Discussion 
The presence of a cytotoxic, inflammatory tumour micro-environment has been demonstrated to 
cause a concomitant upregulation of negative feedback mechanisms such as IDO, PD-L1 and FoxP3+ 
Tregs.4 Even though these immunosuppressive mediators are targets for current immunotherapies in 
melanoma, there is insufficient data on their expression by the different immune cells in the peripheral 
blood. In this paper we demonstrated that IDO, PD-L1 and CTLA-4 expression in the peripheral blood 
of melanoma patients is not only interconnected but also associated with advanced disease and a 
negative prognosis independent of disease stage.   
With regard to IDO, we demonstrated that spontaneous expression can be detected in the peripheral 
blood of melanoma patients, predominantly in pDCs and mMDSCs. IDO expression in mMDSCs is higher 
in patients with advanced disease. Up till now, systemic IDO expression was unreported in melanoma 
patients, but it had already been detected in other conditions. During pregnancy, circulating DCs 
express more IDO, contributing to foetal tolerance.16 IDO+ pDCs have been proposed to be a regulatory 
DC subset.6 In breast cancer patients, IDO expression by MDSCs in the tumour stroma was recently 
demonstrated to suppress immune responses.17 Circulating IDO+ cells could not be detected, but this 
might be due to insufficient numbers of recorded events during flow cytometry. As can be deduced 
from table 2, absolute  numbers of IDO+ cells in the peripheral blood are low, so analysing a large 
sample (500.000 cells) is necessary for detection. The IDO expression we detected is metabolically 
active, as it is associated with tryptophan consumption in the serum. Tryptophan degradation by IDO 
was more prominent in patients with high grade or active disease, as previously reported.18  
Tryptophan degradation was also associated with relative lymphopenia, a phenomenon that has also 
been observed in patients with myelodysplastic syndromes.19 Low tryptophan levels were associated 
with increased PD-L1+ cytotoxic T-cells and a higher mDC/pDC ratio. Taken together, our data suggest 
that IDO expression in the peripheral blood of melanoma patients is clinically relevant and is associated 
with tryptophan catabolism that seems to affect immune cell maturation and function. 
Regarding PD-L1, we demonstrated that this marker is expressed by multiple circulating immune cells. 
The current paradigm on the PD1/PD-L1 axis states that PD-L1 expression by malignant cells will cause 
anergy by binding with PD-1 on T-cells.10 We demonstrated that clinically relevant PD-L1 expression 
also occurs in circulating cytotoxic T-cells, conferring a worse prognosis on OS, independent of tumour 
stage. To the best of our knowledge, these data have not been reported so far. Moreover, PD-L1+ 
cytotoxic T-cell cell counts were higher in disease-free patients who relapsed within a year after sample 
procurement, suggesting that PD-L1+ cytotoxic T-cells could already increase before relapse is clinically 
detected. 
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In our study, the levels of circulating Tregs were not related to disease stage or prognosis, but high 
CTLA-4 expression by Tregs did have a negative effect on OS independent of disease stage. Tregs have 
been reported to be overrepresented in the peripheral blood of melanoma patients, but contrary to 
their increased presence in the tumour micro-environment, the impact of circulating Tregs on 
prognosis had not been established yet.20 
In this study we demonstrated that IDO, PD-L1 and CTLA-4 positivity of circulating immune cells are all 
individually of clinical importance. However, the expression of these three markers is also significantly 
intertwined. There was a strong correlation between the expression of IDO and PD-L1 in PBMCs. 
Furthermore the level of PD-L1+ cytotoxic T-cells was associated with increased CTLA-4 expression by 
Tregs. The combined expression of these three immunosuppressive markers was previously reported 
in the metastatic melanoma microenvironment.4 Both the interactions between PD-L1 and PD-1 and 
between CTLA-4 and CD80/CD86 have been abundantly described and provide the rationale for 
current melanoma immunotherapies.10 Nevertheless, our results support previous studies 
demonstrating that these markers have a much more complex, network-like interplay. In vitro 
experiments showed that when CTLA-4 on Tregs binds CD80/CD86 on dendritic cells, an IFN-γ 
dependent induction of IDO is elicited with subsequent tryptophan catabolism.21 However, we could 
not withhold a correlation between CTLA-4 expression by Tregs and IDO in pDCs, suggesting that this 
might not be a dominant mechanism of IDO induction in the peripheral blood. Tregs have also been 
reported to functionally crosstalk with MDSCs through the PD-L1 pathway during melanoma 
development in mice.22 We did find a correlation between Treg and MDSC frequencies and PD-L1 
expression in our patients, justifying further research on this interaction in the peripheral blood of 
melanoma patients.  
Our results also illustrate that important immune changes can occur in melanoma patients with 
invaded and even with tumour-free sentinel lymph nodes. This is of importance, as about half of all 
melanoma-related deaths occur in those patients who had local stage disease (AJCC stage I and II) at 
the time of diagnosis.23 Sentinel node invasion was associated with systemic immune changes with a 
median delay of 19 months (Fig. 2). Nevertheless we observed that irrespective of invasion, IDO 
expression in the sentinel also conferred systemic immunological changes. In patients with an IDO+ 
sentinel, a higher frequency of circulating DCs was seen (implying immune activation) but higher 
frequencies of IDO+ mMDSCs were also observed (suggesting concomitant immunosuppression). This 
clustering of IDO expression in the sentinel and in PBMCs is remarkable, as we previously showed that 
IDO expression is also consistent in the primary, sentinel and even metastatic tissue of melanoma 
patients.8 Our results indicate that IDO expression by host cells is important in the pathogenesis of 
melanoma, but the question remains how this IDO expression is induced. Soluble tumour-derived 
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factors could be responsible, but alternatively this clustering could also indicate a certain patient-
related predisposition. Gene polymorphisms of both the IDO and IFN-γ genes have been demonstrated 
to be associated with an upregulation of IDO expression and tryptophan metabolism in healthy 
individuals.24, 25 If this would also be the case in melanoma patients, it could help explain a patient-
dependent IDO expression pattern.  
There is a solid basis for investigating the effect of IDO inhibitors as part of combination strategies with 
other immunotherapies in melanoma patients. If IDO expression is associated with the spontaneous 
host anti-tumour immune response, it could also be induced by immunotherapy, hence limiting the 
effectiveness of the treatment.4 In a B16 mouse melanoma model, Holmgaard et al. have 
demonstrated that host IDO expression has an inhibitory role in both anti-CTLA-4 and anti-PD1/PD-L1 
therapy and that pharmacological inhibition of IDO combined with CTLA-4 blockade gives superior 
effects.26 IDO expression analysis could also be useful for predictive immunoprofiling, as 
immunohistochemical IDO-positivity in the tumour microenvironment has been shown to predict 
response to anti-CTLA-4 therapy in patients with metastatic melanoma.27 Others have also 
demonstrated that lower levels of circulating mMDSCs before initiation of anti-CTLA-4 therapy are 
associated with increased response.28, 29 The relevance of the IDO+ mMDSCs we observed should 
therefore be evaluated in melanoma patients, as it could not only provide predictive information, but 
also help elucidate the counter-regulatory mechanisms that hamper the efficacy of current 
immunological checkpoint inhibitors.  
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Abstract  
Objectives: Interferon-alpha (IFN-α) is the only approved adjuvant treatment for high-risk melanoma 
patients in Europe, but impact on overall survival is low. Although it is believed that IFN-α exerts its 
effects through immunomodulation, data on its impact on circulating immune cells are scarce.  
Methods: Flow cytometry was performed on peripheral blood mononuclear cells of 8 IFN-α2b-treated 
stage III melanoma patients and 26 untreated stage III melanoma patients as controls, to enumerate 
myeloid and plasmacytoid dendritic cells (mDC and pDC), monocytic and polymorphonuclear myeloid-
derived suppressor cells (mMDSC and pmnMDSC) and cytotoxic and regulatory T-cells (Tregs). The 
expression of several immunosuppressive markers [indoleamine 2,3-dioxygenase (IDO), programmed-
death ligand-1 (PD-L1) and CTLA4] was explored. IDO activity in the blood was confirmed by ultra-
performance liquid chromatography (UPLC). 
Results: Compared to controls, IFN-α2b treatment was associated with increased IDO expression by 
pDCs (P=0.021) and an increased kynurenine/tryptophan ratio in the serum (P=0.004), compatible with 
IDO enzyme activity. Furthermore, IFN-α2b-treated patients had a decreased mDC/DC ratio (P=0.002), 
decreased CD3+ lymphocytes (P=0.034) and increased circulating Treg (P<0.001) and PD-L1+ cytotoxic 
T-cell (P=0.001) frequencies.  
Conclusion: IDO expression is upregulated in circulating pDCs of high-risk melanoma patients treated 
with adjuvant IFN-α2b. This is associated with tryptophan consumption in the patients’ serum and 
higher Treg and PD-L1+ cytotoxic T-cell frequencies. We hypothesize that in IFN-α2b-treated patients, 
IDO activity acts as a negative feedback mechanism and might limit the clinical efficacy of IFN-α2b 
therapy. The underlying mechanism should be explored as this could lead to more efficient 
immunotherapies. 
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1. Introduction 
Melanoma incidence and mortality have been increasing worldwide over the past decades. Currently, 
interferon-alpha (IFN-α) is the only therapy approved in Europe for adjuvant use in patients with 
resected melanoma at high risk of recurrence. Significant relapse-free survival (RFS) benefits have been 
demonstrated, but impact on overall survival (OS) is modest.1 Nonetheless, adjuvant treatment 
options remain important as treatment of stage IV melanoma only produces long-term clinical 
responses in a minority of patients.2 
Some studies have suggested that only a subset of patients is sensitive to IFN-α.2, 3 This hypothesis is 
substantiated by the fact that there is no association between the outcome of treatment with adjuvant 
IFN-α and dose or duration of the treatment regimen. Currently, ulceration of the primary melanoma 
seems to be a promising predictive biomarker to pre-identify responders. However this remains to be 
validated in (ongoing) prospective trials,4 and the molecular mechanisms behind this effect are 
unknown to date.1 
The mechanism of action of IFN-α is believed to be mainly immunomodulatory, but results of previous 
research to elucidate it have been inconclusive so far.1, 5 Nevertheless, a systemic immunomodulatory 
effect can be inferred from the observed correlation between clinical response to IFN-α therapy and 
the occurrence of auto-immune phenomena such as vitiligo and circulating auto-antibodies.6 
IDO is the enzyme that catalyses the initial rate-limiting step in the degradation of the essential amino 
acid tryptophan into kynurenine metabolites. We were previously able to show that IDO expression in 
the sentinel lymph node is an independent negative prognostic marker that is inversely related to a 
cytotoxic immune response in the primary tumour.7, 8 IDO, together with programmed-death ligand 1 
(PD-L1) and FoxP3+ regulatory T-cells (Tregs), was also recently shown to be upregulated in the T-cell 
inflamed melanoma microenvironment.9 
In this study, we analysed circulating DC, MDSC, cytotoxic and regulatory T-cell populations, and the 
expression of IDO, PD-L1 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in the relevant 
subpopulations. The enzymatic activity of IDO was measured by the kynurenine (kyn) to tryptophan 
(trp) ratio in the patient’s serum. 
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2. Methods 
 Patients 
Eight American Joint Committee on Cancer (AJCC) stage III melanoma patients under adjuvant 
treatment with intermediate-dose IFN-α2b (IntronA, induction phase of 10x106 U/m² IV 5d/week, 
followed by maintenance phase of 5x106 U subcutaneously 3x/week for 2 years) were enrolled in this 
retrospective study. As a control population, 21 untreated melanoma patients with comparable AJCC 
stage III disease were included. Some differences in prognostic factors did exist between both patient 
groups, these are outlined in Table 1. Blood samples were prospectively  collected during clinical 
follow-up in the maintenance phase (mean interval of 175 days after start of therapy). This study was 
approved by the local medical ethical committee; all included patients signed written informed 
consent. 
Table 1: Patient characteristics 
 Stage III 
IFN-α2b-treated 
Stage III 
untreated 
Number of patients, n 8 21 
Follow-up time since inclusion, months 
(median - IQR) 
13.0 (8.0-30.5) 29.0 (15.0-45.5) 
Follow-up time since diagnosis, months 
(median – IQR) 
36.0 (18.5-58.5) 67.0 (27.5-147.5) 
Age at diagnosis, years (median - IQR) 46.5 (32.0-57.0) 53.0 (31.5-67.5) 
Female sex, % (n) 37.5 (3) 52.4 (11) 
Stage at inclusion, % (n) 
Stage IIIa / / 
Stage IIIb 75.0 (6) 61.9 (13) 
Stage IIIc 25.0 (2) 38.1 (8) 
Stage IV / / 
Melanoma characteristics 
Breslow (median, IQR) 2.74 (1.83-5.85) 2.10 (1.09-4.00) 
Ulceration, % (n) 50.0 (3) 33.3 (7) 
Location of primary melanoma 
Head & neck, % (n) 12.5 (1) 20.0 (4) 
Trunk, % (n) 62.5 (5) 25.0 (5) 
Extremities, % (n) 25.0 (2) 55.0 (11) 
Unknown primary / 1 
  IFN-α: interferon-alpha. IQR: interquartile range. 
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 PBMC isolation, culture and stimulation  
Peripheral blood mononuclear cells (PBMCs) were isolated as previously described 7. PBMCs were 
thawed by submersion at 37° for 1-2 minutes and resuspended in a medium containing Iscove’s 
Modified Dulbecco’s Medium (IMDM) supplemented with 20% FBS and 1% glutamine. Two separate 
samples were cultured overnight at 37°C in 10% CO2 in the same medium, one without stimulation 
and one with 1000 U/ml human recombinant interferon-gamma (IFN-γ, Imukin). Patient serum was 
collected at the time of PBMC isolation and stored at -80°C. 
 Flow cytometry 
Flow cytometry was performed on freshly thawed PBMCs. MDSCs were characterized by the HLA-DR- 
lineage- (CD3, CD19, CD56) CD33+ CD11b+ phenotype, mMDSCs are CD14+, pmnMDSCs are CD14-. 
Dendritic cells were characterized by the HLA-DR+ lineage- (CD3, CD14, CD16, CD19, CD20, and CD56) 
phenotype, pDCs are CD123+ CD11c- and mDCs are CD123- CD11c+. Tregs were defined as CD3+ CD4+ 
CD25+ FoxP3+ and cytotoxic T-cells as CD3+ CD8+ cells. All antibodies used in this study were 
fluorescently conjugated mouse anti-human monoclonal antibodies. The following antibodies were 
purchased from BD Biosciences; CD3 BV421, CD4 APC-Cy7, CD25 FITC, CD33 BV421, CD11b APC-Cy7, 
CD123 BV421. The following antibodies were purchased from eBioscience; B7-H1 PE-Cy7, CD8 APC, 
CD3 FITC, CD19 FITC, CD56 FITC, CD14 APC, CD11c APC, HLA-DR PerCP-Cy5.5. For intracellular stainings, 
PBMCs were fixed and permeabilized with fixation⁄permeabilization solution (BD Biosciences), and 
then stained with antihuman IDO and FoxP3 antibodies. Live/dead staining was performed using 
Live/dead® fixable aqua dead cell stain (Life Technologies Europe). Cells were analysed on a 
FACSCanto™ II  flow cytometer (BD Bioscience, Erembodegem, Belgium) using FlowJo software (Tree 
Star Inc, Ashland, OR, USA). For setting the gates, isotype and fluorescence-minus-one (FMO) controls 
were used. To provide a representative sample a median amount of 500000 cells were analysed per 
cell type. The reported frequencies of circulating cell types are percentages of live PBMCs, except for 
Treg frequencies which are percentages of CD4+ cells. 
 Ultra-performance liquid chromatography (UPLC) 
Tryptophan, kynurenine and its other downstream metabolites in patient sera were quantified by 
UPLC-MS/MS (Waters Acquity TQD), according to previously published methods, with slight 
modifications.10, 11 
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 Statistical analysis 
Median values between 2 groups were compared by the Mann-Whitney U-test, between >2 groups 
with Kruskall-Wallis testing. All statistical analyses were performed using SPSS 21.0 (SPSS Inc., Chicago, 
IL, USA), a P-value less than 0.05 was considered statistically significant (double-sided), without 
correction for multiple testing. 
 
3. Results 
 Shifts in circulating cell frequencies 
In patients treated with IFN-α2b, we observed lower frequencies of circulating CD3+ lymphocytes 
(P=0.034) and a lower mDC/DC ratio (P=0.002) resulting in a decreased mDC/pDC ratio (P=0.025) 
compared to untreated stage III patients. There was no difference in circulating MDSC (subset) 
frequencies between the patient groups. Compared to untreated stage III patients, the IFN-α2b treated 
patients had a higher circulating Treg/CD4 ratio (P<0.001, Fig. 1a). 
 Expression of IDO, PD-L1 and CTLA-4 by circulating immune cells 
Compared to untreated stage III patients, the IFN-α2b treated patients had higher frequencies of 
circulating PD-L1+ cytotoxic T-cells (P=0.001, Fig. 1b) and a trend towards higher CTLA-4 expression by 
Tregs (P=0.078).  
We have previously described IDO expression by pDCs and mMDSCs in melanoma patients (data 
submitted for publication), so IDO levels in all circulating cell subsets were compared. IFN-α2b treated 
patients had significantly higher levels of IDO-expression by pDCs (P=0.021, Fig. 1c), and a trend 
towards higher IDO expression by mMDSCs (P=0.118). 
 IDO metabolism and response to stimulation with IFN-γ 
To analyse whether the observed IDO expression corresponded with metabolic enzyme activity, UPLC 
for tryptophan and kynurenin was performed on the corresponding patients’ serum. When comparing 
patients treated with IFN-α2b with untreated stage III patients, we observed a significant rise in kyn/trp 
ratio (P=0.004, Fig. 1d) with an underlying decrease of Trp levels (P=0.011) and a trend toward 
increased levels of the different kynurenine metabolites. IFN-α2b-treated patients had lower 5-HT 
levels (P=0.046). This pattern is in accordance with tryptophan consumption, and thus with IDO 
activity.  
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Subsequently, to assess whether IFN-α2b treated patients respond differently to an inflammatory 
stimulus, PBMCs were stimulated with IFN-γ. In patients in the IFN-α2b treatment group, the absolute 
number of PBMCs that was capable of upregulating IDO or PD-L1 was lower compared to the untreated 
stage III patients (P=0.002 for both). 
 
 
 
Figure 1 
Box- and whisker plots showing that in our cohort of stage III melanoma patients, patients treated with 
adjuvant IFN-α2b had higher circulating levels of (a) regulatory T-cells (Tregs), (b) programmed-death 
ligand 1 (PD-L1)+ cytotoxic T-cells, (c) indoleamine 2,3-dioxygenase (IDO)+ plasmacytoid dendritic cells 
(pDCs) and (d) a higher kynurenine/tryptophan ratio compared to untreated controls.  
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 Immunological changes in patients with ulcerated melanoma 
As ulceration is being investigated as a possible biomarker for response to IFN-α therapy, we explored 
whether patients with an ulcerated primary melanoma had a different circulating immune profile. No 
differences were observed with regard to lymphoid cells or MDSC subsets. However, patients with an 
ulcerated primary had lower frequencies of circulating DCs (P=0.037), due to both lower mDC 
(P=0.012) and lower pDC (P=0.034) frequencies.  
 
4. Discussion 
The effect of adjuvant treatment with IFN-α on OS in melanoma patients is modest and currently 
limited data exist on its mechanism of action or predictors of response. Only few studies have focused 
on changes in circulating immune cells during adjuvant IFN-α treatment. 
In our patient population, significantly increased circulating Treg frequencies were observed, as well 
as a decrease in circulating CD3+ lymphocytes. Decreases in both CD4+ and CD8+ T-cell subsets have 
been previously described in IFN-α-treated patients, and one trial reported reduced Treg frequencies 
during high-dose IFN-α therapy, but this did not reach significance.12, 13 However, our data also point 
towards a role for circulating DCs during IFN-α treatment. Treatment with adjuvant IFN-α2b was 
associated with a decrease of the mDC/pDC ratio in the peripheral blood, while in untreated stage III 
melanoma patients circulating DC frequencies are unaltered (data submitted for publication).14 Taken 
together, these data show systemic alterations of adaptive immune cells during treatment with IFN-
α2b, but the consequences remain to be elucidated. 
We observed a remarkable overexpression of IDO by pDCs and to a lesser extent mMDSCs in stage III 
melanoma patients treated with IFN-α2b compared to untreated controls. Moreover, this 
overexpression was correlated with concomitant tryptophan consumption, corroborating that IDO 
expression by pDCs is associated with enzymatic IDO activity in the blood. The prototypical cytokine 
known to induce IDO expression directly by transcriptional activation is IFN-γ, but IFN-α can also induce 
IDO expression indirectly via downstream cytokines such as TNF-α and IFN-γ.15 Overactivation of IDO 
in response to IFN-α treatment in melanoma patients has been demonstrated, it is a key event in the 
pathogenesis of IFN-α-related depression.16 Indeed, in patients with melanoma and renal cell 
carcinoma receiving IFN-α therapy, serum tryptophan concentrations are negatively correlated with 
depressive symptoms, further supporting the presence of systemic IDO-activity.17  
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Not only was IDO upregulated in our IFN-α2b treated patients, we also found higher levels of PD-L1+ 
cytotoxic T-cells and FoxP3+ Tregs. To the best of our knowledge, this has not been reported in 
literature before. The combined upregulation of IDO, PD-L1 and Tregs was recently demonstrated to 
occur in response to IFN-γ secretion in the melanoma microenvironment.9 In theory, treatment with 
IFN-α could unwantedly contribute to the parallel induction of immunosuppressive negative feedback 
mechanisms. The development of a negative feedback response is indeed a logic sign of an induced 
immune activation. Dendritic cells have been shown to express IDO upon activation, resulting in the 
inhibition of T-cell proliferation.18 Moreover, IDO expression by pDCs has also been proposed as a 
negative factor for other immunotherapies such as DC vaccination.19 However, as the treatment 
scheme of intermediate-dose IFN-α2b takes 2 years, these mechanisms could persist and limit the 
efficacy of the treatment. The existence of both an initial immune recognition and a resulting immune 
effector phase is believed to be beneficial for the success of checkpoint inhibitors such as ipilimumab.9 
Therefore, one could also hypothesize that treatment with IFN-α contributes to this necessary immune 
recognition, but is insufficient to overcome the negative feedback loops, which would be essential for 
a longstanding final effector phase.  
We also observed borderline increased IDO expression in mMDSCs in IFN-α2b-treated patients. Even 
though MDSCs are not the typical IDO+ cell type in cancer patients, IDO+ MDSCs mediating 
immunosuppression have been described in breast cancer.20 Low MDSC levels before anti-CTLA4 
therapy in melanoma patients could predict response to anti-CTLA4 therapy, and MDSC frequencies 
remained stable during the treatment course.21 In combination with our current observations, it could 
thus be interesting to assess IDO expression by MDSCs in other immunotherapies. 
As ulceration is currently tested as a possible predictive biomarker, we evaluated the associated 
systemic immune changes and found decreased circulating DC frequencies in patients with an 
ulcerated primary melanoma. A correlation between ulceration and reduced DCs in the sentinel lymph 
node has been described,22 but as far as we know lower DC frequencies in the peripheral blood were 
unreported. These observations suggest that future research should explore the role of (p)DCs to work 
out the mechanism behind the possible predictive value of ulceration of the primary melanoma. 
Our study is the first to observe increased systemic IDO expression by pDCs and to a lesser extent 
mMDSCs in melanoma patients treated with adjuvant IFN-α2b, compared to untreated controls. 
Moreover, a concomitant increase in Tregs and PD-L1+ cytotoxic T-cells was present, suggesting the 
existence of negative feedback mechanisms in IFN-α2b-treated patients. We hypothesize that these 
could represent a persistent counterregulatory mechanism, possibly limiting the clinical effects of this 
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therapy. The underlying mechanism should be explored as this could lead to further optimization of 
IFN-α2b and other immunotherapies.  
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 Discussion 
1. Lessons for immunoprofiling 
The need for local and systemic immunological biomarkers is increasingly recognized and subject of 
intensive investigation.1-3 These immunoprofiling efforts are often focussed on providing prognostic 
information, trying to improve the current TNM classification. In the current era of immunotherapy for 
melanoma, predictive immunoprofiling is also gaining interest. This domain chiefly focuses on the 
immune micro-environment, looking for markers to predict the susceptibility of patients for different 
immunotherapeutic strategies.4-6  
 
 IDO expression in melanoma patient tissues 
In the first part of this thesis, we demonstrated that IDO-positivity in peri-tumoral endothelium is 
consistent in corresponding primary melanomas, sentinel lymph nodes and metastases. Sentinel IDO-
positivity was also inversely correlated with CD8+ lymphocytes and TILs in the primary melanoma. We 
hypothesized that IDO expression in the sentinel node of melanoma patients could be used as an early 
marker that describes the patients’ anti-tumour immune response. 
In our patients, we detected IDO expression in both host and tumour cells in the primary melanoma. 
Whereas the host IDO expression had an independent negative impact on overall survival, the IDO 
expression by melanoma cells did not. IDO expression by melanoma cells was scored for intensity on 
a 4-tiered scale (Fig. 1). Amelanotic melanomas also stained positive for IDO, making interference from 
underlying melanin in the staining less likely. We had the impression that the intensity of IDO 
expression by tumour cells was heterogeneous, as this could vary per tumour cell nest. Remarkably, 
there was no correlation between IDO expression by tumour cells and IDO expression by host cells. 
 
Chapter 5 | Discussion & future perspectives 
173 
 
 
Figure 1: IDO expression by melanoma cells in the primary melanoma.  
Slides were scored on a four-tiered scale showing IDO expression as (A) absent, (B) weak, (C) moderate 
and (D) strong.  
 
IDO expression by tumour cells can exert a biologic effect in cancer patients, which is illustrated by the 
prognostic impact in different malignancies. However, the fact that IDO expression by tumour cells has 
also been reported to lead to tumour cell apoptosis, suggests that the tumour could somehow need 
to “lose” its IDO positivity to be able to grow. We did observe an inverse correlation between the 
intensity  of IDO expression by melanoma cells and Breslow tumour thickness. This could indirectly 
support the hypothesis that continued IDO expression might somehow also impede expansive tumour 
growth. 
It goes beyond doubt that IDO can be expressed by both tumour and host cells, but why some patients 
in our study remained either IDO-positive or IDO-negative in their host cells throughout the disease 
course is unclear. This relative consistency of IDO expression per patient could be in favour both of a 
tumour-derived IDO-induction and of a host-dependent IDO-expression. Tumours could be associated 
with a particular signature of tumour-derived soluble factors, leading to a similar IDO induction 
throughout different disease stages. TGF-β, a regulatory cytokine that inhibits T-cell differentiation and 
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promotes Treg induction, has for example been proposed to be an inducer of IDO expression.7 One of 
the TGF-β family members, TGF-β2, was identified in primary melanoma cells and suggested to induce 
tolerogenic DCs.8 However, our attempts to immunohistochemically stain for TGF-β2 in primary 
melanomas succeeded in replicating the published images, but did not convince us that TGF-β2 was 
truly identified. The staining significantly overlapped with melanin expression by the tumour cells, and 
was most prominent in macrophages.  
The observation that IDO expression in metastases and peripheral blood of melanoma patients was 
consistent with IDO expression in the sentinel lymph node (resp. median 41.5 and 19 months earlier) 
does indicate that a certain host predisposition should be considered as well. It would indeed be 
striking if IDO expression in the absence of a detectable tumour load would still be orchestrated by the 
tumour cells. The host-related paradigm does not preclude the influence of the tumour, on the 
contrary. It is the presence of a tumour that elicits a certain host immune response, but the adequacy 
of this response is likely to co-depend on the host. This idea is supported by the existence of IDO and 
IFN-γ gene polymorphisms. Gene polymorphisms of both INDO and IFNG have been demonstrated to 
be associated with an upregulation of IDO expression and tryptophan metabolism in healthy 
individuals.9, 10 The role of these polymorphisms in melanoma patients remains to be elucidated, but 
it is not impossible that they could help explain a patient-dependent IDO expression pattern. 
 Circulating immune cell subsets in melanoma patients 
In melanoma, it is currently unclear which circulating immune cell types confer the most powerful 
prognostic information. Besides T-cells, myeloid-derived suppressor cells and dendritic cells are the 
most elaborately studied cell types, but research is often focused on the tumour microenvironment. 
We therefore performed a comparative evaluation of the presence of different circulating immune 
subsets in untreated melanoma patients in different stages of disease. Additionally, the expression of 
immunosuppressive molecules was also assessed. Although our data are observational and therefore 
cannot provide mechanistic insight, several patterns can be discerned when all data are analysed 
together (Table 1, in which clusters of significant observations are highlighted).  
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Table 1: Association of MDSCs and pDCs with disease course and other immune markers 
 MDSCs pDCs 
Association with disease state and prognosis 
Systemic disease Increased (P=0.046) Decreased (P=0.001) 
Active disease Increased (P=0.095) Decreased (P=0.002) 
Death Increased (P=0.073) Decreased (P=0.009) 
Correlation with other immune markers 
CD3 cells Inverse (P<0.001) None 
CD8 cells Inverse (P=0.017) None 
PD-L1+ CD8 cells Positive (P=0.033) Inverse (P=0.044) 
Tregs Inverse (P=0.007) None 
CTLA-4 expression in Tregs Positive (P=0.003) None 
MDSC: myeloid-derived suppressor cell; pDC: plasmacytoid dendritic cell; PD-L1: Programmed death 
ligand 1; Tregs: regulatory T-cells; CTLA-4: Cytotoxic T-lymphocyte antigen-4. 
 
In our patient population, circulating MDSC frequencies were strongly correlated with alterations in 
various other circulating cell types. In contrast, we observed a much weaker correlation with disease 
course and prognosis. This pattern is compatible with the profile of a principal regulatory function, in 
which case MDSCs are anticipated to influence multiple other cell types that have a downstream 
effector function. With regard to circulating pDCs, we observed that a high frequency was strongly 
correlated with disease activity, the presence of systemic disease and an evolution towards melanoma-
related death. Their impact on prognosis surpassed the MDSCs’. However, pDC frequencies were not 
consistently correlated with alterations in the other circulating cell types. Taken together, these 
observations suggest that compared to MDSCs, the regulatory impact of pDCs is weaker. The pDCs 
might be relevant more downstream, closer to the effector cells. One would expect a loss of effector 
function to be primarily related to disease severity, with a minor effect on other immune cells. Another 
pattern could be observed for circulating Tregs and cytotoxic T-cells. The frequencies of these cell types 
had no prognostic impact as such, but their expression of immunosuppressive markers (resp. CTLA-4 
and PD-L1) did ensue a negative prognostic power. We therefore hypothesize that this might indicate 
an intermediate profile, in which regulatory properties could be enforced in secondary effector cells. 
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The combination of these propositions confers a central role to MDSCs with regard to the various 
alterations in circulating cell frequencies in our melanoma patient population.  
The impact of a defective myeloid differentiation on mature DC levels has been extensively discussed 
in the second research paper and will therefore not be discussed in detail here. In line with our 
observations, an accumulation of immunosuppressive immature myeloid cells such as MDSCs 
combined with reduced frequencies of mature DCs is often seen in cancer patients.11, 12 Our data also 
corroborate those of other groups who observed that pDC defects seem to outweigh mDC defects in 
clinical importance for melanoma patients.13, 14   
 
2. Lessons for immunotherapy 
 Targets for therapy: network of IDO, PD-L1 and CTLA-4 
In this thesis we demonstrated that IDO, PD-L1 and CTLA-4 expression by circulating immune cells are 
not only individually clinically important, but that the expression of these three markers is also 
significantly intertwined. Our results support previous studies demonstrating that these markers have 
a complex, network-like interplay.15, 16 The pattern of combined expression of these three 
immunosuppressive markers was previously reported in the metastatic melanoma microenvironment, 
it is part of what is called ‘adaptive immune resistance’.17 This process starts with host type I IFN signals, 
which are required for the priming of antitumor CD8+ T-cells.18 However, even tumours that are 
infiltrated with CD8+ T-cells are not necessarily rejected, and this has been proposed to be due to a 
CD8 and IFN-γ-dependent induction of IDO, PD-L1 and Tregs in the melanoma microenvironment. In 
this study, the authors proposed that the IDO and PD-L1 expression that were detected by RT-PCR 
were attributable to tumour cells, but immunohistochemical staining of a small set of human 
melanoma metastases showed that both molecules were also expressed by stromal cells.17  
Our data in patients who are under adjuvant treatment with the type I interferon IFN-α2b suggest that 
IDO, PD-L1 and Tregs could also be relevant in patients receiving immunotherapy. Figure 2 summarizes 
our observations in a hypothetical model.   
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Figure 2: Summary of the systemic immune alterations observed in IFN-α2b-treated patients.  
Adjuvant IFN-α2b therapy was associated with higher levels of circulating IDO+ pDCs, Tregs and PD-
L1+ cytotoxic T-cells (Tcyt). A concomitant tryptophan consumption in the patients’ serum was also 
observed. We hypothesize that these alterations represent negative feedback mechanisms that could 
be induced by the immune stimulus provided by IFN-α, which is possibly insufficient to overcome the 
resulting effector cell failure.  
 
At first sight, our approach of assessing PD-L1 instead of PD-1 expression in immune cells might seem 
to be in contradiction with the current paradigm on this pathway. However, PD-L1 expression has been 
shown to occur on almost all murine lymphohematopoietic cells at varying levels, and could strongly 
be induced in T-cells after stimulation with IFN-γ.19 It is not merely a T-cell activation marker, as PD-L1 
deficient mice have enhanced T-cell responses and DC function. Moreover, PD-L1 had a role in limiting 
the expansion and survival of murine CD8+ T-cells in vivo.20 In our study, we also detected relatively 
high levels of PD-L1 expression on pmnMDSCs, but this was not related to disease course or prognosis. 
Similarly, PD-L1 expression has been detected in normal murine immature granulocytic progenitor 
cells,19 as well as in melanoma-bearing mice where it was necessary for the immunosuppressive effect 
of MDSCs.21 The functional relevance of this expression pattern in humans is unknown. 
Taken together, both literature and our data suggest that in melanoma patients multiple 
immunosuppressive mechanisms appear to operate in concert, and not just in pairs. Therefore, one 
could imagine that unless two or more of them are targeted together, resistance could emerge.  
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 Therapeutic potential 
Combination strategies 
To optimize immunotherapy for melanoma, combination strategies with the currently available 
compounds could be a successful approach. Clinical trials evaluating the concurrent use of anti-CTLA4 
and anti-PD-1 antibodies are ongoing, and preliminary results suggest excellent response rates 
(objective response rate of 40%) and manageable toxicity.22 The use of anti-PD-L1 antibodies could 
also be interesting, as the first phase I trials showed clinical results comparable to anti-PD-1 therapy.23 
PD-L1 blockade is not only expected to interrupt the PD-1/PD-L1 axis, but could also impact on the 
inhibitory signal to T-cells via CD80.24 The role of circulating PD-L1+ cytotoxic T-cells is unknown, but 
certainly worth investigating as these cells might also be affected by PD-L1 blockade.  
Even though the checkpoint inhibitors are promising as mono- or combination therapies, there seem 
to be limitations to their effects. Combining several immune checkpoint inhibitors is mainly expected 
to improve response rates in the subgroup of metastatic melanoma patients who already have a T-cell 
inflamed tumour microenvironment.25 To truly target the melanoma from different angles, a broader 
view on combination strategies could apply, as illustrated in figure 3.26 In theory, optimal combination 
strategies should be designed to not only break pre-existing tolerance but also provide the immune 
system with a set of tumour antigens. These antigens should be presented in an activated immune 
milieu, with sufficient co-stimulatory signals to drive a potent anti-tumour response.27  
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Figure 3: Proposed model for combination therapy in the future, including IDO inhibitors.  
Multiple applications are suggested in various combinations that include tolerance blockade (immune 
checkpoint inhibitors), active  immunotherapeutic interventions (vaccines), and classical/targeted 
chemotherapy or radiotherapy. Adapted from Prendergast, 2014.26 
 
In mouse models, the administration of an IDO inhibitor as a monotherapy could retard but not stop 
tumour growth,28, 29 so combination strategies are a logical approach. In mice, an upregulation of IDO 
mRNA was observed after treatment with a PD-L1 inhibitor.25 Adding an IDO-inhibitor to either 
checkpoint inhibitors or vaccines might prevent the tumour from escaping the induced immune 
response by reprogramming the inflammatory climate. Holmgaard et al. elegantly showed that IDO 
impedes the function of anti-CTLA-4 and anti-PD-1/PD-L1 therapies. Adding an IDO-inhibitor to anti-
CTLA-4 therapy significantly increased response rates in B16 melanoma-bearing mice.30 However, 
improved tumour control with combinations of immunotherapies has been reported to depend on an 
increased proliferation and IL-2 secretion of tumour-infiltrating CD8+ T-cells.25 This indicates that 
recognition of the tumour by the immune system is required to achieve the full therapeutic effect. 
Even though melanoma is a highly immunogenic tumour, not all melanomas elicit a spontaneous 
immune response. Strategies to first induce an immune response could therefore be promising, and 
might even be found in currently available treatment options. The mechanism of cell death following 
treatment with a BRAF inhibitor is not known, but animal models suggest apoptosis over necrosis. 
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Apoptotic cell death can cause the release of tumour antigens, which in turn could set the stage for 
more effective immunotherapy.31 Indeed, BRAF-targeted therapy can increase the expression of 
melanocyte differentiation antigens, leading to enhanced recognition by antigen-specific cytotoxic T-
lymphocytes without compromising lymphocyte function in vitro.32 Hypothetically, this could reinforce 
an existing or launch an absent immune response by the host, resulting in more effective 
immunotherapy afterwards. The combined use of ipilimumab and a BRAF-inhibitor unfortunately 
caused unacceptable liver toxicity,33 but sequential treatment might resolve this issue.34 The same 
theory might also apply to chemotherapy. The combination of 1MT with paclitaxel did produce 
improved responses in a murine breast cancer model, compared to paclitaxel or 1MT alone.35 Yet 
another possibility is radiotherapy, which is widely believed to act by inducing lethal DNA damage  in 
tumour cells. However, in a B16 melanoma model, mice receiving local tumour irradiation had 
increased TILs that secreted IFN-γ and lysed tumour cell targets.36 Even more, the induction of type I 
IFN by local radiotherapy was reported to be necessary for the therapeutic effect, by enhancing the 
cross-priming ability of tumour-infiltrating DCs.37  
Vaccination as a strategy to stimulate the adaptive immune system in the context of tumours has often 
been tried, but the various vaccination approaches that have been tested in melanoma so far have at 
best generated moderate effects. It could be worthwhile to investigate the role of IDO in this type of 
treatment, as IDO-mediated immune suppression can be induced when CpG-rich oligonucleotides (a 
commonly used vaccine adjuvant) are delivered systemically.38, 39 Moreover, mature DCs generated for 
therapeutic vaccination have been described to become IDO-positive and be able to induce FoxP3+ 
cells at the injection site.40 It could therefore be interesting to investigate the addition of an IDO-
inhibitor. However, IDO-deficient mice were reported to develop a more severe acute pancreatitis 
upon administration of complete Freund’s adjuvant (CFA) compared to wild-type mice.41 Some caution 
is thus warranted in future clinical trials assessing IDO inhibition combined with vaccine administration.  
Theoretically speaking, IDO inhibitors could also be used in the adjuvant setting. There are no data 
available from mouse models in this context, but combination therapy of anti-PD-L1 and anti-CTLA-4 
was less effective when murine melanomas were allowed to grow larger before therapy was initiated.25 
Our data suggest the continued presence of IDO-based negative feedback mechanisms in high-risk 
melanoma patients treated with IFN-α2b. Adding an IDO inhibitor might help to counteract this.  
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Controversies surrounding the clinical potential of IDO inhibition 
As outlined in the introduction, IDO is a powerful mechanism of acquired systemic tolerance to foreign 
antigens, but is not essential for the maintenance of self-tolerance. The effects of IDO appear to be 
selective, and focused on specific forms of acquired peripheral tolerance. This specificity is a potential 
advantage in case of pharmacological IDO inhibition, as severe autoimmunity is not expected to be a 
limiting side-effect.42 On the other hand, the relative redundancy of IDO raises questions on the 
efficacy of IDO inhibition.  
When we view the idea of IDO blockade in the light of our new data, some remarks have to be made. 
For one, the in vivo role of IDO+ pDCs in melanoma patients remains unclear. IDO+ DCs with 
immunosuppressive properties were identified as CD123+ CCR6+ cells, generated from blood 
monocytes.43 Neither the IDO expression nor the immunosuppressive effects of these CCR6+ pDCs 
could be confirmed by another group.44 One proposed factor that could account for these 
discrepancies is that the studies identifying IDO expression in DCs used a highly cross-reactive 
polyclonal rabbit antibody that has been reported to also display non-specific staining.43, 45, 46 In our 
research, IDO expression was detected in CD123+ pDCs, but this was not associated with disease 
progression or survival. Monocytic MDSCs also expressed IDO, but the functional implications are 
equally unclear. The role of IDO in pDCs and mMDSCs in melanoma should therefore be further 
investigated. 
Some authors have reported positive prognostic effects of IDO expression, causing concern about the 
consequences of inhibition. Based on the available evidence, IDO seems to mainly play a role in chronic 
inflammation, and not so much in acute. Depending on the context, chronic inflammation may either 
promote or suppress neoplastic transformation. Hence, it is conceivable IDO could play a dual role in 
tumorigenesis by restricting the development of cancers that are driven by chronic inflammation, 
while promoting the development of tumours that are kept under control by chronic inflammation. 
This theory is supported by the observation that IDO-knock-out mice were reported to develop more 
colon carcinomas in a model of induced colitis.41 In contrast, IDO-deficient mice were more resistant 
to tumour formation in a chemically-induced skin carcinogenesis model.47 An alternative hypothesis is 
that IDO’s tumour-promoting role is only evident in patients who already have an active immune 
response against the tumour, in which IDO can act as a negative feedback mechanism. In patients in 
whom the tumour is not recognized by the immune system, IDO cannot impede the immune response 
and might then act as a tumour cell growth inhibitor.44 The eventual effect of IDO thus seems to depend 
on the context of its expression, but how this is determined remains subject to debate.  
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Even though these arguments illustrate that a certain degree of caution regarding the use of IDO 
inhibition in cancer patients is warranted, history has also taught that a thorough understanding of the 
mechanism of action of a compound often lags behind its therapeutic utility. The first clinical trials 
using IDO inhibitors are indeed already ongoing, and results are eagerly awaited.  
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 Future perspectives 
1. IDO as a possible predictive marker for response to  immunotherapy? 
Prognostic markers are useful to make a risk-assessment for an individual patient and can provide 
insights in the biology of a certain tumour. However, contrary to predictive biomarkers, they do not 
confer information on the likelihood of therapeutic effectiveness.48 Over the last few years, 
immunoprofiling efforts have increased as immunotherapeutic strategies gain importance in the 
management of melanoma and other cancers. Several (combinations of) markers with predictive or 
prognostic quality have been suggested, mainly focusing on the tumour microenvironment.49, 50 Apart 
from its prognostic properties, IDO expression analysis could also be useful for predictive 
immunoprofiling, as immunohistochemical IDO-positivity in the tumour microenvironment has been 
shown to predict response to anti-CTLA-4 therapy in patients with metastatic melanoma.51 Similarly, 
overexpression of the IDO1 gene correlated with the effectiveness of ipilimumab in another trial.52 We 
have therefore started to collect melanoma tissue samples (FFPE, primary melanoma, sentinel lymph 
nodes and metastatic melanoma) with a known response to ipilimumab to assess the relevance of IDO 
expression as a possible marker for response. Others have also demonstrated that lower levels of 
circulating mMDSCs before initiation of anti-CTLA-4 therapy are associated with increased response.53, 
54 The relevance of the IDO+ mMDSCs we observed could therefore also be evaluated in melanoma 
patients. These projects might not only provide predictive information, but also help to elucidate the 
counter-regulatory mechanisms that seem to hamper the efficacy of current checkpoint inhibitors.  
 
2. Endothelial IDO expression 
IDO activity has been most extensively studied in dendritic cells, but there is also evidence that IDO 
expression by endothelial cells plays an important role in immune regulation. The most mature data 
on this topic come from transplantation experiments, because the first cells that are encountered by 
a T-cell when moving into a solid organ transplant are endothelial cells. Spontaneous IDO expression 
has been found in human umbilical vein endothelial cells (HUVECs) and overexpression of IDO by 
endothelial cells could prevent T-cell activation in vitro.55 IDO expression in the placenta protects the 
foetus from attack by maternal lymphocytes, so one could deduce that IDO upregulation in tumour-
surrounding endothelium may likewise form a barrier that protects malignant cells from attack by 
circulating immune cells.  
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The in vivo importance of endothelial IDO has been demonstrated by experiments in mice, where IDO-
expression by endothelial cells could prevent the rejection of cardiac allografts.56, 57 In humans, IDO 
expression in monocyte-derived endothelial-like cells has also been described in infantile 
haemangioma.58 Moreover, IDO expression in tumour-associated endothelial cells was found to have 
a positive prognostic effect in patients with renal cell cancer, but the prognostic data were based on 
qRT-PCR, and not on immunohistochemistry.59 A recent clinical study also demonstrated that IDO 
expression, partly by endothelial cells, is an independent risk factor for poor response in melanoma 
patients treated with anti-CTLA-4 therapy.51  
In our studies, we have found a remarkable correlation between peri-tumoral endothelial IDO 
expression in the primary melanoma and IDO expression by high-endothelial venules in the 
corresponding sentinel lymph node. This raises the question of whether the origin of the peri-tumoral 
IDO-expressing endothelial cells is vascular or lymphatic. We will therefore perform 
immunohistochemistry on serial sections of primary melanomas for IDO, CD31 (a vascular marker) and 
podoplanin (a lymphatic marker). 
 
3. Prospective bio-banking essential in future of translational research 
In our studies we observed that in disease-free patients who relapse shortly after sample procurement, 
a decline in pDCs and a rise in PD-L1+ cytotoxic T-cells can be seen before relapse is clinically detected 
(Fig. 4). These observations suggest that pDCs and PD-L1+ cytotoxic T-cells might be interesting 
biomarkers for follow-up of high-risk, disease-free melanoma patients. However, as these data were 
obtained in a cross-sectional study, confirmation in a prospective longitudinal study with multiple 
follow-up samples during disease course is necessary before any conclusions can be drawn. 
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Figure 4: Circulating pDC and PD-L1+ cytotoxic T-cell levels before relapse.  
Scatter plots showing a decline in pDCs (left) and a rise in PD-L1+ cytotoxic T-cells (right) in disease-
free melanoma patients. The ‘zero’ time point indicates the moment that disease relapse was 
diagnosed.  
 
To assess the validity of these observations, we will start to prospectively recruit all high-risk (stage II-
III) melanoma patients who are disease-free after surgery for the primary tumour. Blood samples for 
PBMC isolation will be collected every 3 months, to enable the detection of alterations in cell subset 
frequencies over time. Functional assessment of systemic immunity by CFSE suppression assays will be 
done to compare patients who relapse to those who remain disease-free. This will be focussed on pDCs 
and PD-L1+ cytotoxic T-cells. Plasmacytoid DCs will be isolated by MACS and tested for their expression 
of markers for activation vs tolerogenicity, as well as their IDO expression. This could identify new 
targets to stimulate the DC populations that are failing in patients with relapsing disease. The function 
of PD-L1+ cytotoxic T-cells is unknown. These cells will likewise be separated, to allow for further 
characterisation. Mart-1 tetramer+ CD8+ TILs have previously been reported to be PD-1+.60 One 
hypothesis is that these circulating PD-L1+ cytotoxic T-cells might thus be tumour-specific T-cells, so a 
tetramer analysis will also be performed.  
Similarly, prospective longitudinal PBMC sample collection will be initiated in stage III and IV melanoma 
patients who start on IFN-α2b or ipilimumab therapy, to further evaluate the role of systemic IDO 
expression by pDCs and mMDSCs during immunotherapy.   
Chapter 5 | Discussion & future perspectives 
186 
 
References 
1. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, 
Bifulco C, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant 
tumours. The Journal of pathology 2014; 232:199-209. 
2. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti 
G, et al. Cancer classification using the Immunoscore: a worldwide task force. Journal of translational 
medicine 2012; 10:205. 
3. Bindea G, Mlecnik B, Fridman WH, Pages F, Galon J. Natural immunity to cancer in humans. 
Current opinion in immunology 2010; 22:215-22. 
4. Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarkers for Immunostimulatory 
Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types. Clinical 
Cancer Research 2013; 19:1009-20. 
5. Ji RR, Chasalow SD, Wang LS, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-
Kunkel M, Siemers NO, et al. An immune-active tumor microenvironment favors clinical response to 
ipilimumab. Cancer Immunol Immun 2012; 61:1019-31. 
6. Gajewski TF. Molecular Profiling of Melanoma and the Evolution of Patient-Specific Therapy. 
Semin Oncol 2011; 38:236-42. 
7. Belladonna ML, Orabona C, Grohmann U, Puccetti P. TGF-beta and kynurenines as the key to 
infectious tolerance. Trends in molecular medicine 2009; 15:41-9. 
8. Polak ME, Borthwick NJ, Gabriel FG, Johnson P, Higgins B, Hurren J, McCormick D, Jager MJ, 
Cree IA. Mechanisms of local immunosuppression in cutaneous melanoma. British journal of cancer 
2007; 96:1879-87. 
9. Soichot M, Hennart B, Al Saabi A, Leloire A, Froguel P, Levy-Marchal C, Poulain-Godefroy O, 
Allorge D. Identification of a variable number of tandem repeats polymorphism and characterization 
of LEF-1 response elements in the promoter of the IDO1 gene. PloS one 2011; 6:e25470. 
10. Raitala A, Pertovaara M, Karjalainen J, Oja SS, Hurme M. Association of interferon-gamma 
+874(T/A) single nucleotide polymorphism with the rate of tryptophan catabolism in healthy 
individuals. Scandinavian journal of immunology 2005; 61:387-90. 
Chapter 5 | Discussion & future perspectives 
187 
 
11. Lindenberg JJ, Fehres CM, van Cruijsen H, Oosterhoff D, de Gruijl TD. Cross-talk between tumor 
and myeloid cells: how to tip the balance in favor of antitumor immunity. Immunotherapy 2011; 3:77-
96. 
12. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell 
defects. Nature reviews Immunology 2004; 4:941-52. 
13. Failli A, Legitimo A, Orsini G, Romanini A, Consolini R. Numerical defect of circulating dendritic 
cell subsets and defective dendritic cell generation from monocytes of patients with advanced 
melanoma. Cancer letters 2013; 337:184-92. 
14. Chavan R, Salvador D, Gustafson MP, Dietz AB, Nevala W, Markovic SN. Untreated stage IV 
melanoma patients exhibit abnormal monocyte phenotypes and decreased functional capacity. Cancer 
immunology research 2014; 2:241-8. 
15. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna 
ML, Bianchi R, Fioretti MC, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nature 
immunology 2002; 3:1097-101. 
16. Fujimura T, Kambayashi Y, Aiba S. Crosstalk between regulatory T cells (Tregs) and myeloid 
derived suppressor cells (MDSCs) during melanoma growth. Oncoimmunology 2012; 1:1433-4. 
17. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-
L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Science 
translational medicine 2013; 5:200ra116. 
18. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN 
signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. The 
Journal of experimental medicine 2011; 208:2005-16. 
19. Ishida M, Iwai Y, Tanaka Y, Okazaki T, Freeman GJ, Minato N, Honjo T. Differential expression 
of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic 
tissues. Immunology letters 2002; 84:57-62. 
20. Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, Klemm M, Kuchroo VK, Freeman GJ, Sharpe 
AH. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues 
negatively regulates T cells. Proceedings of the National Academy of Sciences of the United States of 
America 2004; 101:10691-6. 
Chapter 5 | Discussion & future perspectives 
188 
 
21. Fujimura T, Ring S, Umansky V, Mahnke K, Enk AH. Regulatory T cells stimulate B7-H1 
expression in myeloid-derived suppressor cells in ret melanomas. The Journal of investigative 
dermatology 2012; 132:1239-46. 
22. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, 
Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. The New England journal 
of medicine 2013; 369:122-33. 
23. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, 
Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New 
England journal of medicine 2012; 366:2455-65. 
24. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 
interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 
27:111-22. 
25. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor 
rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and 
proliferation of CD8(+) T cells directly within the tumor microenvironment. Journal for immunotherapy 
of cancer 2014; 2:3. 
26. Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ. 
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. 
Cancer immunology, immunotherapy : CII 2014; 63:721-35. 
27. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. The Journal 
of clinical investigation 2007; 117:1147-54. 
28. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde 
BJ. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by 
indoleamine 2,3-dioxygenase. Nature medicine 2003; 9:1269-74. 
29. Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, 
Antonia SJ. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated 
rejection. International journal of cancer Journal international du cancer 2002; 101:151-5. 
30. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a 
critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. The Journal of 
experimental medicine 2013; 210:1389-402. 
Chapter 5 | Discussion & future perspectives 
189 
 
31. Cartlidge RA, Thomas GR, Cagnol S, Jong KA, Molton SA, Finch AJ, McMahon M. Oncogenic 
BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment cell & melanoma 
research 2008; 21:534-44. 
32. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, 
Lawrence DP, Fisher DE, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma 
without affecting lymphocyte function. Cancer research 2010; 70:5213-9. 
33. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of 
vemurafenib and ipilimumab. The New England journal of medicine 2013; 368:1365-6. 
34. Schreuer M, Chevolet I, Jansen Y, Seremet T, Wilgenhof S, Liénard D, del Marmol V, Neyns B. 
Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor 
failure. . Melanoma research 2014. 
35. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of 
indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, 
potentiates cancer chemotherapy. Nature medicine 2005; 11:312-9. 
36. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of 
B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to 
the tumor. Journal of immunology 2005; 174:7516-23. 
37. Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, Auh SL. The 
efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive 
immunity. Cancer research 2011; 71:2488-96. 
38. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH. Cutting edge: CpG 
oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-
dependent T cell regulatory functions via IFN Type 1 signaling. Journal of immunology 2005; 175:5601-
5. 
39. Wingender G, Garbi N, Schumak B, Jungerkes F, Endl E, von Bubnoff D, Steitz J, Striegler J, 
Moldenhauer G, Tuting T, et al. Systemic application of CpG-rich DNA suppresses adaptive T cell 
immunity via induction of IDO. European journal of immunology 2006; 36:12-20. 
40. Wobser M, Voigt H, Houben R, Eggert AO, Freiwald M, Kaemmerer U, Kaempgen E, Schrama 
D, Becker JC. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-
dioxygenase expression. Cancer immunology, immunotherapy : CII 2007; 56:1017-24. 
Chapter 5 | Discussion & future perspectives 
190 
 
41. Chang MY, Smith C, DuHadaway JB, Pyle JR, Boulden J, Soler AP, Muller AJ, Laury-Kleintop LD, 
Prendergast GC. Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory 
enzyme indoleamine 2,3-dioxygenase. Cancer biology & therapy 2011; 12:1050-8. 
42. Mellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A, Koni PA, Iwashima M, Munn 
DH. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses 
T cell clonal expansion. Journal of immunology 2003; 171:1652-5. 
43. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, 
Antonia SJ, Burgess R, et al. Potential regulatory function of human dendritic cells expressing 
indoleamine 2,3-dioxygenase. Science 2002; 297:1867-70. 
44. Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P. Inhibitors of indoleamine-2,3-
dioxygenase for cancer therapy: can we see the wood for the trees? Nature reviews Cancer 2009; 
9:445-52. 
45. Lee JR, Dalton RR, Messina JL, Sharma MD, Smith DM, Burgess RE, Mazzella F, Antonia SJ, 
Mellor AL, Munn DH. Pattern of recruitment of immunoregulatory antigen-presenting cells in 
malignant melanoma. Laboratory investigation; a journal of technical methods and pathology 2003; 
83:1457-66. 
46. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, 
Mellor AL. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-
draining lymph nodes. The Journal of clinical investigation 2004; 114:280-90. 
47. Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA, 3rd, Kahler DJ, 
Pihkala J, Soler AP, Munn DH, et al. Chronic inflammation that facilitates tumor progression creates 
local immune suppression by inducing indoleamine 2,3 dioxygenase. Proceedings of the National 
Academy of Sciences of the United States of America 2008; 105:17073-8. 
48. Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic 
and predictive immune markers in cancer. Current opinion in immunology 2013; 25:261-7. 
49. Ascierto PA, Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A, Marincola FM, Ciliberto G, Galon 
J, Fox BA. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for 
cancer treatment. Journal of translational medicine 2013; 11:54. 
Chapter 5 | Discussion & future perspectives 
191 
 
50. Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarkers for immunostimulatory 
monoclonal antibodies in combination strategies for melanoma and other tumor types. Clinical cancer 
research : an official journal of the American Association for Cancer Research 2013; 19:1009-20. 
51. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gomez H, 
Bastholt L, et al. A prospective phase II trial exploring the association between tumor 
microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. Journal of 
translational medicine 2011; 9:204. 
52. Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-
Kunkel M, Siemers NO, et al. An immune-active tumor microenvironment favors clinical response to 
ipilimumab. Cancer immunology, immunotherapy : CII 2012; 61:1019-31. 
53. Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, Michielin O, 
Romano E, Speiser DE. Frequencies of circulating MDSC correlate with clinical outcome of melanoma 
patients treated with ipilimumab. Cancer immunology, immunotherapy : CII 2014; 63:247-57. 
54. Kitano S, Postow MA, Cortez C, Rasalan T, Gallardo HF, Panageas K, Yuan JD, Wolchok JD, 
Lesokhin AM. Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10mg/kg 
to predict for overall survival in patients with metastatic melanoma. Journal of Clinical Oncology 2012; 
30. 
55. Beutelspacher SC, Tan PH, McClure MO, Larkin DF, Lechler RI, George AJ. Expression of 
indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses. 
American journal of transplantation : official journal of the American Society of Transplantation and 
the American Society of Transplant Surgeons 2006; 6:1320-30. 
56. Guillonneau C, Hill M, Hubert FX, Chiffoleau E, Herve C, Li XL, Heslan M, Usal C, Tesson L, 
Menoret S, et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, 
IFN-gamma, and indoleamine 2,3-dioxygenase. The Journal of clinical investigation 2007; 117:1096-
106. 
57. Thebault P, Condamine T, Heslan M, Hill M, Bernard I, Saoudi A, Josien R, Anegon I, Cuturi MC, 
Chiffoleau E. Role of IFNgamma in allograft tolerance mediated by CD4+CD25+ regulatory T cells by 
induction of IDO in endothelial cells. Am J Transplant 2007; 7:2472-82. 
58. Herbert A, Ng H, Jessup W, Kockx M, Cartland S, Thomas SR, Hogg PJ, Wargon O. Hypoxia 
regulates the production and activity of glucose transporter-1 and indoleamine 2,3-dioxygenase in 
Chapter 5 | Discussion & future perspectives 
192 
 
monocyte-derived endothelial-like cells: possible relevance to infantile haemangioma pathogenesis. 
The British journal of dermatology 2011; 164:308-15. 
59. Riesenberg R, Weiler C, Spring O, Eder M, Buchner A, Popp T, Castro M, Kammerer R, Takikawa 
O, Hatz RA, et al. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with 
long-term survival of patients with renal cell carcinoma. Clinical cancer research : an official journal of 
the American Association for Cancer Research 2007; 13:6993-7002. 
60. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg 
SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are 
functionally impaired. Blood 2009; 114:1537-44. 
 193 
 
 
 
 
 
DANKWOORD 
  
 194 
 
 Dankwoord 
Een doctoraatsverdediging kan ten onrechte de indruk wekken dat het gepresenteerde werk 
uitsluitend de verdienste is van de hoofdrolspeler, de doctorandus. In werkelijkheid gaat hierachter de 
inzet van een volledig team schuil. Dit proefschrift zou daarom niet compleet zijn zonder een woord 
van dank aan iedereen die dit mee mogelijk heeft gemaakt.  
Een uitnodiging van Prof. Lieve Brochez was de aanzet van dit doctoraat. Ze werd mijn promotor, 
zonder haar zou dit onderzoek nooit begonnen zijn. Ik wil je bedanken Lieve, voor de inspiratie, de 
motivatie en het vertrouwen. Vier jaar geleden heb je me overtuigd van het belang van dit onderwerp, 
sindsdien heb je me steeds met overgave en een grote betrokkenheid begeleid. De vrijheid die je me 
bood om dit project uit te werken was voor mij van onschatbare waarde. Ik heb de voorbije jaren veel 
van je geleerd, en hoop dat we in de toekomst nog vaak zullen samenwerken.  
Eens de intentie tot doctoreren bestond, was financiering vinden de volgende hindernis. Deze 
opdracht werd mijn eerste kennismaking met Dr. Mireille Van Gele, mijn co-promotor. Bedankt 
Mireille, voor al je hulp bij het schrijven van die projecten. Je was steeds aanwezig en jouw organisatie 
van de researchactiviteiten vormde het onontbeerlijke decor waarin mijn onderzoek zich afspeelde. Je 
zorgde ervoor dat mijn kostbare projecten in goede handen waren, ook als ik er zelf eens niet was. 
Zonder jou was ik verloren gelopen in deze nieuwe wereld.  
Als derde speler in dit verhaal verscheen Reinhart ten tonele. Hem slechts ‘mijn voorganger’ noemen 
zou zijn rol oneer aandoen. Je hebt talloze nieuwe ideeën aangereikt, waar nodig de mijne bijgestuurd 
en met de glimlach mijn vele vragen beantwoord. Ik prijs me gelukkig dat ik van je voorbeeld heb 
mogen leren. 
Het mag duidelijk zijn dat ik dit project heb kunnen aanvangen met een optimale entourage, maar 
helaas was ik een protagonist zonder praktijkervaring. Dat ik nu epjes van cryotubes kan 
onderscheiden en weet wat ermee gedaan, is de verdienste van onze doorwinterde laboranten. 
Bedankt Els, Marie-Chantal en Martine voor jullie uitleg, geduld en bereidwillige assistentie. Waar 
nodig kwam de hulp zelfs van over de vakgroepsgrenzen heen, in het bijzonder van Gaby en Olga.  
Eens de bezetting compleet was, kon de uitvoering beginnen. Dit werk rust sterk op een grote biobank. 
Het verzamelen van de bloed- en weefselstalen die de bron voor dit translationele onderzoek vormen 
is een werk zonder einde. Ik ben al het personeel van de polikliniek dermatologie dan ook zeer 
dankbaar voor de ondersteuning die zij hierin boden. De inzet van de verpleegkundigen, de 
supervisoren en de collega’s assistenten is en blijft een conditio sine qua non voor dit soort onderzoek. 
 195 
 
Onze oncologisch verpleegkundige speelde hierin een centrale rol. An, het plezier en de efficiëntie 
waarmee je de rekrutering in handen hebt genomen werkten aanstekelijk. Ik heb je inspirerende 
positivisme erg gewaardeerd. Een bijzonder woord van dank gaat ook naar de melanoompatiënten. Zij 
waren nagenoeg altijd bereid om deel te nemen aan deze studie, ondanks de vaak moeilijke 
omstandigheden. Deze mensen verdienen hiervoor een warm applaus. 
Met enig vallen en opstaan werden resultaten behaald, papers geschreven en kon tenslotte deze thesis 
worden samengesteld. Nazicht en deliberatie doen elke tekst wel varen, voor een proefschrift is het 
niet anders. Dit werk heeft in elk stadium kunnen profiteren van opbouwende kritiek; eerst tijdens de 
onderzoeksvergaderingen van de DRU, vervolgens door mijn trouwe co-auteurs en tenslotte door de 
juryleden. Ik ben iedereen die inbreng heeft gehad zeer erkentelijk voor hun bijdrage aan de kwaliteit 
van mijn thesis.  
Zonder financiering blijven ideeën  slechts ideeën, en zou van een doctoraat nu geen sprake zijn. Mijn 
aspirantschap bij het FWO was de aanzet, de fondsen van het Kankerplan via Prof. Bart Neyns waren 
het vervolg. Ik dank jullie voor jullie vertrouwen en interesse in dit project.  
Men denkt wel eens dat het leven van een onderzoeker eenzaam is, opgesloten tussen cellen en 
toestellen in een labo. Wie in het MRB gewerkt heeft, weet dat het tegendeel waar is. De laboranten, 
post-docs en doctoraatsassistenten vormen een goed team, met ploeggeest en wederzijdse 
sympathie. De sfeer waarin ik heb kunnen werken was fantastisch. Ik wens de andere 
doctoraatsstudenten Ana-Karina, Anesh, Eline en Isabelle heel veel succes bij hun projecten, met als 
beloning een welverdiend doctoraat. Isabelle, je bent de voorbije 2 jaar uitgegroeid tot meer dan een 
collega. Ik hoop dat we in de toekomst samen kunnen blijven lachen, en alle grote en kleine problemen 
op aarde oplossen tijdens de lunch.  
Ik heb werkelijk genoten van mijn werk als doctorandus, maar niets is te vergelijken met het plezier 
dat ik heb met mijn vrienden. De steun, het begrip en het geluk waarvan jullie de bron zijn, geeft mijn 
leven kleur. We zien elkaar thuis en op restaurant, op weekend en op reis, en telkens weer doet jullie 
gezelschap me lachen. Mijn nakende meterschap van Ingeborgs’ Baby Pluis maakt me trotser dan wat 
dan ook. 
Een ereplaats in dit dankwoord komt toe aan de regisseurs van mijn bestaan. Mama en papa, jullie 
liggen aan de basis van alle kleine en grote successen in mijn leven. Het warme gezin waarin ik ben 
opgegroeid heeft me gemaakt tot wie ik ben. Jullie leerden me doorzetten en steeds rustig te blijven. 
Dankzij jullie heb ik zowel vertrouwen als plezier in alles wat ik onderneem. Ook mijn zus Aude verdient 
 196 
 
een medaille. Zusje, zonder het te beseffen leer je me creatiever denken en buiten mijn comfortzone 
treden. Je onvoorwaardelijke steun sterkt me enorm.  
Doorheen de voorbije tien jaar heb ik in de Schreuers een tweede familie gevonden. Ik had me geen 
betere schoonouders dan Tania en Rodolphe kunnen wensen. Bovendien zijn mijn schoonbroers en –
zussen echte vrienden geworden. Mijn eigen grootouders kunnen dit niet meer meemaken, maar 
dankzij Bonnemaman en opa en oma Bril voelt het alsof ik nog steeds grootouders heb. 
Zo kom ik bij de apotheose van dit dankwoord, en die wil ik wijden aan mijn echtgenoot Max. Je 
kritische oog heeft menigeen van mijn ideeën en teksten verbeterd, je bent een klankbord voor alle 
beslissingen die ik neem. Maar boven alles ben je mijn beste vriend, mijn partner voor het leven en de 
papa van onze kleine Roxane. Mijn echte thuis is waar jij bent, met jouw steun kan ik alles aan.   
 
Inès 
20 augustus 2015 
  
 197 
 
 
 
 
 
CURRICULUM VITAE 
  
 198 
 
 Curriculum Vitae 
 
PERSONAL DATA 
Name:  Inès Chevolet 
Date & place of birth:  May 4th, 1986, Ghent 
Nationality: Belgian 
Marital status: Married 
Address: UZ Gent, De Pintelaan 185, 9000 Gent, Belgium 
Tel. +32 (0) 9 332 48 06 
E-mail: ines.chevolet@ugent.be 
 
EDUCATION 
2012-2015 PhD fellow (FWO fellowship, Ghent University) 
2011-2017 Residency Dermatology (Dept. of Dermatology, Ghent University Hospital) 
2004-2011 Medical doctor, summa cum laude (Ghent University) 
1998-2004 Latin-Mathematics, magna cum laude (Sint-Pietersinstituut Ghent) 
 
POSTGRADUATE COURSES 
2013 EADO School “Fundamentals of cutaneous oncology” (EADO, Berlin) 
2012 Statistical analysis, advanced course (Ghent University) 
2012 Statistical analysis, basic principles (Ghent University) 
2008 Basic principles of electrocardiography (Ghent University) 
 
 199 
 
A1 PUBLICATIONS 
Hoorens I, Vossaert K, Pil L, Boone B, De Schepper S, Ongenae K, Annemans L, Chevolet I, Brochez L. 
Participation rate, effectiveness, and cost of standard total-body examination vs lesion-directed 
screening. Journal of the American Medical Association for Dermatology 2015; doi: 
10.1001/jamadermatol.2015.2680. 
Chevolet I, Schreuer M, Speeckaert R, Neyns B, van Geel N, Krüse V, Hennart B, Allorge D, Van Gele M, 
Brochez L. Systemic immune changes associated with adjuvant IFN-α-therapy in stage III melanoma 
patients: failure at the effector phase? Melanoma Research 2015; 25(4):357-61. 
Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, Hennart B, Allorge D, van Geel N, 
Van Gele M, Brochez L. The in vivo immune network of IDO, tryptophan metabolism, PD-L1 and CTLA-
4 in circulating immune cells in melanoma. Oncoimmunology 2015; 4(3): e982382. 
Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, Van Gele M, van Geel N, Brochez 
L. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in 
melanoma. Journal of Translational Medicine 2015; 16:13-9. 
Schreuer M, Chevolet I, Jansen Y, Seremet T, Wilgenhof S, Liénard D, del Marmol V and Neyns B. 
Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor 
failure. Melanoma Research 2015; 25(1):68-74. 
Chevolet I, Speeckaert R, Haspeslagh M, Neyns B, Krüse V, Schreuer M, Van Gele M, Van Geel N, 
Brochez L. Peri-tumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of 
resistance to immune control? British Journal of Dermatology 2014;171(5):987-95. 
Chevolet I, Hoorens I, Janssens A, Speeckaert R, Van Geel N, Van Maele G, Vossaert K and Brochez L. 
Brief report: A short dermoscopy training increases diagnostic performance in both inexperienced and 
experienced dermatologists. Australasian Journal of Dermatology 2015;56(1):52-5. 
van Geel N, Speeckaert M, Chevolet I, De Schepper S, Lapeere H, Boone B, Speeckaert R. 
Hypomelanoses in Children. Journal of Cutaneous and Aesthetic Surgery 2013;6(2):65-72. Review. 
Dynoodt P, Speeckaert R, De Wever O, Chevolet I, Brochez L, Lambert J, Van Gele M. miR-145 
overexpression suppresses the migration and invasion of metastatic melanoma cells. International 
Journal of Oncology 2013;42(4):1443-51.  
van Geel N, Speeckaert R, De Wolf J, Bracke S, Chevolet I, Brochez L, Lambert J. Clinical significance of 
Koebner phenomenon in vitiligo. British Journal of Dermatology 2012;167(5):1017-24. 
 200 
 
Speeckaert R, Van Geel N, Lambert J, Boone B, Chevolet I, Van Gele M, Speeckaert MM, Brochez L. 
Immune mediated mechanisms of melanocyte destruction: Paving the way for efficient 
immunotherapeutic strategies against melanoma. Oncoimmunology 2012;1(4):526-528. 
 
ABSTRACTS/POSTERS/NON-A1 PUBLICATIONS 
Brochez L, Chevolet I. IDO as an early marker of immune resistance in melanoma. 11th EADO congress 
2015; Marseille, France.  
Hoorens I, Vossaert K, Pil L, Boone B, De Schepper S, Ongenae K, Annemans L, Chevolet I, Brochez L. 
Participation rate, effectiveness, and cost of standard total-body examination vs lesion-directed 
screening. 3rd international UV&skin cancer congress  2015; Melbourne, Australia. 
Brochez L, Chevolet I, Speeckaert R, van Geel Na, Van Gele M, Lambert J. Characterisation of the in 
vivo immune network of IDO, tryptophan metabolism, PD-L1 and CTLA-4 in circulating immune cells in 
melanoma. 23rd World Congress of Dermatology 2015; Vancouver, Canada.  
Schreuer M, Meersseman G, Jansen Y, Seremet T, Chevolet I, Bott A, Wilgenhof S, Maertens G, Neyns 
B. Quantitative assessment of BRAF V600 mutant cell-free tumor DNA from plasma as a diagnostic and 
therapeutic biomarker in pts with BRAF V600 mutant melanoma. ASCO annual meeting 2015; Chicago, 
USA. 
Schreuer M, Chevolet I, Jansen Y, Seremet T, Wilgenhof S, Liénard D, del Marmol V, Neyns B. Objective 
responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure. 
Society for Melanoma Research Meeting 2014; Zürich, Zwitserland. 
I Chevolet, I Hoorens, JF Baurain, A Nikkels, V Del Marmol, M Garmyn, F Sales, P Specenier, M Stas, P 
Wolter, L Brochez. The Belgian Assocciation of Dermato-Oncology (BADO) launch meeting: Verslag van 
de vergadering. OncoHemato 2014;8(2):74-81. 
Chevolet I, Speeckaert R, Boone B et al. The Effect of CD8+Tumor-Infiltrating Lymphocytes on Sentinel 
Lymph Node Immune Status. Journal Der Deutschen Dermatologischen Gesellschaft 2013; 11 SI (7):17-
18. 
Brochez L, Chevolet I, De Munter S et al. Yield of a Lesion-Directed Screening Initiative in Flanders, 
Belgium. Journal Der Deutschen Dermatologischen Gesellschaft 2013; 11 SI (7):29. 
  
 201 
 
ORAL PRESENTATIONS 
2014 Oncopoint: “Peri-tumoral indoleamine 2,3-dioxygenase expression in 
melanoma: an early marker of immune resistance?” (University Hospital 
Ghent) 
2014 Wetenschapsdag: “Endothelial indoleamine 2,3-dioxygenase is consistently 
expressed in the immune micro-environment and influences prognosis.” (Het 
Pand, Gent) 
2014  Wetenschapsdag: “Yield of a lesion-directed screening initiative in Flanders, 
Belgium.” (Het Pand, Gent) 
2013  8th World Congress of Melanoma: “CD8+ TILs and sentinel lymph node: 
indications for altered loco-regional immunity” (EADO, Hamburg) 
2013 PEARLS Centre of excellence: “Introduction to Ghent University Hospital” 
(University Hospital Ghent) 
2013 PEARLS Centre of excellence: “Outlines of melanoma and pigment cell 
research in the DRU” (University Hospital Ghent)  
2012  AGL Gent: presentation on a facial variant of frontal fibrosing alopecia (Aula, 
Gent)   
 
MISCELLANEOUS 
2012-2015 FWO aspirant 
Reviewer for Melanoma Research 
  
 202 
 
 
